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As clinical datasets have increased in size and a wider range of molecular profiles can be credibly
measured, understanding sources of heterogeneity has become critical in studying complex phenotypes.
Here, we investigate and develop statistical approaches to address and analyze technical variation,
genetic diversity, and tissue heterogeneity in large biological datasets.
Commercially available methods for normalization of NanoString nCounter RNA expression data are
suboptimal in fully addressing unwanted technical variation. First, we develop a more comprehensive
quality control, normalization, and validation framework for nCounter data, benchmark it against existing
normalization methods for nCounter, and show its advantages on four datasets of differing sample sizes.
We then develop race-specific and genetic ancestry-adjusted tumor transcriptomic prediction models from
germline genetics in the Carolina Breast Cancer Study (CBCS) and study the performance of these models
across ancestral groups and molecular subtypes. These models are employed in a transcriptome-wide
association study (TWAS) to identify four novel genetic loci associated with breast-cancer specific survival.
Next, we extend TWAS to a novel suite of tools, MOSTWAS, to prioritize distal genetic variation in
transcriptomic predictive models with two multi-omic approaches that draw from mediation analysis. We
empirically show the utility of these extensions in simulation analyses, TCGA breast cancer data, and
ROS/MAP brain tissue data. We develop a novel distal-SNPs added-last test, to be used with MOSTWAS
models, to prioritize distal loci that give added information, beyond the association in the local locus
around a gene. Lastly, we develop DeCompress, a deconvolution method from gene expression from
targeted RNA panels such as NanoString, which have a much smaller feature space than traditional RNA
expression assays. We propose an ensemble approach that leverages compressed sensing to expand the
feature space and validate it on data from the CBCS. We conduct extensive benchmarking of existing
deconvolution methods using simulated in-silico experiments, pseudo-targeted panels from published
mixing experiments, and data from the CBCS to show the advantage of DeCompress over reference-free
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CHAPTER 1: LITERATURE REVIEW
1.1 Normalization of NanoString nCounter expression
The NanoString nCounter platform offers a comparatively inexpensive alternative for gene
expression measurement of a panel of pre-specified genes due to its ability to measure mRNA
expression without requiring cDNA synthesis or any amplification steps18. The technology offers key
advantages in sensitivity, technical reproducibility, and strong robustness for analysis of formalin-fixed,
paraffin-embedded (FFPE) samples19. Given these advantages, the NanoString nCounter platform is
increasingly being used in academic settings globally to study differential gene expression, despite the
admitted limitation of requiring pre-specification of genes to measure20–23. nCounter is especially
attractive for longitudinal studies involving FFPE samples carried out over several years24 and
diagnostic assays in clinical settings, as shown by the Clinical Laboratory Improvement
Amendments-approved PAM50-based breast cancer signature assay developed by Prosigna25,26. The
following section gives a quick discussion of the importance of proper quality control and normalization
for mRNA expression panels and overviews existing methods specific to nCounter.
1.1.1 Importance of proper normalization
Proper normalization and quality control (QC) of mRNA expression is necessary prior to statistical
analysis to mitigate any confounding noise from unwanted biological and technical variables that are
associated with potentially important covariates of interest, such as batch effects or degradation of
groups of samples that have been stored over time27,28. Often times, all sources of unwanted noise
cannot be enumerated a priori or measured, beyond those that are easily catalogued in a sample
table, such as different research centers, technicians, or storage units for samples. In all cases, it is
advised to use a proper quality control and normalization pipeline to address any degraded samples
and estimate any such technical noise. All normalization methods deal with a trade-off between any
bias that needs to be corrected and the variance that may be introduced to the data due to estimation
of bias effects29. Naïve normalization methods may err too heavily on the side of bias correction and
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result in adding excessive variance to the expression measurements. Molania et al have recently
suggested an iterative process to normalization, wherein several parameters (i.e. number of
housekeeping genes, number of detected outliers, number of dimensions of technical noise) are tuned
over several iterations with several relevant biological checks used as validation, in nCounter datasets
with technical replicates28.
1.1.2 Normalization using the nSolver software
NanoString provides nSolver 4.0, a graphical user interface software, that aids in QC and
normalization. After imaging, binding density, positive control, and limit of detection quality controls,
NanoString provides two forms of normalization in its nSolver Analysis Software30: (1) a more
user-friendly procedure with optional background correction, followed by positive control and
housekeeping gene normalization and (2) the Advanced Analysis tool, a wizard-based add-on that
draws from the NormqPCR R package31,32.
Briefly, the nSolver normalization procedure is as follows: the arithmetic mean of the geometric
means of the positive controls for each lane is computed and then divided by the geometric mean of
each lane to generate a lane-specific positive control normalization factor30,31. The counts for every
gene are then multiplied by its lane-specific normalization factors. To account for any noise introduced
into the nCounter assay by positive normalization, the housekeeping genes are used similarly as the
positive control genes to compute housekeeping normalization factors used to scale the expression
values30,31.
1.1.3 NanoStringDiff
Wang et al generated a normalization method for NanoString using negative binomial linear
modelling with an empirical Bayes approach33. This method introduces three normalization
parameters to quantify variation and noise across different experimental conditions: (1) the positive
control size factor (ci), accounting for lane-by-lane variation; (2) the background noise parameter (θi),
quantifying the non-specific background level; and (3) the housekeeping size factor (di), adjusting for
the variation in the amount of input sample material.
Here, we denote the observed count from gene g in sample i with Ygi, and the unobserved
expression rate by λgi. The data is assumed to be generated from the following hierarchical model:
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Ygi|λgi ∼ Poisson(cidiλgi + θi)
λgi|ugi, ηg ∼ Gamma(ugi, ηg)
ηg ∼ Normal(m0, τ2)
logugi = XiβTg ,
where ugi and ηg denote the mean and log-dispersion of the expression rate λgi to deal with
overdispersion. The mean parameter ugi is specified based on a generalized linear model with
logarithmic link function, where Xi gives the ith row of the design matrix of covariates X and βg is a
vector of regression coefficients.
Hyper-parameters are empirically estimated from the expression data for endogenous genes. For
each endogenous gene, the maximum likelihood estimate (MLE) of the log-dispersion parameter η̂g is
calculated. These estimates are only used from endogenous genes with read counts larger than the
maximum value of negative controls to estimate further hyperparameters due to background noise in
endogenous genes with low read counts. The median of η̂g for endogenous counts is used to find
m̂o = mediang (η̂g). As Wu et al points out34, the sample variance of η̂g overestimates τ and
accordingly, Wang et al apply an ad hoc method to compute pseudo datasets with τ2 = 0 to estimate
var(η̂g|ηg) and subtract it from the sample variance of η̂g to obtain an estimate of τ2. Model parameters
βg and ηg are then estimated through an iterative process that maximizes the conditional likelihoods of
βg|ηg and ηg|βg until convergence.
1.1.4 Remove Unwanted Variation III (RUV-III)
Molania et al proposed a method in the line of Remove Unwanted Variation (RUV) methods27,29
that is catered to a NanoString nCounter panel with technical replicates. RUV-III estimates a
user-defined k dimensions of unwanted variation from differences between expression values of
technical replicates and and the distribution of expression of negative control transcripts.
Here, we assume that we have data from m nCounter assays on m′ < m distinct samples. Let M
be the alliteratively-named m×m′ mapping matrix that maps assays to samples, such that the i, j-th
element of M mi,j = 1 if the i-th assay is an assay of sample j. We assume that all assays have n
probes. Let Y be the m× n matrix of observed log-transformed expression values and we model
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Ym×n = Xm×pβp×n +Wm×kαk×n + ϵm×n (1.1)
where Xβ is the biological variation, Wα is the unwanted variation, ϵ is random error. We assume
p+ k < m and k < m−m′. Here, X corresponds to biological factors of interest and not technical
factors, like batch. In the most general case of RUV-III, both X and W are unobserved. Lastly,
assume that nc < n of the probes are negative controls. We herein indicate sub-matrices of the
matrices identified in Equation 1.1 with a subscript of c. These negative control probes are assumed to
unaffected by factors in X.
Note that if two assays are technical replicates of sample j, then the rows of X corresponding to
this assay are identical. Thus, we have X = MX, where Xm′×p as the biological factors of interest in
terms of samples. The goal is to estimate Wα in Equation 1.1 and regress it out of Y , leaving Ŷ that is
used in downstream analysis. Let
RM = I −M(M ′M)M−1M,
be the residual operator of M . Thus,
RMY = RM (Xβ +Wα+ ϵ)
= RMMXβ +RMWα+RM ϵ
= RMWα+RM ϵ.
α may be estimated with a form of factor analysis on RMY , as long as RMW is full rank. Let α̂ be
the first k singular vectors of RMY , and accordingly Ŵ = Ycα̂′c(α̂cα̂′c)−1. It is easy to show that
Ŵ ≈ W .
1.1.5 Summary
It is becoming increasingly popular in both clinical and academic settings to use mRNA
expression measurements from the NanoString nCounter platform. Even though groups have
addressed normalization in this setting previously, the most popular method for normalization is the
NanoString-provided nSolver software. Proper evaluation of this normalization method has not been
conducted before, especially in large cohorts without technical replicates.
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1.2 Transcriptome-wide association studies (TWAS)
1.2.1 Applications of TWAS in breast cancer
Few genome-wide association studies (GWAS) have studied the relationship between germline
variation and survival outcomes in breast cancer, with most focusing instead on genetic predictors of
risk11,35. Recently, GWAS have shown evidence of association between candidate common germline
variants and breast cancer survival, but these studies are often underpowered36,37. Furthermore, the
most significant germline variants identified by GWAS, in either risk or survival, are often located in
non-coding regions of the genome, requiring in vitro follow-up experiments and co-localization
analyses to interpret functionally38. It is important to seek strategies for overcoming these challenges
in GWAS, especially because several studies in complex traits and breast cancer risk have shown that
regulatory variants not significant in GWAS account for a large proportion of trait heritability39–41.
Novel methodological approaches that integrate multiple data types offer advantages in
interpretability and statistical efficiency. Escala-García et al has suggested that aggregating variants
by integrating gene expression or other omics may better explain underlying biological mechanisms
while increasing the power of association studies beyond GWAS36. To alleviate problems with
statistical power and interpretability, a recent trend in large-scale association studies is the
transcriptome-wide association study (TWAS). TWAS aggregates genomic information into
functionally-relevant units that map to genes and their expression. This gene-based approach
combines the effects of many regulatory variants into a single testing unit that increases study power
and provides more interpretable trait-associated genomic loci42,3,43. Here, we describe a few current
approaches to transcriptomic imputation and subsequent downstream tests of associations.
1.2.2 PrediXcan
Gamazon et al’s PrediXcan42 identifies trait-associated genes by estimating the genetic control of
of phenotype through the mechanism of genetic control. Gene expression levels are decomposed into
(1) the genetically regulated expression (GReX) components, (2) a component altered by the trait
itself, and (3) a remaining component attributed to environmental or other factors. PrediXcan tests the
mediated effect of gene expression by quantifying the association between GReX and the phenotype
of interest.
Reference transcriptome datasets from GTEx44, GEUVADIS45, and DGN46 were used to train





wk,gXk + ϵ, (1.2)
where Yg is the expression trait of gene g, wk,g is the effect size of marker k for gene g, Xk is the
number of reference alleles of marker k, and ϵ is the contribution of other factors that determine the
expression trait assumed to independent of the genetic component. Gamazon et al have built
PredictDB, a database of predictive models using DGN using LASSO47, elastic net48, and/or the
polygenic score at various P -value thresholds.
The genetic heritability of gene expression serves as an upper bound for the prediction of the
GREx of a given gene. Here, the cis-heritability (cis-h2) was estimated for each gene using a variance
component model with a genetic relationship matrix (GRM) estimated from genotype data within 1
Megabase (Mb) of the gene with minor allele frequency (MAF) > 0.05 and in Hardy-Weinberg
Equilibrium (P > 0.05). Gamazon et al calculated the proportion of the variance of gene expression
explained by local single nucleotide polymorphisms (SNPs) using linear mixed modelling in GCTA49:
Y = Xb+Glocal + e, var(Y ) = Alocalσ2local + Iσ2e ,
where Y is a gene expression trait, b is a vector of fixed effects, Alocal is the GRM from local
SNPs, and the random effect Glocal is the genetic effect attributable to the set of local SNPs with
var(Glocal) = Alocalσ2local..
Given an optimal vector ŵk,g fitted with Elastic Net48 with α = 0.5 that best predicts Yg as
assessed by 10-fold cross-validation R2, the PrediXcan framework imputes the GREx of each gene in





These imputed ˆGReXg values are then employed in downstream tests of association to identify
gene-trait associations.
PrediXcan has several advantages in identifying gene-trait associations. It has a much smaller
multiple-testing burden than GWAS, with approximately 10,000 gene-based tests as opposed to 5-10
million single variant tests in GWAS. No transcriptome data is needed since the predicted expression
levels are a function of genetic variation alone and thus can be applied to any existing GWAS panel.
Reverse causality is not a concern since disease status or drug treatment cannot alter germline
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genetic variation. PrediXcan also lends itself seamlessly to meta-analysis as less stringent
harmonization between studies is required.
1.2.3 FUSION
Gusev et al proposed a similar transcriptome-wide association study approach, called FUSION,
nearly concurrently with Gamazon et al’s PrediXcan method3. Again, FUSION uses a reference panel
in relevant tissue to train predictive models of mRNA expression from cis-genotypes. Then, using
these optimally trained models, FUSION either (1) directly predicts expression in genotype samples
using effect-sizes from the predictive models and measures association between predicted expression
and trait or (2) indirectly estimates association between predicted expression and trait as a weighted
linear combination (weighted burden test) of SNP-trait standardized effect sizes while accounting for
linkage disequilibrium among SNPs, as first proposed in Pasaniuc et al50. Similar to PrediXcan, by
focusing on the genetic-component of expression, FUSION avoids instances of expression-trait
associations that are not a consequence of genetic variation but are driven by variation in trait. Figure
1.1, adapted from Gusev et al3, summarizes the possible models of causality for the relationship
between genetic markers, gene expression, and trait.
Model fitting in FUSION is very similar to that in PrediXcan. For genes that are cis-heritable at
P < 0.05, the same additive model for gene expression as in Equation 1.2 is fit using one of the
following schemes:
• the cis-eQTL, the single most significantly associated cis-eSNP (SNP in an eQTL) in the training
set was used as the only predictor;
• LASSO or elastic net47,48 with mixing parameter α ∈ {0, 0.5} and λ tuned over 5 folds;
• the best linear predictor (BLUP)51 which estimates the causal effect-sizes of all SNPs in the
cis-locus jointed using a single-variance component;
• the Bayesian linear mixed model (BSLMM) which estimates the underlying effect-size distribution
and then fits all SNPs in the locus jointly.
The BLUP and BSLMM are fit using all post-QC SNPs using GEMMA52 and perform shrinkage of
the SNP weights, but not variable selection. Predictive accuracy was measured by five-fold
cross-validation in a random sampling of 1,000 of the highly heritable genes using the predictive R2
between predicted and true expression across all predicted folds.
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Figure 1.1: Modes of expression causality using FUSION. Diagrams here shown the possible modes
of causality for the relationship between genetics markers (labelled SNP in blue), gene expression (GE,
green), and trait (red). Models A-D describes scenarios that are considered null models by the TWAS
framework. E-G shows scenarios that can be identified as significant and can be further studied func-
tionally. Modified from Gusev et al3.
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FUSION’s novelty comes in its summary-based imputation that extends the ImpG-Summary
algorithm50 to train on the cis-genetic component of expression. Let Z be a vector of standardized
effect sizes (z-scores) of SNP on trait at a given cis-locus. Here, the Wald-type test statistics (i.e.
β
SE(β) ) are considered. The z-score of the expression and trait is imputed as the linear combination of
elements of Z with weights W . With Σe,s as the covariance matrix between all SNPs at the locus and




Under the null of no association and a multivariate Gaussian assumption Z ∼ N (0,Σs,s), it can
be shown that the imputed z-score of expression and trait (WZ) has variance WΣs,sW ′. Thus, the






FUSION optionally further subjects significant TWAS-identified loci to a highly conservation
permutation test that tests the loci conditional on high GWAS effects. The eQTL weights are reshuffled
1,000 times to construct a null distribution for the TWAS z-score. This permutation test assesses if the
same distribution of eQTL effect sizes could yield a significant association by chance. The test is
implemented adaptively, so permutation will stop after a sufficient number of significant observations
(or at the maximum specified). This statistic is highly conservative as truly causal genes can fail the
test if their eQTLs are in high LD with many other SNPs, and intended to prioritize associations that
are already significant in the standard test for follow-up3.
1.2.4 Alternative methods for TWAS
Here, we briefly survey three further methods relevant to TWAS: (1) UTMOST53, (2) TIGAR54,
and (3) FOCUS55:
The UTMOST (Unifed Test for MOlecular SignaTures) method performs cross-tissue expression
imputation and gene-level association analyses to unify complex traits that are modulated across
various tissues in the human body. Cross-tissue expression imputation is formulated as a penalized
multivariate regression problem:
YN×P = XN×MBM×P + ϵN×P ,
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where N is the sample size of the training data, M is the number of SNPs in the imputation
models, and P is the number of tissues. Under the assumption that only a subset of tissues was
collected from each individual, expression data in Y is incomplete and the sample sizes for different
tissues are unbalanced. UTMOST estimates B by minimizing the squared loss function with a LASSO
















where Yi, Xi, Ni are the observed expressions, genotypes, and sample sizes of the ith tissue,
respectively.
Per-tissue tests of association are computed similarly to PrediXcan and FUSION. Imputed gene
expression in the ith tissue is computed as Ei = XiB̂.i and is tested for associated with the trait using





where Z̃ denotes the SNP-trait z-scores and Γi is a diagonal matrix wit the ratio between the
standard deviations of the jth SNP and the imputed expression in the ith tissue. Under the null of no
SNP-trait association, Z̃ ∼ N(0, D), where D is the LD matrix for the SNPs and accordingly,
Cov(Z) = Λ′DΛ, where Λ = (B̂.1Γ1, . . . , B̂.PΓP ). Lastly, the per-tissue gene-trait association results
are combined using a generalized Berk-Jones test, taking into account the covariance among
single-tissue test statistics56.
TIGAR adds to the transcriptomic imputation methods employed by PrediXcan and FUSION by
introducing a non-parametric Bayesian model using a latent Dirichlet process regression (DPR)
model57. The cis-eQTL effect sizes w are given a Normal prior N(0, σ2w) and Dirichlet process (DP)
prior58 for the effect-size variance σ2w such that
wi ∼ N(0, σ2w), σ2w ∼ D, D ∼ DP (IG(a, b), ξ).
σ2w is a latent variable and integrating it out induces a non-parametric prior distribution on wi that








k ∼ IG(ak, bk), πk = νk
k−1∏
l=0
(1− νl), νk ∼ Beta(1, ξ).
10
Conjugate hyperpriors ξ ∼ Gamma(aξ, bξ) and σ2ϵ ∼ IG(aϵ, bϵ) are assumed and are generally set
as non-informative. The posterior estimates for w are then obtained by either Markov Chain Monte
Carlo or variational Bayesian algorithms59,60.
FOCUS, a fine-mapping method proposed by Mancuso et al, extends the TWAS testing
framework outlined in Pasaniuc et al and Gusev et al50,3 that models correlation among TWAS signals
to assign a probability for every gene in the risk region to explain the observed association signal.
Here, a quantitative trait y is modelled by a linear combination of expression levels for m genes
G ∈ Rn×m as
Y = Xβ +Gα+ ϵ,
where X ∈ Rn×p is the genome-wide genotype matrix at p SNPs, β is the p pleiotropic effects of
X on y, α is the vector of causal effects for the m genes, and ϵ is the random environmental noise. As
in TWAS predictive models, G = XW , where W is the eQTL effect-size matrix. The marginal TWAS







where Ω is an estimate of W from an independent reference panel and σe is the diagonal variance
parameter for ϵ.
Marginalizing out unknown causal gene effects α, the sampling distribution for the marginal
TWAS test statistics is
ZTWAS |λsnp,Ω, V, c, nσ2c ∼ N(ΩTV λsnp,VDcV + V),
where V = n−1XTX is the LD matrix, λsnp is the pleiotropic SNP non-centrality parameter,
V = ΩTV Ω is the predicted expression covariance, and Dc is the prior variance for effects at causal
genes (nσ2c ) as indicated by a binary status vector c. Inference for which genes are causal given the
TWAS statistics is performed by computing the posterior distribution of any set of causal genes c,
assuming a Bernoulli prior (with default probability 10−3) for the causal status of a given gene. The




Transcriptome-wide association studies are quickly being used to increase power in detection of
SNP-trait associations over traditional genome-wide association studies. Questions of predictive
performance of predictive gene expression models across ancestrally-different populations and in
understudied tissues is still open. Furthermore, it is also important to assess how TWAS performs to
granularity introduced by sample-specific, biological, and disease subtype heterogeneity.
1.3 Mediation analysis in gene regulation
1.3.1 Implications of the omnigenic model
The omnigenic model of the genetics of complex traits advanced that human gene regulatory
networks are so interconnected that thousands of individual genes contribute at least slightly to the
phenotype through expression in relevant cells41. This model extended upon the infinitesimal model,
first proposed in 1918, that quantitative phenotypes are the sum of a genetic and non-genetic
component, such that the genetic component is distributed within families as a Normal random
variable with variance independent of parental traits63. The omnigenic model also includes the
concept of universal pleiotropy, wherein genetic variation in one region of the genome potentially has
an indirect effects on many traits64. If the omnigenic model holds true, then many complex traits are
driven by large numbers of genetic variants with small effects on a phenotype of interest, and thus
implicating most regulatory variants that are active in disease-relevant tissues41. Boyle et al
hypothesized further that disease risk is largely driven by gene with no direct relevance to disease and
is propagated through multi-level regulatory networks with a small number of core genes with direct
effects and a much larger set of peripheral genes with indirect effects41.
These ideas of core and peripheral gene effects on phenotype are similar to ideas of genetic
regulation of genes. Identification of expression trait quantitative loci (eQTLs) is one of the most
important methods of discovering potential genetic regulators of the mRNA transcription of a gene. An
eQTL is a genomic locus that explains a portion of variance in the expression level of the mRNA
transcript of a given gene. eQTLs can be classified by their relative distance to the gene of interest
(local or distal based on a defined window around a gene) or the mechanism of action on the
transcription of a gene (cis- and trans-eQTLs act directly and indirectly, respectively)65.
Liu et al models the contribution of core and peripheral genes to complex trait heritability66:
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Yi = Ȳ +
M∑
j=1
γj(xi,j − x̄j) +
N∑
j−M+1
0× (xi,j − x̄j) + ϵYi ,
where Yi is the phenotype value of individual i, Ȳ is the population mean of the phenotype, γj
represents the direct effect of a unit change in expression of core gene j on E(Yi), and xi,j is the
expression of gene j in individual i (with population mean x̄j). We assume that there are M core
genes out of N total expressed genes in a tissue, and the random error ϵYi has mean 0 and is
independent of genotype and gen expression. Although the N −M peripheral genes have no direct
effects on the phenotype, they may modify the expression of core genes as trans-eQTLs. Phenotypic






















Here, Vj,cis and Vj,trans are the genetic variances of of core gene j determined by cis and trans
effects, respectively. Cj,k represents the genetic covariance of expression of genes j and k. The first
pair of terms on the right-hand side of this variance decomposition depend on the relative importance
of cis and trans effects in determining expression heritability of core genes. Liu et al estimates that, in
general, about 70% of expression heritability is caused by these trans effects. The last term depends
on covariances between core genes. As core genes are seldom adjacent in the genome, genetic
covariances arise from trans effects. As there are more core gene pairs (M2) than singleton core
genes (M ), these trans effects dominate the heritability for most traits66.
The effects of a single SNP may potentially fan through multiple core genes to affect the
phenotype. Suppose SNP s is an eQTL for a core gene j. We let αs,j be the effect size of SNP s on
the expression of gene j and the change in phenotype Y due to one additional copy of the alternative
allele as δs. In the case that s is a trans-eQTLs for multiple core genes, the total phenotypic effect of s
is a sum of trans-effects mediated through each core gene j, and δs =
∑M
j=1 αs,jγj = M ¯αs,j , γj . If we
assume that the effects of SNP s has expectation 0 and are uncorrelated across j, then the effects
cancel out on average, the variance scales multiplicatively with M , and the total effect is not large.
Alternatively, if there exist peripheral master regulators that drive coordinated effects on many
downstream target core genes, these trans-effects can be considerable66.
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1.3.2 Inference on trans-eQTLs
Many groups have cast the omnigenic model directly onto the eQTL framework, treating the
problem of identifying trans-eQTLs for genes as a mediation problem67–69. Distal or trans-eQTLs are
far more difficult to detect that local or cis-eQTLs due to the significant multiple testing burden of
comparing millions of SNPs to thousands of transcripts. Trans-eQTLs are especially important in
identifying to understand tissue-specific gene regulatory mechanism70. Here, we review a few
methods for trans-eQTL prioritization based extensions on mediation analysis.
Brynedal et al demonstrated an approach to look for SNPs associated with the expression of
many genes simultaneously, finding that hundreds of trans-eQTLs each affect hundreds of
transcripts68. At each marker, they tested for overdispersion of association − log10(P )-values across
all probe sets with a null hypothesis that − log10(P ) values are exponentially distributed with λ = 1
against the joint alternative hypothesis that a subset of association statistics are non-null (i.e. λ ̸= 1).
Evidence for these hypotheses were compared as a likelihood ratio test for the cross-phenotype meta
analysis, where the test statistic is defined as
SCPMA = −2× log
(
P (Data|λ = 1)
P (Data|λ = λ̂)
)
∼ χ21,
where λ̂ is the observed exponential decay in the data. Correlation between the probe set levels
across individuals was accounted for using empirical significant testing by simulating eQTL association
studies under the null expection of no association to any marker given the observed correlation
between probe sets68. In summary, Brynedal et al discovered that target transcripts of a
high-confidence set of trans-eQTLs encode proteins that interact more frequently than expected by
chance and are bound by the sample transcription factors68.
A more recent paper by Shan et al establishes a simple mediation framework to identify
trans-eQTLs that are mediated by multiple mediating cis-eGenes. First, a candidate trio composed of
a SNP, one or more cis-genes to the SNP, and the trans-gene of interest were selected. Trans
SNP-gene pairs were included if the association has P ≤ 10−6 69. Mediating cis-genes were selected if
they were associated with the SNP at false discovery rate- (FDR) adjusted P ≤ 0.05. The following set
of linear models are chosen to assess the mediation effect. For the ith subject, let Yi be the
expression level of the trans-gene, Xi by the SNP dosage, Mi = (Mi1, . . . ,Mip)T be the expression
levels of the p cis-genes, and Ci represents the q covariates. Consider:
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Yi = β0 +XiβX +MTi βM + CTi βC + ϵYi
Mij = α0j +XiαXj + CTi αCj + ϵMij ,
where βM =
(
βM1 , . . . , βMp
)T is the effect of the p cis-genes on the trans-gene, adjusting for the
SNP and covariates, αX = (αX1 , . . . , αXp)T is the effect of the SNP on the p cis-genes, adjusted for
covariates. ϵYi and ϵMij are the measurement errors, independent and distributed normally such that
dependence is allowed among the p cis-genes. Two quantities are estimated and tested for equality to
0 via bootstrapping71: the total mediation effect (TME) ∆ = αTXβM and the component-wise effects
δ = (δ1, . . . , δp)
T , where δj = αXjβMj . The test of TME is a broader class of null than the test of CME.
In the case of positive mediation effect through one cis-gene and negative mediation through another,
the test of CME can be more powerful than the TME test72.
Lastly, we consider a pair of cross-condition mediation methods from Yang et al: CCmedgene and
CCmedGWAS. CCmed takes in summary statistics from multiple studies, tissue types, or conditions and
aims to detect robust mediation and trans-association effects shared across conditions. To validate the
trait-associations of the identified trans-genes for GWAS SNPs, a two sample Mendelian
randomization method robust to correlated and some invalid instruments (MR-Robin) was developed.
CCmedgene detects candidate trios of eQTL set, cis-gene, and trans-gene that show evidence of
cross-tissue trans-association and mediation effects by quantifying the joint probability of the following
two conditions being satisfied in at least K1 out of K tissue types: (1) gene-level cis-associations and
(2) non-zero correlations between the expression levels of the cis- and trans-genes conditioning on the
eQTL genotypes. For each trio (Li, Ci, Tj), where Li is a set of eQTL genotypes for a cis-gene i, Ci is
the cis-gene expression, and Tj is the expression level of a trans-gene j, Pmed,ij , the probability that
Ci mediates the effects of Li on Tj in at least K1 tissue types, is computed as follows:
Pmed,ij = P (Li → Ci → Tj in at least K1 out of K tissues)
= P (αC ̸= 0 in all K tissues)× P (β1 ̸= 0 in at least K1 tissues),
where αc is a vector of cis-association effects for the set of eQTLs in a single tissue type, and β1
is the conditional correlation of cis- and trans-gene expression levels in a single tissue type.
To quantify the cross-tissue cis-association probability P (αc ̸= 0 in all K tissues), the gene-level
cis-association statistics are obtains for M cis-genes by F -tests. Using Gleason et al’s integrative
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association analysis approach Primo73, the estimated P̂ (αc ̸= 0 in all K tissues) for genes 1 ≤ i ≤ M .
Similarly, Primo is applied to the conditional correlation statistics from K tissue types for the M ′i
trans-genes for each cis-gene i to estimate the probability of non-zero conditional correlation in at
least K1 tissue types for all trans-genes of a cis-gene. The product of these two probabilities gives a
lower bound on the probability of gene-level cis-mediated trans-associations for each trio.
CCmedGWAS detects trans-genes associated with GWAS SNPs similarly to CCmedgene using Primo to
estimate the probability that (1) the GWAS SNP is also a cis-eQTL for the cis-gene conditional on
other cis-eQTLs and (2) there is a non-zero correlation between the cis- and trans-gene expression
levels conditioning on the genotypes of eQTL and GWAS SNPs.
1.3.3 Incorporation of regulatory information in TWAS
Here, we give a brief review of an extension of traditional cis-only TWAS that incorporates
information from regulatory elements into the prediction framework. Traditional cis-only prediction
models treat all local genotypes as equally predictive of expression, though variants that lie with
cis-regulatory elements like promoters or enhancers are more likely to affect expression74–76. To this
end, Zhan et al proposes EpiXcan, a simple extension of the PrediXcan, that prioritizes local SNPs
around the gene of interest if they are involved in a cis-regulatory element77. Here, epigenomic
annotations for a given tissue are obtained from the Reference Epigenome Mapping Centers78 to
estimate a posterior probability that a given eQTL is causal for the regulation of the given gene based
on the annotations. This posterior probability is estimated using qtlBHM79, a Bayesian framework that
uses eQTL summary statistics and functional annotations. These posterior probabilities are then
rescaled to penalty factors using Bézier curves employing a shifting-window strategy to approximate
the data-driven function. Finally, these penalty factors are included into a weighted elastic net
prediction model that minimizes a modification of the elastic net objective function:
f(β, λ, α) =
n∑
i=1
(yi −Xiβ)2 + λα
m∑
j=1
ωj |βj |+ λ(1− α)βTΩβ,
where β is the SNP effect-sizes on gene expression, yi is the gene expression for the ith sample,
Xi is the dosages for cis-genotypes of the ith sample, ω is the vector of SNP penalties, Ω is a matrix
with diagonal ω and 0 for off-diagonal elements, and λ and α are penalization parameters as in elastic
net47,48. The optimal β gives the SNP weights for the predictive model of the gene of interest. In
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general, this prioritization of cis-SNPs generates a small, yet considerable, gain in prediction of gene
expression and increases the power to detect significant gene-trait associations77.
1.3.4 Summary
In general, several studies have shown that variation in both phenotypes and gene expression is
attributed to the aggregation of countless distal variants with small effects on the trait or gene
expression. Groups have shown that a mediation framework is powerful to identify these most
important trans variants, usually associating trans-eQTLs with cis-regulators that cascade effects to
many distal genes that are important in a given tissue. TWAS extensions have also shown the utility of
included regulatory information into the TWAS predictive framework. However, there are gaps in
current transcriptomic prediction in identifying, prioritizing, and leveraging these distal or trans-SNPs
for increase predictive power and power to detect gene-trait associations.
1.4 mRNA expression-based cell-type deconvolution
Here, we discuss another source of biological heterogeneity: cell-type composition in bulk tissue.
Bulk tissue, especially in cancerous tumors, comprise of many different cell types, many rare, and
each contributing a different amount to the assay of interest (i.e. mRNA expression, DNA methylation,
etc)80,81. This cell-type heterogeneity makes it difficult to distinguish gene expression variability that
reflects shifts in cell populations from variability that reflects changes of cell-type-specific expression82.
Since the advent of RNA-seq technology, cell-type deconvolution from mRNA expression has become
important in genetic and genomic association testing, either using compositions in regression models
as covariates to adjust for the association between cell-type proportions and phenotype83–85 or use
them as inputs to solve for cell-type specific quantities6.
mRNA expression-based cell-type deconvolution can be formulated as a matrix factorization of X,
a n× p matrix of raw scale mRNA expression from p genes and n samples:
X = PS (1.3)
where P is the n× k proportion matrix for n samples across k cell types, and S is the k × p
expression signature matrix for k cell-types across p genes. In all cases of deconvolution, X is known
and is a required input. In many studies, references for cell-type gene signatures are known; in these
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reference-based methods, estimation of S is direct from the references, and P can be estimated via
some modification of regression. Alternatively, when reference gene signatures are not readily
available for a given sample, there are multiple reference-free methods. Here, we outline several
reference-based and reference-free methods for cell-type deconvolution.
1.4.1 Reference-based deconvolution methods
Early reference-based methods have approached reference-based deconvolution using some
form of non-negative or constrained least squares method. After filtering out low and high variance










pki = 1, pki ≥ 0, ∀i.
The unmix method in Love et al’s DESeq2 package modifies this objective function to include low
and high variance genes by employing a variance stabilizing transformation V ST (·)16 and solves it
with a limited-memory Broyden–Fletcher–Goldfarb–Shanno algorithm:
k∑
i=1
(|V ST (X.i)− V ST (PS.i)|q) , such that
k∑
i=1
aki = 1, aki ≥ 0, ∀i.
The Digital Sorting Algorithm (DSA) is an extension of these regression based methods that use
gene signatures, rather than reference cell-type expression profiles, to first estimate S 87. DSA requires
an input of cell-type specific gene signatures. We encode the average of all genes highly expressed in
a single cell-type in the rows of S̃, which is not observed. Instead, let X̃s be the average of all genes
highly expressed in the observed mixed sample. We then consider the rearrangement of Equation 1.3
as S̃−1s X̃s = W , and since each column of W sums to 1, the elements of S̃s can be determined with
least squares. Accordingly, P can be estimated via non-negative least squares from this estimated S̃s.
There are other reference-based approaches that employ other statistical techniques to estimate
cell-type proportions. Quon et al builds upon their own ISOLATE computational strategy in the ISOpure
algorithm by maximum a posteriori estimation of tumor proportions88. Given R healthy (or non-tumor)
profiles in the data denoted b1, . . . , bR, the nth sample’s total tumor profile tn can be expressed as





where θn,1, . . . , θn,R are parameters to be estimated by ISOpure with the assumptions that these
parameters are non-negative and satisfy αn +
∑R
r=1 θn,r = 1. The ISOpure algorithm reduces to the
maximization of a count vector xn under a multionomial distribution whose probability vector over
transcripts is x̂n = αncn +
∑R
r=1 θn,rbr. The score of a given parameter setting is the product of the
score of the parameters under the Dirichlet prior distributions and the probability of the discretized
tumor profiles under the multinomial distribution for x̂n.
Another reference-based method, DeMixT, is a semi-supervised approach to tumor deconvolution
that assumes that bulk tumor tissue expression Yig for a single gene g is a mixture of a single tumor
component Tig and two non-tumor components N1,ig and N2,ig 89:
Yig = π1,iN1,ig + π2,iN2,ig + (1− π1,i + π2,i)Tig.
Here, only two of N1,ig, N2,ig Each of the component expressions are assumed to be
log2-normally distributed and all model parameters are estimated via maximum likelihood using
iterated conditional modes90. DeMixT is a powerful method, however the assumption of three total
tissue components for tumors may be untenable.
More specifically for the deconvolution of immune infiltrate, CIBERSORT uses a ν-support vector
regression to solve for the P matrix, given inputs for X and S 91. Briefly, the method defines a
hyperplane that captures as many data point as possible given defined constraints and reduces
overfitting by only penalizing data point outside an error radius using a linear epsilon-insensitive loss
function. The orientation of the hyperplane determines the estimated P .
In many cases, microdissection or pure samples of cell-types cannot be obtained. In this case,
external reference panels can also be applied, with several methods addressing this approach. In
particular, Dong et al proposed SCDC that deconvolves bulk gene expression using multiple single-cell
RNA sequencing (scRNA-seq) references92 in an ensemble approach. Based on every single-cell
reference i obtained, we can obtain an estimated proportion matrix P̂i and integrate these estimated
proportion matrices with weights wi, such that P̂ =
∑R
i=1 wiP̂i. The weights can be optimized by
minimizing the difference P − P̂ . Since P is unknown, the surrogate X and Xi can be used to find




using numerical method based on grid search to maximize the Spearman correlation between X
and X̂.
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Concurrently, Wang et al constructed MuSiC, a method that also utilizes cell-type specific gene
expression from scRNA-seq data to characterize cell type compositions from bulk RNA-seq data93. A
key concept in MuSiC is marker gene consistency - that, when using scRNA-seq data as a reference
for cell type deconvolution, cross-subject and cross-cell consistency must be considers to guard
against bias in subject selection and cell capture in scRNA-seq, respectively. Rather than pre-selecting
marker genes from scRNA-seq based only on mean expression, MuSiC gives weights to each gene to
allow for the use of more genes. Genes with low cross-subject variances are down-weighted, whereas
genes with high cross-subject variances are up-weighted. To deal with collinearity from correlated
genes, MuSiC uses a tree-guided process that recursively finds closely related cell types.
1.4.2 Reference-free deconvolution methods
The precursor to reference-free deconvolution methods was deconf, a algorithm based on
non-negative matrix factorization and iteration of estimation of S and P until ∥X − PS∥ reaches
convergence12. Since then, a population form of reference-free methods uses a geometric approach.
UNDO, a method from Wang et al, assumes tumor and stroma compartments for bulk cancerous
tissue and attempts to discern relative proportions with the assumption that there exist genes that are










where stumor(i) and sstroma(i) are the gene expressions in pure cells and x(i) are the gene
expression values in heterogeneous samples, and ajk are the mixing proportions, such that
a11 + a12 = a21 + a22. Given this assumption of cell-specific marker genes, the linear latent variable
model above is identifiable. Marker genes are located by searching along the two radii of a scatter
sector that correspond to genes with the minimum and maximum ratio between the two mixed
samples. From here, the tumor-stroma proportions are estimated using the marker gene expression
and the cell-specific expression profiles are obtained via matrix inversion94.
Zaitsev et al extends this simplex hunting formulation for multiple cell-types in LINSEED motivated
by a mutual linearity assumption that proposes that genes that are highly co-expressed in a single cell
type are directly proportionally expressed13. Given the inputted matrix of observed mixed expressions
X, each row is normalized by its sum aligns this proportion between co-expressed genes in a cell-type
to 1 and X is transposed. Using the SISAL algorithm95, the vertices of the geometric simplex can be
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identified and the top genes per corner can be obtained as a gene signature for a given cell type.
These gene signatures can then be inputted to the DSA framework to deconvolve the bulk expression
signal87. Singular value decomposition on X to find the number of linearly independent components
that contribute to variation can be used to obtain the number of cell types in the dataset.
CDSeq, a Bayesian framework for deconvolution from raw RNA-seq data, provides an alternative
to full reference-free deconvolution using a Latent Dirichlet Allocation model5. Here, the random
variable that models the cell-type specific gene expression profiles depends on gene length. Next, the
probability of having a read from a cell type depends on both the proportion of the cell type in the
sample and the typical amount of RNA produced by cells of that type. Together, these assumptions
account for the ratio of mRNA expression contributed by a specific cell type to the size of the cell.
Lastly, an iterative algorithm by Li and Wu called TOAST that better selects features by identifying
features showing distinct profiles among difference cell types, without known the pure cell type profiles
or mixing proportions a priori 14. The general rule of thumb for selecting informative features are genes
with low within-cell type variation and high cross-cell type variation. Assume, for the p-th feature, we
have Yp = [Yp1, . . . , Ypn]T . The proportions obtained for the ith sample are denoted as
θi = (θi1, . . . , θsk). With known proportions, the observed data can be modeled by a linear model:
E(Yp) = V βp, where V is the matrix of θ proportions and βp is the mean levels for the pth feature in the
jth cell type. This model allows for the testing of the null hypothesis
H0 : µpj − (k − 1)
∑
i ̸=j
µpi = 0, j = 1, . . . , k.
Features with significant test results are cell-type specific features. TOAST can be used with any
form of reference-free deconvolution method to improve estimation of S and P iteratively14.
1.4.3 Recapitulation of cell-type specific expression
A moonshot goal for many deconvolution methods is recapitulating cell-type expression profile per
sample. DeMixT addresses this goal by successive parabolic interpolations to find the maximum of the
joint density function with respect to the expressions specific to the normal compartments89, with
positive constraints such that sum of the normal components cannot exceed the total mixed
expression. The tumor-specific compartment can then be easily estimated from there.
Wang et al also develop a method based on linear mixed modeling for the purpose of estimating
the cell-type specific expression profiles per sample93. MIND extends single-measure deconvolution
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by borrowing information across multiple measurements t = 1, . . . , Ti from the same tissue for subject
i to estimate subject-specific and cell-type specific gene expression. First, cell-type fractions for
subject i and measure t (denoted Wit) can be estimated and combined across measures to yield Wi a
Ti × k matrix. Next, treating Wi as known, the problem is reversed to estimated the cell-type specific
expression. For gene j in subject i, the observed gene expression Xij is a Ti-dimensional vectors that
represents Ti measurements, rather than a scalar and can be modelled as a product of Wi and the
cell-type specific expressions Aij , such that Xij = WiAij + eij . It is assumed that Aij ∼ N(aj ,Σc) and
eij ∼ N(0, σ2eIT ). Parameters aj and Σc are estimated with an Expectation-Maximization and Aij is
estimated via an empirical Bayes procedure.
1.4.4 Summary
We have outlined several deconvolution methods, both reference-based and reference-free.
Each method hinges on identifying genes whose distributions can distinguish different, often rare, cell
types. This is already a challenging problem in many RNA-seq datasets with thousands of genes. In
targeted panels that assay gene expression with only hundreds of genes, the limited feature space
casts a considerable statistical challenge in inferring cell-type proportions and recapitulating cell-type
specific expression from bulk mRNA expression.
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CHAPTER 2: AN APPROACH FOR NORMALIZATION AND QUALITY CONTROL
FOR NANOSTRING RNA EXPRESSION DATA
In this chapter, we provide a framework for the quality control and normalization of mRNA
expression count data from the NanoString nCounter platform, using a large dataset of breast tumor
expression from the Carolina Breast Cancer Study (CBCS) and various other cohorts of differing
sample size. We illustrate some of the pitfalls in the popularly-used nSolver method of background
correction and positive control normalization and provide an alternative approach that uses RUVSeq27,
which efficiently estimates unwanted variation from endogenous housekeeping genes. Lastly, we
provide various quality checks for normalization and outline the impact of proper normalization on
inference for endogenous genetic associations and expression-based disease subtyping.
2.1 Overview of quality control and normalization process
The full quality control and normalization process using nSolver and RUVSeq is summarized in
Figure 2.1, starting with familiarization of the raw data (Figure 2.1.1), technical quality control (Figure
2.1.2), pre-normalization assessment of housekeeping genes (Figure 2.1.3) and data visualization to
detect problematic samples and assess whether flagged samples should be removed (Figure 2.1.4).
Normalization is performed with either nSolver or RUVSeq (Figure 2.1.5), and the processed
expression data is assessed for validity through relevant visualization and biological checks (Figure
2.1.6). If validation is unsatisfactory and technical variation is still present, this process is iterated.
2.1.1 Technical quality control flags
The first step in quality control is an assessment of the assay quality. nSolver provides several
quality control (QC) flags to assess the quality of the data for imaging, binding density, linearity of the
positive controls, and limit of detection. The definition and implementation of thess QC flags are
summarized in detail in the nSolver30 and NanoStringNorm31 documentation. Here, we mark any
sample that is flagged in at least one of these four QC assessments as technical quality control. We
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1. Data familiarization
• Determine limit of detection.
• Determine raw median expression per sample.
2. Technical quality control
• Using nSolver Functions: Flag samples with Imaging, Binding Density, Positive Control
Linearity, and Limit of Detection QC flags.
• Using Endogenous Genes: Flag samples with high proportions of endogenous genes
below the limit of detection (LOD)
• Using Housekeeping Genes: Flag samples with high proportions of housekeeping genes
below the LOD.
3. Identify housekeeping genes for normalization
• Assess expression of housekeeping genes across biological variables.
• Flag housekeeping genes frequently detected below the LOD.
4. Pre-normalization data visualization
• Create RLE plots/principal component plots to visually inspect flagged samples and 
identify outliers indicative of sample/assay-level failure.
• Assess variation across technical and experimental variables
5. RUVSeq normalization
• Perform upper quartile normalization (Bullard 2010)
• Perform normalization with RUVg (Risso 2014)




• Create RLE plots/principle component plots
• Assess variation across technical variables
6b. Biological checks




Figure 2.1: Graphical summary of both nSolver and RUVSeq normalization pipelines. The quality con-
trol and normalization process starts with familiarization with the data (Step 1) and technical quality
control to flag samples with potentially poor quality (Step 2). After a set of housekeeping genes are
selected (Step 3), important unwanted technical variables are also investigated through visualization
techniques (Step 4). Problematic samples (e.g. those that are flagged multiple times in technical qual-
ity control checks) are excluded. Next, the data is normalized using upper quartile normalization and
RUVSeq (Step 5), and the normalized data is visualized to assess the removal of unwanted technical
variation and retention of important biological variation (Step 6). Steps 3—6 are iterated until technical
variation is satisfactorily removed, changing the set of housekeeping genes or the number of dimen-
sions of unwanted technical variation (k) estimated using RUVSeq. This data can then be used for
downstream analysis (Step 7).
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use these QC flags in both nSolver normalization and RUVSeq normalization to indicate samples that
may be of poor quality.
2.1.2 Housekeeping gene assessment
Next, we consider the genes on the nCounter assay that can potentially serve as housekeepers in
nSolver- or RUVSeq-normalization. Housekeeping genes serve two purposes: (1) for QC purposes to
remove samples with overall poor quality and (2) to use for assessing the amount of technical variation
and further normalization. There are differences in the definition of housekeeping genes (or negative
control probes) between the nSolver and RUVSeq-based processes27–30. We define a good
housekeeping gene for nCounter expression as one that has little-to-no variability across all treatment
conditions and is not expressed below the limit of detection in samples that pass QC. NanoString
further suggests that ideal housekeeping genes are highly expressed, have similar coefficients of
variation, and have expression values that correlate well with other housekeeping genes across all
samples. Because of these definitions, these targets will ideally vary only due to the level of technical
variation present. To assess the potential for housekeeping correction to introduce bias, housekeeping
genes were assessed for differential expression across a primary biological covariate of interest
(estrogen receptor status in CBCS, tumor stage in the kidney and bladder cancer data, and treatment
groups in Sabry et al) using negative binomial regression on the raw counts from the MASS package96.
Genes with Benjamini-Hochberg1 FDR-adjusted P < 0.05 were flagged, as their association with the
outcome of interest may lead to removal of biological variance due to the primary outcome of interest.
2.1.3 Below limit of detection (LOD) quality control
Lastly, as samples with high proportions of both endogenous and housekeeping genes below the
limit of detection (LOD) may be indicative of reduced assay or sample quality, we define another QC
flag: the number of genes measured at below the LOD per sample. Here, we define the per-sample
limit of detection as the mean of the counts of negative control probes for that given sample. We
further assessed the percent of counts below the LOD in the housekeeping genes per sample as an
added QC step to flag both poor quality samples and poor housekeeping genes. Samples were
flagged if they have more than one housekeeping gene missing and a median percent below LOD in
the endogenous genes greater than the 75th percentile of the samples with all housekeeping genes
present. Based on the age of samples and the level of degradation detected, this per-sample LOD can
be tuned. For example, the LOD can be shifted by multiples of the standard deviation to allow for more
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liberal or conservative cutoffs. We further assessed the percent of counts below the LOD in the
housekeeping genes per sample as an added QC step to flag both housekeeping genes and samples
with high proportions of below the LOD. For a given sample, an inflated proportion below the LOD in
housekeeping genes may indicate degradation of the sample, especially when it correlates with a high
proportion below the LOD in endogenous genes.
2.2 Normalization of mRNA expression
2.2.1 Background correction with nSolver
NanoString whitepapers and guidelines suggest background corrections30,31 by either subtraction
or thresholding for an estimated background noise level for experiments in which low expressing
targets are common, or when the presence or absence of a transcript has an important research
implication29,31. We believe that the datasets we consider in this work do not fall under this criterion,
and accordingly, we do not background correct by either thresholding or subtraction. However, we
contend that this step may introduce bias in most analyses conducted on NanoString data and should
be generally avoided, as Freytag et al and Irizarry et al point out97,98.
Background thresholding led to increased per-sample variance while per-sample medians
remained relatively similar (Supplemental Figure S1A). The distributions of per-sample median
expression values were more right-skewed (greater mean than median) when using background
thresholding prior to normalization compared to not using background thresholding (Supplemental
Figure S1B). Based on this analysis, we did not perform background correction prior to normalization
for all cohorts analyzed.
2.2.2 Positive control and housekeeping gene-based normalization with nSolver
For nSolver normalization, the arithmetic mean of the geometric means of the positive controls for
each lane is computed and then divided by the geometric mean of each lane to generate a
lane-specific positive control normalization factor30,31. The counts for every gene are then multiplied
by its lane-specific normalization factors. To account for any noise introduced into the nCounter assay
by positive normalization, the housekeeping genes are used similarly as the positive control genes to
compute housekeeping normalization factors used to scale the expression values30,31. NanoString
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also flags samples with large housekeeping gene scaling factors (we call this a housekeeping QC flag)
and large positive control spike-in scaling factors (positive QC flag).
2.2.3 RUVSeq normalization pipeline
After quality control and housekeeping assessment, we alternatively also started the
RUVSeq-based normalization process, an alternative approach to nSolver normalization (see Figure
2.1). We rescaled distributional differences between lanes with upper-quartile normalization99.
Unwanted technical factors were estimated in the resulting gene expression data with the RUVg
function from the RUVSeq Bioconductor package27,29. RUV-III has been created specifically for
normalization of NanoString data with technical replicates28; however, as the datasets we discuss
here do not have technical replicates, we proceeded with RUVg. Unwanted variation was estimated
using the distribution of the endogenous housekeeping genes not associated with the outcome of
interest on the NanoString gene expression panel. We removed k dimensions of unwanted variation
(varied by dataset) from the variance-stabilized transformed-scaled counts of gene expression
data100,16. We lastly used relative log-expression (RLE) plots and principal component analysis to
detect systemic deviation across various technical and biological groups and any potential outliers.
2.2.4 Alternative normalization methods for benchmarking
Using CBCS data, we compared the normalized datasets from nSolver, RUVSeq29,
NanoStringDiff33, and RCRnorm101 with the raw data through visualization methods outlined above
(Figure 2.1.1 to 2.1.4, RLE plots and scatter plots of principal components over important technical
and biological sources of variation). Details about these methods are provided in Supplemental Table
S1.
2.3 Results
We evaluated the ability of normalization methods to remove technical variation while retaining
biologically meaningful variation across four cohorts of differing sample size and varying sources of
technical bias. Known sources of technical variation included age of sample (study phase) and
different study sites. The cohorts varied in preservation methods; two cohorts used fresh-frozen
specimens, while two used archival FFPE specimens. The number of genes measured for both
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endogenous genes and housekeeping genes also varied by study. In addition, some studies used
validated and optimized code sets for specific gene signatures versus a more general code set.
In cohorts with large technical biases, RUVSeq provided superior normalization with more robust
removal of technical variation and provided stronger biological associations compared to other
normalization methods. In two of the datasets, we found that downstream analyses performed on data
normalized with nSolver and RUVSeq detected substantially different biological associations.
However, when few strong technical biases were present or if a validated and optimized code set (e.g.
PAM50 genes) was used, nSolver and RUVSeq performed comparably.
2.3.1 Case study: targeted panel from the Carolina Breast Cancer Study (CBCS)
The Carolina Breast Cancer Study (CBCS) is a multi-phase cohort of women with breast cancer
in North Carolina. Samples were collected during three study phases: Phase 1 (1993-1996), Phase 2
(1996-2001), and Phase 3 (2008-2013). Paraffin-embedded tumor blocks were reviewed and assayed
for gene expression using the NanoString nCounter system as discussed previously24,102. Study
phase gives the relative age of the tumor block. In total, 1,649 samples from patients with invasive
breast cancer from CBCS, across all three study phases, were analyzed on a custom panel of 417
genes. All assays were performed in the Translational Genomics Laboratory (TGL) at the University of
North Carolina at Chapel Hill (UNC). After quality control and normalization, 1,264 samples remained
in the nSolver-normalized data, and 1,219 samples remained in the RUVSeq-normalized data. This
dataset was also used to benchmark against NanoStringDiff33 and RCRnorm101, using the same
1,264 samples in the nSolver-normalized set.
2.3.1.1 Quality assessment of expression levels using LOD of housekeeping genes
We used the housekeeping genes to assess if the lack of expression of endogenous genes was
due to biology or due to technical failures. We compared the level of missing endogenous genes in
samples with all housekeeping genes present to those with increasing number of housekeeping genes
below LOD. There was a strong positive correlation for increasing proportions of genes below the LOD
in both the endogenous and housekeeping genes (Figure 2.2A and Supplemental Figure S1).
Samples with higher numbers of genes below the LOD were from earlier phases of CBCS (i.e. Phase
1 from 1993-1996 and Phase 2 from 1996-2001), and thus associated with sample age (Figure 2.2A
and Supplemental Figure S2). Samples with a higher proportion of endogenous genes below the
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) Percent of silhouette values > 0
Figure 2.2: Quality control and normalization validation in CBCS. (A) Boxplot of percent of endogenous
genes below the limit of detection (LOD) (Y -axis) over varying numbers of the 11 housekeeping genes
below LOD (X-axis), colored by CBCS study phase. Note that the X-axis scale is decreasing. (B) Kernel
density plots of deviations from median per-sample log2-expression from the raw, nSolver-, RUVSeq-,
NanoStringDiff-, and RCRnorm-normalized expression matrices, colored by CBCS study phase. (C)
Plots of the first principal component (X-axis) vs. second principal component (Y -axis) colored by
estrogen receptor subtype of the raw, nSolver-, RUVSeq-, NanoStringDiff-, and RCRnorm-normalized
expression data. (D) Violin plots of the distribution of per-sample silhouette values, as calculated to
study phase, using raw, nSolver-, RUVSeq-, NanoStringDiff-, and RCRnorm-normalized expression.
The boxplot shows the 25% quartile, median, and 75% quartile of the distribution, and the plotted triangle
shows the mean of the distribution.
29
2.3.2 Evaluation of normalization methods
We benchmarked RUVSeq and nSolver with two other normalization methods, NanoStringDiff33
and RCRnorm101. We observed differences across the four normalization strategies (described in
Supplemental Table S1), namely greater remaining technical variation using nSolver and
NanoStringDiff than RCRnorm and RUVSeq (Figure 2.2B-D). A large portion of the variation in the
raw expression could be attributed to study phase (Supplemental Figure S4A). While all methods
reduced study phase associated variation compared to the raw data, there were considerable
differences in the deviations from the median log-expressions in the nSolver- and
NanoStringDiff-normalized expression that are not present in the RUVSeq- and RCRnorm-normalized
data (Figure 2.2B). The nSolver and NanoStringDiff methods retained technical variation, either not
fully corrected or re-introduced during the nSolver normalization process.
We examined the ability of each normalization method to retain biological variation. Estrogen
Receptor (ER) status is one of the most important clinical and biological features in breast cancer and
is used for determining course of treatment103,104. ER status drives many of the molecular
classification105–107 and even drives separate classification of breast tumors in TCGA’s pan-cancer
analysis of 10,000 tumors108. In the raw expression, variation due to ER status was captured in PC2
rather than PC1 (study age); however, after RUVSeq-normalization, ER status was reflected
predominantly in PC1 (Figure 2.2C). In the nSolver-, NanoStringDiff-, and RCRnorm-normalized data,
ER status was shared between PC1 and PC2, suggesting that unresolved technical variation was still
present. RUVSeq demonstrated effective removal of technical variation and boosting of the true
biological signal. The PAM50 molecular subtypes109, which are also linked with ER status, were also
clearly separated by PC1 for RUVSeq-normalized data, but this was not the case for nSolver-,
NanoStringDiff-, or RCRnorm-normalization (Supplemental Figure S4B). These results suggest that
RUVSeq-normalization best balances the removal of technical variation with the retention of important
axes of biological variation, with RCRnorm showing better performance than nSolver and
NanoStringDiff, but not superior to RUVSeq. A significant disadvantage of RCRnorm is its
computational cost: RCRnorm was unable to run on the CBCS dataset (N = 1278 after QC) on a
64-bit operating system with 8 GB of installed RAM, requiring RCRnorm-normalization to be performed
on a high-performance cluster. We summarize the maximum memory used by method in CBCS in
Supplemental Table S1.
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We used silhouette width to assess extent of unwanted technical variation from study phase






where ai is the mean distance between sample i and all other samples in the same study phase
and bi is the smallest mean distance of sample i to all points in any other study phase. Larger positive
silhouette values indicate within-group similarity (i.e. samples clustering by study phase). Per-sample
silhouettes across the alternatively normalized datasets showed that RUVSeq best addressed the
largest source of technical variation identified in the raw data (Figure 2.2D; Supplemental Figure
S5A) while also not removing a significant portion of biological variation (Supplemental Figure S5B).
NanoStringDiff also demonstrated less similarity of samples across study phase similar to RUVSeq but
removed biologically relevant similarity of samples grouped by ER status. Due to the performance of
NanoStringDiff and computational limitations of RCRnorm, for subsequent analyses and datasets, we
only illustrate differences between nSolver- and RUVSeq-normalized data.
2.3.3 Genomic analyses and expression profiles across normalization methods
We evaluated the impact of normalization choice on downstream analyses including eQTLs,
PAM50 molecular subtyping, known expression patterns, and similarity to RNA-seq data. In a full
cis-trans eQTL analysis accounting for race and genetic-based ancestry, we found considerably more
eQTLs using nSolver as opposed to RUVSeq, thresholding at nominal P < 10−3 (2,050 vs. 1,143).
We identified strong cis-eQTL signals in both normalized datasets; however, stronger FDR values
were identified with RUVSeq (Figure 2.3A, densely populated around the 45-degree line). We
observed considerably more trans-eQTLs using nSolver, including a higher proportion of trans-eQTLs
across various FDR-adjusted significance levels (Figure 2.3B; Supplemental Figure S8). We
suspected that spurious trans-eQTLs may have resulted from residual technical variation in expression
data that was confounded with study phase, subsequently being identified as a QTL due to ancestry
differences across study phase. In cross-chromosomal trans-eQTL analysis, distributions of absolute
differences in minor allele frequency (MAF) for trans-eSNPs across women of African and European
ancestry were wide for both methods (Supplemental Figure S8). However, we observed substantially
more trans-eSNPs with moderate absolute MAF differences across study phase with nSolver,
compared to RUVSeq. This provides some evidence for the presence of residual confounding
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technical variation in the nSolver-normalized expression data leading to spurious trans-eQTL results
(with a directed acyclic graph for this hypothesis in Supplemental Figure S9), though we cannot
confirm this with eQTL analysis alone.
We compared each normalization method for the ability to classify breast cancer samples into
PAM50 intrinsic molecular subtype using the classification scheme outlined by Parker et al109. Our
PAM50 subtyping calls were robust across normalization methods with 91% agreement and a Kappa
of 0.87 (95% CI (0.85, 0.90)) (Supplemental Figure S6). Among discordant calls, approximately half
had low confidence values from the subtyping algorithm, and half had differences in correlations to
centroids less than 0.1 between the discordant calls. Most of these discordant calls were among
HER2-enriched, luminal B and luminal A subtypes, which are molecularly similar111.
We observed noticeable differences between the RUVSeq- and nSolver-normalized gene
expression when visualized after hierarchical clustering via heatmaps, similar to the principal
component analysis. Using this method, we identified 14 additional samples with strong technical
errors in the nSolver-normalized data not previously marked by QC flags (Supplemental Figure S10),
emphasizing the need for post-normalization data visualization. In early breast cancer clustering
papers, the first major division was by ER status separating basal-like and HER2-enriched molecular
subtypes (predominantly ER-negative) from luminal A and B molecular subtypes (predominantly
ER-positive)109. This pattern was observed in RUVSeq-data but only partially preserved with nSolver
normalization (Supplemental Figure S10). Rather, nSolver data clustering was driven by a
combination of ER status and study phase. Study phase dominated two of the groups and were
formed by Phase 1 and Phase 3 samples, respectively—samples with a 10+ year difference in age.
Lastly, we compared normalization choices for NanoString data to RNA-seq data performed on
the same samples. CBCS collected RNA-seq measurements for 70 samples that have data on a
different nCounter codeset (162 genes instead of 417) and RNA-seq normalized using standard
procedures. A permutation-based test of independence using the distance correlation112,113 revealed
that the distance correlation between the RNA-seq and nSolver data was small and near 0 (distance
correlation = 0.051, P = 0.24) while the distance correlation between the RNA-seq and RUVSeq- data
was larger (distance correlation = 0.36, P = 0.02). The permutation-based test rejected the null
hypothesis of independence (distance correlation of zero for unrelated datasets) between
RUVSeq-normalized nCounter data and RNA-seq data but fails to reject the null hypothesis for
nSolver-normalization nCounter and RNA-seq data. We conclude that RUVSeq produced normalized
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Figure 2.3: eQTL analysis in CBCS. (A) Cis-trans plots of eQTL results from nSolver-normalized (left)
and RUVSeq-normalized data with chromosomal position of eSNP on the X-axis and the transcription
start site of eGene on the Y -axis. Points for eQTLs are colored by FDR-adjusted P -value of the associ-
ation. The dotted line provides a 45-degree reference line for cis-eQTLs. (B) Number of cis- (left) and
trans-eQTLs (right) across various FDR-adjusted significance levels. The number of eQTLs identified
in nSolver-normalized data is shown in red and the number of eQTLs identified in RUVSeq-normalized
data is shown in blue.
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2.3.4 Case study: differential expression analysis in natural killer cells
We looked at the impact of the two normalization methods in a small cohort (N = 12) on DE
analysis across natural killer (NK) cells primed for tumor-specific cells and cytokines from Sabry et al4.
RLE plots before and after normalization showed minor differences between the two normalization
methods (Supplemental Figure S10).
Using DESeq216, we identified genes differentially expressed in NK cells primed by CTV-1 or IL-2
cytokines compared to unprimed NK cells at FDR-adjusted P < 0.05. The two normalization methods
led to a different number of differentially expressed genes with a limited overlap of significant genes by
both methods (Figure 2.4A). The raw P -value histograms from differential expression analysis using
nSolver-normalized expression exhibited a slope toward 0 for P -values under 0.3, which can indicate
issues with unaccounted-for correlations among samples114, such as residual technical variation. The
distributions of P -values using the RUVSeq-normalized data were closer to uniform throughout the
range [0, 1] for most genes (Figure 2.4B). While the log2-fold changes were correlated between the
two normalization procedures, the genes found to be differentially expressed only with
nSolver-normalized data tended to have large standard errors with RUVSeq-normalized data and
therefore not statistically significant using RUVSeq (Figure 2.4C). These differences in DE results
emphasize the importance of properly validating normalization prior to downstream genomic analyses.
2.3.5 Further case studies
2.3.5.1 Case study: bladder cancer gene expression
RUVSeq reduced technical variation (study site) while maintaining the biological variation (tumor
grade). RUVSeq data showed the most homogeneity in per-sample median deviation of
log-expressions compared to raw and nSolver data (Figure 2.5A). The first principal component of
nSolver data had significant differences by study sites, which was not present in RUVSeq data (Figure
2.5B). In addition, there was a stronger biological association with tumor grade in the first principal
component of expression using RUVSeq data (Figure 2.5C).
2.3.5.2 Case study: kidney cancer gene expression
We only found subtle differences in the deviations from the median expression between the
normalization procedures for the kidney cancer dataset (Figure 2.6A). This cohort did not have the







































































































































































































Figure 2.4: Differential expression analysis from Sabry et al4 (A) Venn diagram of the number of differ-
entially expressed genes using nSolver-normalized (blue) and RUVSeq-normalized data (red) across
comparisons for IL-2-primed (top) and CTV-1-primed NK cells (bottom). (B) Raw P-value histograms
for differential expression analysis using nSolver-normalized (blue) and RUVSeq-normalized (red) data
across the two comparisons. (C) Scatterplots of log2-fold changes from differential expression analysis
using RUVSeq-normalized data (X-axis) and nSolver-normalized data (Y-axis) for any gene identified
as differentially expressed in either one of the two datasets. Points are colored by the datasets in which
that given gene was classified as differentially expressed. The size of point reflects the standard error
of the effect size as estimated in the RUVSeq-normalized data. X = 0,Y = 0, and the 45-degree lines

































































































































































































































































































































































































































































































































Figure 2.5: Normalization differences in bladder cancer dataset. (A) RLE plot from bladder cancer
dataset, colored by assay month. (B) Boxplot of first principal component of expression by tumor col-
lection site (location) across nSolver- (top) and RUVSeq-normalized (bottom) data. (C) Boxplot of first
principal component of expression by tumor grade across nSolver- (top) and RUVSeq-normalized (bot-
tom) data.
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the RNA came from fresh-frozen material. We evaluated normalization methods on a source of
technical variation, DV300, the proportion of RNA fragments detected at greater than 300 base pairs
as a source of technical variation, and tumor stage as a biological variable of interest. The first two
principal components colored by level of DV300 (Figure 2.6B) and tumor stage (Figure 2.6C) showed
little difference across the two normalization methods. When there were limited sources of technical




Figure 2.6: Equal performance of normalization procedures in kidney cancer dataset. (A) RLE plot of
per-sample deviations from the median for raw, nSolver, and RUVSeq-normalized data. (B) Scatter plot
of the first and second principal component of nSolver- (left) and RUVSeq-normalized (right) expression,
colored by high and low DV300. (C) Scatter plot of the first and second principal component of nSolver-
(left) and RUVSeq-normalized (right) expression, colored by tumor stage.
2.4 Discussion
Proper normalization is imperative in performing correct statistical inference from complex gene
expression data. Here, we outline a sequential framework for NanoString nCounter RNA expression
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data that provides both quality control checks, considerations for choosing housekeeping genes, and
iterative normalization with biological validation using both NanoString’s nSolver software30,31 and
RUVSeq29. We show that RUVSeq provided a superior normalization to nSolver on three out of four
datasets by more efficiently removing sources of technical variation, while retaining robust biological
associations. We also benchmark RUVSeq-normalization with two other normalization methods
implemented in R and show that RUVSeq outperformed all methods in reducing technical variation.
We observed that normalization methods were sensitive to the quality and the set of
housekeeping genes. Several genes thought to behave exclusively in a “housekeeping” fashion in fact
associate with biological variables under certain conditions115 or across different tissue types116. A
careful validation of housekeeping gene stability on a case-by-case basis and separately for new
studies, considering both technical and biological sources of variation in each dataset, is therefore
imperative for an optimized normalization procedure.
We developed a quality metric to assess sample quality: samples with high proportions of genes
detected below the LOD in both endogenous genes and housekeepers were indicative of either
low-quality samples or reduced assay efficiency. Sample age was correlated with higher proportions of
genes below the LOD in both endogenous and housekeeping genes, which was likely due to RNA
degradation over time. We stress that missing counts in endogenous genes alone does not suggest
poor sample quality in the absence of additional QC flags but could represent genes not expressed
and therefore not detected under certain biological conditions or cell types. An example includes using
an immuno-oncology gene panel in a tumor sample with little to no immune cell infiltration. Conversely,
many samples with counts below the LOD in both endogenous genes and housekeepers had
additional quality control flags including those derived from nSolver’s assessment of data quality. We
excluded these samples for analysis in both the nSolver- and RUVSeq-based procedures.
nSolver-normalized data was prone to residual unwanted technical variation when there were
known technical biases, such as in CBCS and the bladder example. We checked for known biological
associations that are intrinsic to the sample, as in eQTL analysis, to judge the performance of the
normalization process117,70. A full cis-trans eQTL analysis using nSolver- and RUVSeq-normalized
data showed a strong cis-eQTL signal in data from both normalization methods. We found significantly
more trans-eQTLs with the nSolver-normalized data. However, many of the trans-eSNPs for the loci
found with nSolver-normalized data tended to have moderate MAF differences across phase, leading
us to suspect they were spurious associations driven by residual technical variation in gene
expression. Such spurious associations from population stratification have been described in many
previous studies of eQTL analysis118–121.
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The choice of normalization procedure is less of a concern in cohorts with minimal sources of
technical variation or in nCounter targeted gene panels that have been optimized for robust
measurement across preservation methods. In the CBCS breast cancer cohort, we identified
significant differences in gene expression between normalization methods across the entire gene set
(417 total genes). However, PAM50 subtyping was robust across the two normalization procedures.
The genes in the PAM50 classifier were selected due to their consistent measurement in both FFPE
and fresh frozen breast tissues109, suggesting that robustly measured genes may be less affected by
different normalization procedures. Furthermore, we see minimal differences in residual technical
variation in the kidney cancer dataset and the Sabry et al dataset, both of which were measured on
either robustly validated genes or nCounter panels. The kidney cancer example had newer,
fresh-frozen specimens that were profiled using a small and well-validated set of genes important in
that cancer type. This dataset gives an opportunity to stress the importance of the general principles of
normalization: as Gagnon-Bartsch et al and Molania et al recommend27,29, normalization should be a
part of scientific process and should be approached iteratively with visual inspection and biological
validation to tune the process. One normalization procedure is not necessarily applicable to all
datasets and must be re-evaluated on each dataset.
In conclusion, we outline a systematic and iterative framework for the normalization of NanoString
nCounter expression data. Even without background correction, a technique which has been shown to
impair normalization of microarray expression data98,97, we believe that relying solely on positive
control and housekeeping gene-based normalization may result in residual technical variation after
normalization. Here, we show the merits of a comprehensive procedure that includes sample quality
control checks including the addition of new checks, assessments of housekeeping genes,
normalization with RUVSeq29 and data analysis with popular count-based R/Bioconductor packages,
as well as iterative data visualization and biological validation to assess normalization. Researchers




IES IN BREAST CANCER IN DIVERSE STUDY POPULATIONS
This chapter provides a framework for transcriptome-wide association studies for complex
disease outcomes in diverse study populations using transcriptomic reference data from the Carolina
Breast Cancer Study, a multi-phase cohort that includes an over-representation of African American
women122. We train race-stratified predictive models of tumor expression from germline variation and
carefully validate their performance, accounting for sampling variability and disease heterogeneity, two
aspects that previous TWAS in breast cancer have not considered. This framework shows promise for
scaling up into larger GWAS cohorts for further detection of risk- or outcome-associated loci.
3.1 The Carolina Breast Cancer Study
The Carolina Breast Cancer Study (CBCS) is a population-based study conducted in North
Carolina that began in 1993. Study details and sampling schemes are described in previous CBCS
work122,123. Patients of breast cancer aged between 20 and 74 years were identified using rapid case
ascertainment in cooperation with the NC Central Cancer Registry, with self-identified African
American and young women (ages 20-49) oversampled using randomized recruitment122.
Randomized recruitment allows sample weighting to make inferences about the frequency of subtype
in the NC source population. Details regarding patient recruitment and clinical data collections are
described in Troester et al24.
Date of death and cause of death were identified by linkage to the National Death Index. All
diagnosed with breast cancer have been followed for vital status from diagnosis until date of death or
date of last contact. Breast cancer-related deaths were classified as those that listed breast cancer
(International Statistical Classification of Disease codes 174.9 and C-50.9) as the underlying cause of
death on the death certificate. By the end of follow-up, we identified 674 deaths, 348 of which were
due to breast cancer.
In total, we compiled 3,828 samples with 1,865 self-identified African American (AA) women and
1,963 self-identified white (WW) women from all phases of CBCS with relevant survival and clinical
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variables. All 3,828 samples have associated germline genotype data, measured using the OncoArray
genotyping assay developed by Illumina and the OncoArray Consortium124. This data was imputed
using the October 2014 (v.3) release of the 1000 Genomes Project dataset as a reference panel using
SHAPEIT2 for phasing and IMPUTEv2 for imputation125–128. SNPs with minor allele frequency (MAF)
less than 1% and significant deviations from Hardy-Weinberg equilibrium at P < 10−8 were excluded.
Of these 3,828 samples, we consider 1,199 (621 AA and 578 WW) samples with NanoString
nCounter expression data for subsequent eQTL analysis and training of predictive expression models.
Quality control and normalization was conducted as detailed in Sections 2.1 and 2.2.
3.2 eQTL analysis
Using the 1,199 samples (621 AA, 578 WW) with expression data, we assessed the additive
relationship between the gene expression values and genotypes with linear regression analysis using
MatrixeQTL129, in the following model:
Eg = Xsβs +XCβC + ϵg,
where Eg is the gene expression of gene g, Xs is the vector of genotype dosages for a given SNP
s, C is a matrix of covariates, βs and βC are the effect-sizes on gene expression for the SNP s and the
covariates C, respectively, and ϵ is assumed to be Gaussian random error with mean 0 and common
variance σ2 for all genes g.
We calculated both cis- (variant-gene distance less than 500 kb) and trans-associations between
variants and genes. Classical P -values were calculated for Wald-type tests of H0 : βs = 0 and were
adjusted post-hoc via the Benjamini-Bogomolov hierarchical error control procedure, TreeQTL130. We
conducted all eQTL analyses stratified by race. Age, BMI, postmenopausal status, and the first 5
principal components of the joint AA and WW genotype matrix were included in the models as
covariates in C. Estimated tumor purity was also included as a covariate to assess its impact on
strength and location of eQTLs. Any SNP found in an eQTL with Benajmini-Bogomolov adjust P -value
BBFDR < 0.05 is defined as an eSNP. The corresponding gene in that eQTL is defined as an eGene.
We exclude samples with Normal-like subtype, as classified by the PAM50 classifier, due to generally
low tumor content. We developed a formal quality control procedure to follow-up on significant eQTLs
by define a further MAF cutoff based on additive genotypes (i.e. 0,1, and 2 copies of the minor allele)
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Figure 3.1: CBCS eQTL results across race and compared with GTEx. (A) Cis-trans plot of top eQTL
by gene stratified by self-reported race. Each point represents the top eQTL for a given gene. The color
and size of each point reflects the Benjamini-Bogomolov FDR-adjusted P -value (BBFDR) for that eQTL.
eGenes with BBFDR < 0.01 are labelled. (B) Comparison of effect sizes of eGenes with significant
cis-eQTLs in CBCS (Y-axis) and GTEx (X-axis) over tissue type, stratified by race. eGenes are colored
by the GTEx tissue that shows the largest effect size. GTEx effect sizes on the X-axis are multiplied by
the sign of the correlation between the genotypes of the GTEx and CBCS eSNPs.
42
At a Benjamini-Bogomolov130 FDR-corrected P -value (BBFDR < 0.05) and after quality control,
we identified 266 cis-eQTLs and 71 trans-eQTLs in the AA sample across 32 eGenes, and 691
cis-eQTLs and 15 trans-eQTLs in the WW sample across 24 eGenes. Of these eGenes, 4 are in
common across race: PSPHL, GSTT2, EFHD1, and SLC16A3. Expressions of PSPHL and GSTT2
have been previously reported to be governed by respective cis-deletions and serve as distinguishing
biomarkers for race131–134. The majority of significant eQTLs in both the AA and WW samples were
found in cis-association with respective eGenes. However, we saw a higher proportion of significant
trans-eQTLs in the AA sample (Supplemental Figure S12). The locations and strengths of top eQTLs
for all 406 autosomal genes are shown in Figure 3.1A, with minor allele frequencies of significant
eSNPs plotted in Supplemental Figure S13.
3.2.1 Adjustment for tumor purity
Geeleher et al. show that only a third of conventional eQTLs in bulk breast cancer tumor
expression could be attributed to cancer cells in TCGA85. We wished to assess the extent to which
this observation bore out in CBCS. A study pathologist analyzed tumor microarrays (TMAs) from 176
of the 1,199 subjects to estimate area of dissections originating from epithelial tumor, assumed here
as a proxy for the proportion of the bulk RNA expression attributed to the tumor. Using these 176
observations as a training set and the normalized gene expressions as the design matrix, we trained a
support vector machine model tuned over a 10-fold cross-validation135,136. The cross-validated model
was then used to estimate tumor purities for the remaining 1,023 samples from their gene expressions.
In general, we do not see significant differences in the strength and location of significant eQTLs,
as shown in comparative cis-trans plots of all eQTLs across race and adjustment for tumor purity
(Supplemental Figures S13 and S14). For most genes, top eQTL regions with linkage disequilibrium
(LD) support had small differences in strength of effect size (Manhattan plot for a representative gene
shown in Supplemental Figure S13). Adjusting for tumor purity, at BBFDR < 0.05 and after quality
control, we identified 266 cis-eQTLs and 84 trans-eQTLs in the AA sample across 36 eGenes, and
634 cis-eQTLs and 14 trans-eQTLs in the WW sample across 23 eGenes, shown in Supplemental
Figure S14. All WW eGenes, adjusting for tumor purity, are in common with WW eGenes from bulk
tumor expression, and 32 of 36 AA eGenes, adjusting for tumor purity, are in common with AA eGenes
from bulk tumor expression. Top eQTLs for eGenes remain largely the same across adjustment for
tumor purity. Due to limited differences when we adjust for tumor purity, all downstream analyses do
not involve our computational estimate of tumor purity.
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We do not observe the same difference in eQTLs across adjustment for tumor purity as in
Geeleher et al85. The NanoString expression data from CBCS includes only 417 genes, all of which
were selected for the panel because of their involvement in breast cancer tumorigenesis, biology, or
outcome disparities due to race. Furthermore, our normalization procedure involves the RUV method,
which accounts for unwanted technical and biological variation, estimated from the distributions of
housekeeping negative controls with an unsupervised method27,29. We hypothesize that the RUV
method accounts for a significant percentage of the variability from cell-type heterogeneity that may
confound traditional eQTL analysis in bulk tumor RNA expression. Further implementations of
deconvolution algorithms specialized for expression measured for targeted panels of genes, as in
NanoString, would aid in distinguishing the source cell types or tissues for various breast tumor eQTLs.
Accurate bulk expression deconvolution may also be important in future TWAS to consider sources of
variation in tumor expression due to tissue heterogeneity and how deconvoluted tumor expression
signals contribute to outcomes of interest.
We lastly sought to evaluate the source of the significant eQTLs we detect in CBCS. Similarly to
previous pan-cancer gerrmline eQTL analyses137, we cross-referenced eGenes found in CBCS with
eGenes detected in relevant healthy tissues from Genotype-Tissue Expression (GTEx) Project:
mammary tissue (breast), subcutaneous adipose, and EBV-transformed lymphocytes (immune). We
attributed all but 7 of the cis-eGenes from CBCS across both AA and WW women found in GTEx to
one of these three tissue types (Figure 3.1B), with the effect sizes of the top eQTLs for these eGenes
correlating very well between CBCS and GTEx (see Supplemental Figure S17). We also found
adequate overlap of cis-eSNPs in these GTEx tissues and TCGA-BRCA based on the P-value of
SNP-gene association (see Supplemental Figure S18). Note that, in GTEx v7, adipose (N = 298)
has a larger sample size that mammary tissue (N = 183) and lymphocytes (N = 114). We were
unable to replicate CBCS trans-eQTLs in GTEx and TCGA-BRCA138. The majority of CBCS
trans-eQTLs were identified in AA women, and the sample sizes of individuals of African descent is
low in GTEx version 7 and TCGA-BRCA.
3.2.2 Local ancestry adjustment of eQTLs
For cis-eGenes that were identified in only one of AA or WW women, we followed up with a
cis-eQTL analysis adjusted for inferred local ancestry. Reference genotypes were downloaded from
the 1000 Genomes Project version 3 for Utah residents with Northern and Western European ancestry
(CEU) and Yoruban individuals from Ibadan, Nigeria (YRI)125. Phased genotypes from the assumed
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admixed samples from CBCS were then compared to reference genotypes using RFMix v1.5.4 to
estimate the posterior probability of CEU and YRI ancestry at a given haplotype, which is converted to
an estimated dosage of inherited YRI alleles139,140. We then follow Zhong et al’s framework for
adjusting eQTLs by estimated local ancestry141. Briefly, for gene expression g, dosage of SNP of
interest s, covariates XC , and estimated local ancestry l for the given SNP, we first residualize and
scale to zero mean and unit variance g,s, and l by XC . We then fit the following linear model to
estimate the local ancestry-adjusted eQTL effects:
g̃ = s̃+ l̃ + ϵ,
where g̃, s̃, and l̃ are the residualized and scaled gene expression, SNP dosage, and estimated
local ancestry, respectively141.
Overall, we find marginal increase in the strength of association between lead SNP and cis-eGene
using an estimated local ancestry-adjustment over the association measured with a genome-wide
ancestry adjustment. However, we did not observe considerable harmonization of stratified cis-eQTLs
across populations; in general, race-specific, local ancestry-adjusted lead cis-eQTLs in a given
race-stratified sample did not show similar association in the other (Supplemental Figure S16).
It has been shown that, due to allele frequency differences between populations, the underlying
genetic and eQTL architecture for complex traits may not be well-correlated across diverse
populations142,143. Zhong et al shows that incorporating local ancestry helps to better characterize the
heritability of gene expression and complex traits and accurately map genetics associations141.
However, our local ancestry-adjusted cis-eQTLs were not well-correlated across AA and WW women.
Perhaps, the persistence of this difference can be due to the simplicity of the commonly used
assumption that t here are two major source populations of admixture in CBCS samples (i.e. CEU and
YRI). Several genetic studies into the genome-wide and local hereditary of admixed populations in the
United States have shown that migratory patterns greatly inform these patterns of genetic
ancestry144,145. Though this follow-up analysis is beyond the scope of this work, a full cis-trans eQTL
ancestry incorporating local ancestry estimates, as well as an assessment of the impact of local
ancestry adjustment on the portability of our eventual predictive models of tumor expression across
ancestral populations, could reveal insights into the genetic architecture of breast tumor expression
heritability in admixed populations.
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3.3 Predictive models of tumor expression
3.3.1 Race-specific predictive models of tumor expression
Cis-heritability (cis-h2) using genotypes within 500 kb of the gene of interest was estimated using
the GREML-LDMS method, proposed to estimate heritability by correction for bias in linkage
disequilibrium (LD) in estimated SNP-based heritability49. We do not consider the trans components in
heritability estimation. Analysis was conducted using GCTA v.1.92146. Briefly, Yang et al shows that
estimates of heritability are often biased if causal variants have a different minor allele frequency
(MAF) spectrums or LD structures from variants used in analysis. They proposed an LD and
MAF-stratified GREML analysis, where variants are stratified into groups by MAF and LD, and genetic
relationship matrices (GRMs) from these variants in each group are jointly fit in a multi-component
GREML analysis. Mean cis-h2 of the 406 genes is 0.016 (SE = 0.019) in AA women and 0.015
(SE = 0.019) in WW women, as estimated by GREML-LDMS analysis49. For downstream analysis,
we only consider genes with cis-h2 significantly greater than 0 at a nominal P -value less than 0.10
from the relevant likelihood ratio test. Considering only these genes, the mean cis-h2 of genes is 0.049
(SE = 0.016) in AA models and 0.052 (SE = 0.016) in WW models.
We adopt general techniques from PrediXcan and FUSION to estimate eQTL-effect sizes for
predictive models of tumor expression from germline variants42,3. First, gene expressions were
residualized for the covariates C included in the eQTL models (age, BMI, postmenopausal status, and
genotype PCs) given the following ordinary least squares model:
Eg = XCβC + ϵg.
We then consider downstream analysis on Ẽg ≡ Eg −Xcβ̂C .
For a given gene g, we consider the following linear predictive model:
Ẽg = Xgwg + ϵg,
where Ẽg is the gene expression of gene g, residualized for the covariate matrix XC , Xg is the
genotype matrix for gene g that includes all cis-SNPs for gene g (within 500 kb of either the 5’ or 3’ end
of the gene) and all trans-eQTLs with BBFDR < 0.01, wg is a vector of effect-sizes for eQTLs in Xg,
and ϵg is Gaussian random error with mean 0 and common variance for all g.
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We estimate wgwith the best predictive of three schemes: (1) elastic-net regularized regression
with mixing parameter α = 0.5 and λ penalty parameter tuned over 5-fold cross-validation42,3,48, (2)
linear mixed modeling where the genotype matrix Xg is treated as a matrix of random effects and ŵg is
taken as the best linear unbiased predictor (BLUP) of wg, using rrBLUP147, and (3) multivariate linear
mixed modeling as described above, estimated using GEMMA v.0.97148.
In these models, the genotype matrix Xg is pruned for LD, prior to modeling using a window size
of 50, step size of 5, and LD threshold of 0.5 using PLINK v.1.90b3149 to account for redundancy in
signal. We believe that our LD-pruning thresholds and window sizes are not stringent150 and noticed
that LD-pruning the design matrix of genotypes lead to greater cross-validation R2 (Supplemental
Figure S19). The final vectors ŵg of effect-sizes for each gene g are estimated by the estimation
scheme with the best 5-fold cross-validation performance. All predicted models are stratified by race,
i.e. an individual model of tumor expression for AA women and WW women for each gene g.
To impute expression into external cohorts, we then construct the germline genetically-regulated
tumor expression GReXg of gene g given ŵg in the predictive model as follows:
GReXg = Xg,newŵg,
where Xg,new is the genotype matrix of all available SNPs in the feature set of ŵg in a GWAS
cohort.
Of the predictive models built for these genes, 125 showed a five-fold cross-validation prediction
performance (CV R2) of at least 0.01 (10% Pearson correlation between predicted and observed
expression with P < 0.05) in one of the two predictive models. Figure 2.2A shows the CV R2 of these
153 genes across race. The median CV R2 for the 153 genes was 0.011 in both AA and WW women.
Cis-h2 and CV R2 are compared in Supplemental Figure S20. We also show mean CV and external
validation (EV) R2 with quantiles for prioritized genes across the training set and both external test
sets in Supplemental Table S2.
Based on model performance in CBCS, we selected 46 genes in AA women and 57 genes in WW
women for association analyses between predicted tumor gene expression and breast cancer survival,
using data from all patients from CBCS with genotype data. These genes were selected because they
showed a CV R2 > 0.01 and cis-h2 ≥ 0 with nominal P < 0.10 in a given race strata.























































































































































































































































































































10−10 10−8 10−6 10−4 10−2

































































10−6 10−5 10−4 10−3 10−2 10−1


















































































































































































































































10−5 10−4 10−3 10−2 10−1
R2 (WW model/AA sample)
R










R2 ≥ 0.01 ● ● ●AA (16) Both (2) Neither (32)
E
Figure 3.2: Predictive performance of models in cross-validation, external validation, and across race.
(A) Comparison of cross-validation R2 across race in CBCS. Cross-validation R2 in CBCS WW women
(X-axis) and CBCS AA women (Y-axis) for each of the 151 analyzed genes. Scales are logarithmic.
Dotted lines represent R2 = 0.01. Colors represent the model with which a given gene can be predicted
at R2 > 0.01. (B) Cross-validation R2 in CBCS (X-axis) and square Spearman correlation between
observed expression and GReX in TCGA-BRCA (Y-axis) in AA sample (left) and WW sample (right).
Pearson correlations between R2 calculated on the raw scale. R2 are plotted on the log-scale. (C)
Comparison of validation R2 across race in TCGA for 149 analyzed genes found in TCGA expression
data. (D) Comparison of validation R2 across race in held-out CBCS samples for 50 analyzed genes. (E)
Comparison of R2 of genes in TCGA AA sample imputed from WW models (X-axis) and the AA models
(Y-axis). (F) Comparison of R2 of genes in held-out CBCS AA sample imputed from WW models (X-axis)
and the AA models (Y-axis)
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3.3.2 Evaluation of predictive models in independent data
Predictive performance was strong across race and biological and molecular subtype in two
external samples: The Cancer Genome Atlas (TCGA) and a held-out CBCS sample set. We defined
the imputed expression of a given gene in an external cohort as the GReX, or the germline-genetically
regulated tumor expression, of that gene.
The first sample is derived from TCGA breast tumor tissues with 179 AA and 735 WW women.
We compared predictive performance by calculating an external validation R2 (EV R2) with squared
Spearman correlations. Of the 151 genes modeled in CBCS training data with significant cis-h2, 149
genes were measured via RNA-seq in TCGA. A comparison of predictive performance in TCGA for
these 149 genes is shown in Figure 3.2, showing adequate performance in AA women (33 genes with
EV R2 > 0.01) and poor performance in WW women (7 genes with EV R2 > 0.01). The top predicted
gene in cross-validation from CBCS for both races, PSPHL, was not present in the TCGA normalized
expression data and could not be validated. Another top cross-validated gene, GSTT2, was present in
TCGA expression data and was validated as the top genetically predicted gene in TCGA by EV R2.
We also imputed expression into entirely held-out samples from CBCS data (1,121 AA and 1,070
WW women) that have gene expression for a subset of the genes (166 of 417 genes) in the CBCS
training set. These samples were largely derived from Phases I and II of CBCS. A comparison of
imputation performance in CBCS for 50 genes (genes with significant cis-h2 in CBCS training set) is
shown in Figure 3.2C, showing adequate performance in both AA and WW women (18 and 15 genes
with EV R2 > 0.01 in AA and WW women).
Predictive models are not applicable across race We find that the predictive accuracy of most
genes was lower when expression was imputed in AA women using models trained in the WW sample.
We employed the WW predictive models to impute expression into AA samples from TCGA and
held-out CBCS data. We compare the performances of the WW model and AA model in the AA sample
in Figure 3.2D (TCGA) and 3.2E (CBCS). In held-out CBCS samples, with the WW model, we could
only predict PSPHL and GSTT2 at R2 > 0.01 in the AA sample, as the expression of these genes is
modulated mostly by strongly associated cis-eSNPs. In TCGA, our WW models performed adequately
in AA women, though the WW models predicted fewer genes at R2 > 0.01 than the AA models.
3.3.3 Evaluation of predictive performance across subtype
While predictive accuracy of expression models was stable across datasets, there was greater
heterogeneity across biological and molecular subtype. In part, this is due to small sample sizes within
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Figure 3.3: Predictive performance of key genes, accounting for sampling variability. Validation R2
across PAM50 molecular subtype and estrogen receptor status, stratified by race, for example genes
with highly variable R2 in TCGA (A) and held-out CBCS (B). Squared Spearman correlation (Y-axis),
denoted R2, between observed and predicted gene expression is plotted for different genes (X-axis),
stratfied by PAM50 subtype and estrogen receptor status. Points are colored and shaped according to
subtype. Error bars provide 90% confidence intervals inverted from the corresponding permutation test.
race and subtype-specific strata. Upon first inspection, we see vast differences in the performance of
our models across subtype (Supplemental Figure S21), with a large majority of genes performing at
EV R2 > 0.01 in rarer subtypes, like HER2-enriched breast cancers. However, we recognized sample
sizes in the TCGA validation set were relatively small, especially when considering AA women and
women of certain subtype, e.g. as low as 16 AA women with HER2-enriched breast cancer. As overall
correlation between observed and imputed expressions are near 0, we sought to account for sampling
variability when imputing into groups of women with such small sample sizes.
To account for sampling variability in calculating correlations in validation cohorts of smaller
sample sizes, we calculated a permutation null distribution for each gene by permuting observed
expressions 10,000 times and calculating a null prediction R2 at each permutation. The sample
validation prediction R2 was compared to this permutation null distribution to generate an empirical
P -value for the sample R2, using Storey’s qvalue package151. We then calculated q-values from these
empirical P -values, controlling for a false discovery rate of 0.051,151. Lastly, we constructed
confidence intervals for R2 by inverting the acceptance region from the permutation test152.
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Supplemental Figure S22 displays q-values in Manhattan form151, showing that the proportion of
genes with EV R2 significantly different from 0 is similar across subtypes. After inverting this
permutation test to construct a confidence interval for EV R2, we find that the EV R2 of several genes
are highly variable across subtypes, even when accounting for differences in sample size and
therefore sampling variation. Key examples of such genes with variable EV R2 across subtypes are
shown in Figure 3.3.
3.4 Association with breast cancer-specific survival
3.4.1 Power analysis of detecting survival associations
Using survSNP153, we generated the empirical power of a GWAS to detect various hazard ratios
with 3,828 samples with 1,000 simulation replicates at a significance level of P = 1.70× 10−8,
corresponding to an FDR-adjusted P = 0.10. We assume an event rate of 10%, a relative allelic
frequency of the risk allele of 0.1 and estimate the 90th percentile of times-to-event as a landmark
time. Similarly, for genes of various cis-h2, we assessed the power of TWAS to detect various hazard
ratios at P = 0.0096 (corresponding to FDR-adjusted P = 0.10) over 1,000 simulation replications from
the empirical distribution function of the GReX of the given gene. It is important to note that the
detectable hazard ratios at 80% for GWAS and TWAS are incomparable due to differences in units of
measure. At 80% power, a GWAS with CBCS data with N = 3,828 is powered to detect a hazard ratio
of breast cancer-specific survival of 1.88 with an addition of one alternative allele in a given SNP. At
80% power, in our study, TWAS can detect hazard ratios 1.186, 1.203, and 1.216 with the GReX of a
gene with cis-h2 ≈ 0.100, 0.055, and 0.030, with respect to an increase of one standard deviation,
respectively (Supplemental Figure S23).
3.4.2 Predicted expression associated with breast cancer-specific survival
Here, we defined a relevant event as a death due to breast cancer. We aggregated all deaths not
due to breast cancer as a competing risk. Any subjects lost to follow-up were treated as right-censored
observations. We estimated the association of GReX with breast cancer survival by modeling the
race-stratified cause-specific hazard function of breast cancer-specific mortality, stratifying on race154.
For a given gene g, the model has form
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Region Gene Hazard Ratio(90% CI)a Z-statistic
a P -valuea GReX R
2
(h2)b
20q13.2 AURKA 0.83(0.73, 0.95) -2.52 1.5× 10
−3 0.021 (0.055)
2p23.1 CAPN13 1.22(1.07, 1.41) 2.76 5.4× 10
−4 0.011 (0.047)
3q26.32 PIK3CA 0.85(0.74, 0.97) -2.34 3.2× 10
−3 0.020 (0.033)
18q21.33 SERPINB5 0.82(0.72, 0.93) -2.85 3.4× 10
−4 0.010 (0.026)
Table 3.1: Genes with GReX found in association with breast cancer-specific survival in AA women.
(a) Hazard ratio and FDR-adjusted 90% confidence intervals, Z-statistic, and P -value of association of
GReX with breast cancer-specific survival. (b) Cross-validation R2 of gene expression in AA models.
λk(t) = λ0(t)exp {GReXgβg + ZCβC} ,
where βg is the effect size of GReXg on the hazard of breast cancer-specific mortality, ZC
represents the matrix of covariates (age at diagnosis, estrogen-receptor status at diagnosis, tumor
stage at diagnosis, and study phase), and βC are the effect sizes of these covariates on survival. λk(t)
is the hazard function specific to breast cancer mortality, and λ0k(t) is the baseline hazard function.
We test H0 : βg = 0 for each gene g with Wald-type tests, as in a traditional Cox proportional hazards
model. We correct for genomic inflation and bias using bacon, a method that constructs an empirical
null distribution using a Gibbs sampling algorithm by fitting a three-component normal mixture on
Z-statistics from TWAS tests of association155. We control of multiple testing burden using the
Benjamini-Hochberg procedure1. For comparison, we run a GWAS to analyze the association
between germline SNPs and breast cancer-specific survival using GWASTools156. We use a similar
cause-specific hazards model with the same covariates as in the TWAS models of association,
correcting for false discovery with the Benjamini-Hochberg procedure.
Of the genes evaluated, we detected 4 whose GReX were associated with breast-cancer specific
survival at FDR-adjusted P < 0.10 in AA women, shown in Table 3.1 and Figure 3.4. We did not
identify any genes with GReX associated with survival in WW women.
An association between increased GReX and increased risk of breast cancer-specific mortality
was identified for CAPN13 (2p23.1). We also found protective associations between higher GReX of
AURKA (20q13.2), PIK3CA (3q26.32), SERPINB5 (18q21.33) and lower risk of breast cancer-mortality
(Figure 3.4C). Of these 4 loci, associations with survival have been reported with SNPs in near the
same chromosomal region as AURKA, PIK3CA, and SERPINB537,157–161, though none of these
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Figure 3.4: GWAS and TWAS results in AA women. (A) Manhattan plot of traditional GWAS on breast
cancer survival. Genomic regions found to be significantly associated with survival in TWAS are repre-
sented in various colors. No SNVs reach Benjamini-Hochberg FDR-adjusted genome-wide significance.
(B) Manhattan plot of TWAS on breast cancer survival. Genomic regions found to be significant at FDR-
adjusted P < 0.10 are highlighted in red. The blue line represents a cutoff of FDR-adjusted α = 0.05
and the dotted black line represents a cutoff of FDR-adjusted α = 0.10. (C) Caterpillar plot of log-hazard
rates with FDR-adjusted 90% confidence levels (X-axis) and genomic position (Y-axis). Results shown
are significant at nominal P < 0.10. Genes highlighted in red represent genes with GReX significantly
associated with survival at FDR-adjusted P < 0.10.
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AURKA rs202100873 87.1 kb 0.84 (0.74, 0.94) 0.027
CAPN13 rs72068647 266.9 kb 1.18 (1.04, 1.33) 0.046
PIK3CA rs66487567 271.9 kb 0.88 (0.78, 1.00) 0.096
SERPINB5 rs376302305 89.4 kb 0.84 (0.75, 0.94) 0.028
Table 3.2: Genes with GReX found in association with breast cancer-specific survival. (a) Top survival-
associated SNP in cis-region of the given gene from GWAS for survival and distance of top cis-SNP
from gene. (b) FDR-adjusted hazard ratio, 90% confidence interval, and P -value for association of
GReX and breast cancer-specific survival, adjusting for adjacent survival-associated SNPs.
reported SNPs were utilized in constructing the GReX of this gene. Furthermore, the GReX of these
four genes were not significantly correlated (P > 0.05 for all pairwise Spearman correlation tests), and
the sets of SNPs used in constructing the GReX of these four genes had no pairwise intersections,
providing evidence that their independent association with breast cancer-specific survival was not a
pleiotropic effect from shared or correlated SNPs.
To determine whether the associations between predicted gene expression and breast
cancer-specific survival were independent of GWAS-identified association signals, we performed
conditional analyses adjusted for the most significant GWAS-identified survival-associated SNPs
closest to the TWAS-identified gene by adjusting the cause-specific proportional hazards model for the
genotype from this SNP. We found that the association for PIK3CA had a small change in effect size
after adjustment for its adjacent survival-associated SNP, and its SNP-adjusted association was
insignificant, while the other genes’ associations remained significant after adjustment (Table 3.2).
This conditional analysis suggests that the GReX of AURKA, CAPN13, and SERPINB5 may be
associated with breast cancer-specific survival independent of the GWAS-identified variant. No
previously reported survival-associated SNPs were found significant at the genome-wide significance
level in our dataset, and none of the closest survival-associated SNPs used in conditional adjustment
were significant (Figure 3.4A). This supports our observation that correctly analyzed TWAS using
relevant tissue gene expression may increase power for association testing.
As we deal with case-only data, we wished to inspect any collider bias that arises from
unmeasured confounders that are associated with both breast cancer incidence and survival (see
Supplemental Figure S24). Since a case-control dataset was not readily available to us to test
associations between the GReX of genes with breast cancer risk, we construct the weighted burden
test, as in FUSION50,3, for the GReX of AURKA, CAPN13, PIK3CA, and SERPINB5 in the GWAS
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summary statistics for breast cancer risk in AA women available from BCAC using the iCOGs dataset
and additional GWAS9,10,162.





where Z is the vector of Z-statistics from iCOGs and W = Σe,sΣ−1s,s such that Σe,s is the
covariance matrix between all SNPs represented in Z and the gene expression of the given gene and
Σs,s is the covariance among all SNPs. We find that none of the GReX of these genes are significantly
associated with breast cancer incidence (Z̃ > 1.96, P < 0.05), suggesting minimal presence of collider
bias in our estimates of association with survival for the GReX of these four genes.
Lastly, we examined the association of the GReX of these four genes with breast cancer-specific
survival in AA women, stratified by estrogen receptor (ER) subtype. We find that overall associations
with survival are often driven by significant associations in a single subtype, though there is evidence
of significant hazardous association in both ER subtypes for CAPN13 (Supplemental Figure S25).
We also did not detect a survival association with the total expression of these 4 genes, as estimated
from breast cancer-specific Cox models (Supplemental Figure S26).
3.5 Discussion
In this paper, we studied the relationship between breast cancer-specific survival and germline
genetics using a TWAS framework. This study is the first systematic TWAS for breast cancer-specific
survival, motivated by a full cis-trans eQTL analysis with one of the largest sample sizes for breast
tumor gene expression in African American women. Our analyses underscore the importance of
accounting for sampling variability when validating predictive models for TWAS and incorporating race
or ancestry in these models, an aspect which confounds naive comparisons involving imputed GReX
across validation sub-groups of different sample size.
Our race-stratified eQTL analysis reveals a strong cis-signal between germline variants and tumor
expression of several genes, that is both differential across race and not exclusively attributable to
healthy breast tissue. We also identified considerably more trans-eQTLs in the AA sample. This result
may reinforce race differences in eQTL architecture as the ratio of detected trans-eQTLs to cis-eQTLs
is not directly linked to sample size44. Differences in allele frequencies and linkage disequilibrium may
contribute to observed differences in cis-eQTLs, as reported by Mogil et al143, and we hypothesize that
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such differences may likewise affect trans-eQTLs. Alternatively, there is a prevailing thought in
literature about trans genetic regulation in admixed populations that the genetic diversity in individuals
of African ancestry leads to added power of eQTL detection68,72.
These race differences in eQTLs motivated the racial stratification of our predictive expression
models72,163. Our models showed strong cross-validation predictive performance in genes with
significant cis-heritability. We also show strong predictive performance in a held-out test set from
CBCS and adequate performance of our WW models in TCGA-BRCA data. We noticed a difference in
EV R2 of our predictive expression models in held-out CBCS samples and TCGA-BRCA. We believe
that this difference can be attributed partly to the difference in genotyping platform between the two
samples (only approximately 85% of SNPs from CBCS represented in TCGA imputed genotype data).
There could also be a lack of cis-heritability of the tumor expression of a majority of genes assayed in
TCGA. For example, Gusev et al. has trained models for gene expression in breast tumors in TCGA;
only 8 of the 417 genes in the CBCS NanoString panel showed significant cis-heritability in their
models3, which we downloaded from the Gusev Lab’s TWAS/FUSION repository. We believe that
predictive performance in TCGA data consistent with CBCS data is a high bar for validation due to both
genotyping and RNA expression platform differences between CBCS (Oncoarray and NanoString) and
TCGA (Affymetrix 6.0 and RNAseq). Reproducible performance in both AA and WW women in our
independent test set from CBCS data suggests that our models are quite robust. Follow-up studies, in
which models of tumor expression are trained in TCGA RNA-seq data and validated in CBCS
NanoString data, could elucidate any discrepancies in predictive performance across platform.
An important implication of our work is the race-specificity of TWAS methods. We find that
expression models trained in WW women generally have poor performance in AA women.
Epidemiological studies have stressed accounting for differences in race by stratification or adjustment
for admixture estimates when constructing polygenic scores164. Our observations suggest that this
epidemiological note of caution extends to creating predictive models for RNA expression. Previous
TWAS studies of breast cancer risk have either used models trained in a sample of predominantly
European ancestries165 or imputed into large cohorts of strictly patients of European descent43.
Hoffman et al. excludes SNPs that were monomorphic in any of the 14 different ancestral populations
they analyze165, though this may not capture all effects of ancestry on genetic regulation of expression,
including the possibility for interactions. We contend that accounting for ancestry or stratifying by race
may be necessary to draw correct inference in large, ancestrally-heterogeneous cohorts.
Our data also suggests that predictive performance may vary by molecular subtype. Previous
groups have shown the predictive utility of catering polygenic risk scores to breast cancer
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subtype166,167, a phenomenon we investigated in our predictive models of tumor expression. Even
after accounting for sampling variability in prediction, we found that several genes have varied degrees
of GReX across subtype and race. Not only does this finding suggest that TWAS predictive models
may need to account for subtype heterogeneity, we reinforce the importance of sampling variability in
validation of predictive models in external cohorts. For example, Wu et al. trained their models in a
relatively small set of 67 women from GTEx and validated their 12,824 models in a validation set of 86
women from TCGA without accounting for sampling variability of predictive performance43. A recent
multi-tissue TWAS in ovarian cancer from Gusev et al. considered validation of their predictive models
by leveraging multiple independent cohorts to assess replication rates168. We recommend such an
approach if multiple independent cohorts are accessible. But, in TWAS evaluation in a single tissue,
studies should place a strong emphasis on validation, accounting for sampling variability of prediction
R2 prior to imputation in larger cohorts.
While many of the most significant findings here are methodological in nature, we also have data
to suggest that four genomic loci in AA women may merit further investigation relative to breast cancer
survival. Two of these 4 TWAS-identified genes have strong functional evidence in breast cancer
survival literature. Mutations in AURKA and PIK3CA have previously been shown to be significantly
associated with breast cancer survival rates157–159. Less is known about the involvement of SERPINB5
and CAPN13 in breast cancer survival, though they have been identified in studies into breast cancer
progression169–173. These four loci merit further studies for validation and functional characterization,
both in large GWAS cohorts and using in vitro studies. We did not observe any significant association
between the total expression of these 4 genes and breast cancer-specific survival. This suggests that
the germline-regulated component of the tumor expression of these genes – a small fraction of the
total expression variation – may be associated with survival outcomes. Numerous factors, including
copy number alterations, epigenetic or post-transcriptional regulation, and exposures and technical
artifacts in measurement contributed to the total expression measured in the tumor. Thus, we do not
expect that significant GReX association implies total expression association, or vice versa.
We also observed that 3 of the 4 associations were driven by very strong effect sizes within a
single subtype. Though we cannot contextualize this result, it highlights an often-overlooked modeling
consideration. In a cohort that is both biologically and ancestrally-heterogeneous, as in CBCS,
investigators should consider modeling choices beyond simple linear adjustments for subtype and race.
Akin to the logic of Begg et al and Martínez et al174,175, it may be prudent in future TWAS to stratify
predictive models on both race and biological subtype to increase power to detect outcome-associated
loci that are strongly present within only one such strata or have heterogeneous effects across strata.
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Since the CBCS analysis was a case-only study, we were wary of potential collider bias by
unmeasured confounders associated with both breast cancer risk and progression176,174,175,177, which
may affect the effect sizes of association between survival and GReX of genes. None of the GReX of
these four genes showed significant transcriptome-wide associations with breast cancer risk in iCOGs
data9,10,162, suggesting that our estimates of association may be free of the collider bias. As
Escala-García et al. highlights, germline variation can affect breast cancer prognosis via tumor
etiology (risk of developing a tumor of a certain subtype), or via mechanisms that are relevant
post-tumorigenesis, such as the cellular response to therapy or the host-tumor micro-environment36.
Ideally, in future TWAS and integrated omic analyses of breast cancer survival, it is prudent to consider
joint models of breast cancer risk and survival to account for pleiotropic effects of germline genotype
and any associations with unmeasurable confounders178.
One limitation of our study is that data on somatic amplifications and deletions were not yet
available for the CBCS cohort we analyzed. Removing the somatic copy number variation signal from
tumor expression profiles may improve our estimates of cis-heritability and perhaps the predictive
performance of our models, though previous TWAS in ovarian cancer shows the effect to be
qualitatively small (approximately less than 2% change in heritability)168. Furthermore, not all genes in
the CBCS NanoString panel have a significant heritable component in expression regulation. These
genes, like ESR1, which have a significant role in breast cancer etiology179, could not be investigated
in our study. Lastly, since CBCS mRNA expression is assayed by the NanoString nCounter system,
we could only analyze 94 aggregated locations on the human transcriptome across race. However, the
NanoString platform allows the CBCS to robustly measure expression from FFPE samples on a
targeted panel of breast cancer and race-related genes, allowing us to leverage the large sample size
from all three phases of the CBCS. One of the greatest strengths of our study is that the CBCS affords
us both a large training and test set of AA and WW women for race-stratified predictive models. Such
data is important in drawing inference in more ancestrally-heterogeneous populations. Accordingly,
the statistical power of our study is high to detect associations for genes with relatively high
cis-heritability. Future studies in large GWAS cohorts, such as those within the Breast Cancer
Association Consortium, will elucidate how to account for ancestral and biological heterogeneity in
detecting survival-associated loci.
We have provided a framework of transcriptome-wide association studies (TWAS) for breast
cancer outcomes in diverse study populations, considering both ancestral and subtype-dependent
biological heterogeneity in our predictive models. From a more theoretical perspective, this work will
inform the utilization of TWAS methods in polygenic traits and diverse study populations, stressing
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rigorous validation of predictive models prior to imputation and careful modeling to capture
associations with outcomes of interest in diverse populations.
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CHAPTER 4: MULTI-OMIC STRATEGIES FOR TRANSCRIPTOME-WIDE ASSOCI-
ATION STUDIES
In this chapter, we outline two extensions to TWAS that draw from ideas of eQTL mediation and
borrowing information from other omics assays. The first extension works backwards from gene
expression by identifying associated, mediating biomarkers (e.g. DNA methylation at relevant loci, or
expression levels of microRNAs and transcription factors) to the gene of interest. We train prediction
models for these mediators using their local SNPs and incorporate their predicted values as fixed
effects in the eventual model of gene expression. The second extension uses mediation analysis to
identify distal eQTLs that show large total mediation effects through local mediators. These prioritized
distal SNPs are upweighted in the eventual gene expression model. Using simulations and data from
the The Cancer Genome Atlas (TCGA)180 and Religious Orders Study and the Rush Memory and
Aging Project (ROS/MAP)181, we show improvements in both in-sample and out-of-sample predictive
performance and power to detect gene-trait associations over local-only models. These Multi-Omic
Strategies for Transcriptome-Wide Association Studies are made available in the R package
MOSTWAS, available freely at www.github.com/bhattacharya-a-bt/MOSTWAS.
4.1 Overview of MOSTWAS
We first outline the two methods proposed in MOSTWAS: (1) mediator-enriched
transcriptome-wide prediction (MeTWAS) and (2) distal eQTL prioritization via mediation analysis
(DePMA). In MOSTWAS, we define that two biological objects (e.g. genetic variant, gene, microRNA,
or CpG site) are local to one another if the genomic distance between them is less than or equal to 0.5
Megabases (Mb). Otherwise, we define the two objects as distal. We adopt local and distal, rather
than cis and trans, to avoid any confusion with biological mechanism.
4.1.1 Heritability estimation
Prior to any predictive modeling, we estimate the heritability of a gene of interest using GCTA
v.1.92146 using all local and distal SNPs considered in either MeTWAS or DePMA. MOSTWAS allows
60
the user the capability to employ the GREML-LDMS method49 to estimate heritability in imputed
genotype panels. MOSTWAS will only proceed to predictive modeling if the gene is heritable from the
specified local and distal SNPs at a user-defined P -value threshold (default P < 0.10 for the relevant
likelihood ratio test).
4.1.2 Mediator-enriched TWAS (MeTWAS)
4.1.2.1 Transcriptomic prediction using MeTWAS
We first describe mediator-enriched TWAS, or MeTWAS, one of the two tools available in the
MOSTWAS R package. Across n individuals, consider the vector YG of expression a gene G of
interest, the matrix XG of local-SNP dosages in a 0.5 Mb window around gene G, and mG mediating
biomarkers that are estimated to be significantly associated with the expression of gene G via a
relevant one-way test of association. These mediating biomarkers could be, for example, DNA
methylation sites, microRNAs, or transcription factors. Accordingly, let the matrix XMj be the
local-SNP dosages in a 500 kilobase (kb) window around mediator j, 1 ≤ j ≤ mG. Furthermore, let
Mj be the intensity of mediator j (i.e. methylation M -value if j is a CpG site or log scale expression if j
is an miRNA or a gene). Prior to any modelling, we scale YG and all Mj , 1 ≤ j ≤ mG to zero mean
and unit variance. We also residualize Mj , 1 ≤ j ≤ mG and YG with the covariate matrix XC to
account for population stratification using principal components of the global genotype matrix and
relevant clinical covariates to obtain M̃j 1 ≤ j ≤ mG and ẼG. The number of genotype principal
components included is user-defined and dependent on the dataset.
Transcriptome prediction in MeTWAS draws from two-step regression, as summarized in Figure
4.1A. First, in the training set for a given training-test split, for 1 ≤ j ≤ mG, we model the residualized
intensity M̃j of training-set specific mediator j with the following additive model:
M̃j = XMj ,trainwj + ϵm, (4.1)
where wj is the effect-sizes of the SNPs in XMj ,train on M̃j in the training set. As in traditional
transcriptomic imputation models42,3, we find ŵm using the method that best predicts expression out of
the following methods: (1) elastic net regression with mixing parameter α = 0.5 and λ tuned over
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Figure 4.1: Modeling schemes for MOSTWAS. (A) Two-step regression scheme in MeTWAS that en-
riches transcriptomic prediction with mediating-biomarkers. (B) Mediation analysis based DePMA pro-
cedure to prioritize distal-eQTLs with large total mediation effects for transcriptomic prediction.
For all j, using these optimized predictive models for Mj as denoted by ŵMj , we estimate the
genetically regulated intensity (GRIn) of the mediator mj , denoted Mmj , in the test set. Denote M̂n×m
as the matrix of estimated GRIn, such that the jth column of M̂j is Mmj across all n samples.
Next, we consider the following additive model for the residualized expression of gene G:
ỸG = M̂βM + XGwG + ϵYG ,
where βM is the fixed effect-sizes of Mmj on ỸG, M̂ is the matrix of estimated GRIn for all mj
mediators, XG are the local-genotypes to gene G, and wG are the “random” or regularized effect sizes





M̂T ỸG. Next, using one of the methods outlined above when estimating ŵMj , we can
generate estimated effect sizes ŵG of the local-genotypes on ỸG, residualized with M̂.
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4.1.2.2 Transcriptomic imputation with MeTWAS
In an external GWAS panel, if individual genotypes are available, we construct the genetically




XMj ,GWASŵMj β̂M,j + XG,GWASŵG,
where XMj ,GWAS and XG,GWAS are the genotypes in the GWAS panel local to mediator j and gene
G, respectively. GReXG can be used in downstream tests of association.
If individual genotypes are not available, then the weighted burden Z-test proposed by Pasaniuc





Here, Z is the vector of Z-scores of SNP-trait associations for SNPs used in estimating ŵMj and
ŵG. The matrix W is defined as Σe,sΣ−1s,s, the product of the covariance matrix between all SNPs and
the expression of gene G and the covariance matrix among all SNPs. These covariance matrices are
estimated from the reference panel used to estimate ŵMj and ŵG. The test statistic Z̃ can be
compared to the standard Normal distribution for inference.
MOSTWAS also implements permutation testing to quantify the significance of the
expression-trait association conditioning on the SNP-trait effects at the locus3. Here, we perform
1,000 permutations of the SNP-expression weights in the predictive model and compute the Z-test
statistic at each permutation. A permutation P -value is calculated by comparing Z̃ to the distribution of
permuted Z-test statistics.
4.1.3 Distal eQTL prioritization via mediation analysis (DePMA)
4.1.3.1 Transcriptomic prediction using DePMA
We now describe Distal eQTL Prioritization via Mediation Analysis (DePMA), the second of two
tools available in MOSTWAS. Expression prediction in DePMA hinges on up-weighting distal eQTLs to
the gene of interest via mediation analysis, adopting methods from previous studies67,69,72. This
process is summarized in Figure 4.1B. We first split data for gene expression, SNP dosages, and any
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potential mediators into k training-testing splits. Depending on the minor allele frequencies of SNPs
and sample size, we generally recommend a low number of splits (i.e. k ≤ 5).
In the training set, we identify mediation test triplets that consist of (1) a gene of interest G with
expression YG (scaled to zero mean and unit variance), (2) a distal eSNP s in association with G at a
user-defined P -value threshold (default of P = 10−6) with dosages Xs, and (3) a set of m biomarkers
local to s that are associated with s at a user-defined P -value threshold (default of FDR-adjusted
P = 0.05) with intensities as m columns of Mn×m. The columns of M are scaled to zero mean and unit
variance. Consider the following mediation model for 1 ≤ j ≤ m:
YG = Xsβs +MβM + XCβC + ϵYG
Mj = XsαMj + XCαC,j + ϵMj
(4.3)
Here, we have βM as the effects of the M mediators local to s on YG adjusting for the effects from
s and the covariates and αM = (αM1 , . . . , αMm)T as the effects of s on mediators Mj , for 1 ≤ j ≤ m.
We assume that ϵYG ∼ N(0, σ2) and ϵM ∼ Nm (0,￿M ), where ￿M may have non-zero off-diagonal
elements that represent covariance between mediator intensities. Further, we assume that ϵYG and ϵM
are independent. We define the total mediation effect (TME)182 of SNP s as
TME = αTMβM.
We are interested in SNPs with large TME, which we prioritize with the test of H0 : TME = 0. We
assess this hypothesis with a permutation test, as more direct methods of computing standard errors
for the estimated TME are often biased71,72, obtaining a permutation P -value. We also provide an
option to estimate an asymptotic approximation to the standard error of TME and conduct a Wald-type
test for TME = 0. This asymptotic option is significantly faster at the cost of inflated false positives.
Corresponding to the t testing triplets identified, we obtain vectors of length t of TMEs and P -values
for each distal eSNP to G. For the predictive model, we select distal SNPs with evidence of TME ̸= 0
at a given q-value threshold (q < 0.10 as a default) and include them with all local genotypes in a
design matrix. We then find estimated SNP weights using either elastic net or weighted least squared
regression.
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4.1.3.2 Asymptotic test of total mediation effect
In DePMA, a distal-eQTL s is tested for its total mediation effect on gene G through m mediators
that are local to s. Consider the following mediation model for 1 ≤ j ≤ m:
YG = Xsβs +MβM + XCβC + ϵYG
Mj = XsαMj + XCαC,j + ϵMj
(4.4)
.
Here, we construct the total mediation effect




Note that TME is distributed as the product of two multivariate Normal distributions. By the
multivariate Delta method183, we can obtain the standard error for the estimated TME. Let
θ = (αM, βM) and define f(θ) = TME =
∑m
i=1 αMiβMi .













where Σ̂αM , Σ̂βM , and Σ̂αMβM are the variances and covariance of α̂M, β̂M, and between α̂M and
β̂M, respectively. Sobel previously has shown, that with sufficient sample size, Σ̂αMβM ≈ 0182,184. Thus,






We then test H0 : TME = 0 against H1 : TME ̸= 0 with the two-sided Wald-type test with the test





and comparing to the null standard Normal distribution.
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We illustrate the trade-off between power and computational speed using the asymptotic Sobel
test and the permutation speed. Consider the following simulation framework with m = 5 mediators, 3
covariates and a sample size of n ∈ {200, 500, 700, 1000} for the model in Equations 4.4:
• an n-length genotype vector for SNP s is drawn from Binomial(2,MAF ), where the minor allele
frequency MAF is set at 0.1 in Figure 4.2 below;
• Under the alternative, we simulated βX ∼ N(0, 1), βM ∼ N5(0, I5), βC ∼ N3(0, I3),
αMj |m=5j=1 ∼ N(0, 1), αC ∼ N5(0, I5).
• Under the null, all regression parameters were simulated as in the alternative case. However, we
set αMj = 0|mj=1 and βM = 0.
• Lastly, ϵYG ∼ N(0, 1− h2) and ϵMj ∼ N(0, 1− h2M ), where h2 = h2M = 0.1 in Figure 4.2 below.
• We then constructed YG and M using Equations 4.4.
We found, that over 10,000 simulations, the permutation test was considerably more powerful,
albeit considerably slower. However, in most cases of implementing DePMA, the number of tests of
mediation are usually on the order of 101 to 102. We recommend the permutation test in most cases,
unless gene G has thousands of identified distal-eQTLs. Parallel implementations have been offered
as options in the MOSTWAS package.
4.1.3.3 Transcriptomic imputation with DePMA
In an external GWAS panel, if individual genotypes are available, we construct the genetically
regulated expression (GReX) of gene G directly using ŵG and ŵt:
GReXG = Xt,GWASŵt + XG,GWASŵG,
where Xt,GWAS is the matrix of dosages of the t distal SNPs and XG,GWAS is the matrix of dosages
of the local SNPs to gene G in the external GWAS panel. GREXG can be used in downstream tests of
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Figure 4.2: Comparison of power and computational speed comparison of permutation and Sobel test.
Power (A) and computational speed (B) of permutation test (red) and asymptotic Sobel test (blue) in
simulation framework
4.1.4 Added-last test of association from distal variants
In addition to the overall TWAS tests of association and permutation testing, as implemented by
Pasaniuc et al and Gusev et al50,3, we develop here a technique to assess whether the distal loci
included in the predictive models are significantly associated with the phenotype of interest, given the
association at the local locus. In the scenario that individual genotype data is available, we can simply
run a group added-last test in the linear or survival model employed to assess the TWAS association
with phenotype. We use similar logic to develop an added-last test for distal variants conditional on the
local association, when only GWAS summary statistics are available.
Let Zl (an nl-vector) and Zd (an nd-vector) be the Z-scores local and distal SNPs identified by a
MOSTWAS model, with Z = [Zl Zd]T (an n vector). The local and distal SNP effects from the
MOSTWAS model are represented in wl (an nl-vector) and wd (an nd-vector), with w = [wl wd]T (an n
vector). Here, we are interested in testing
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H0 : wTd Zd|wTl Zl = Z̃l,obs = 0,
where Z̃l,obs is the observed weighted Z-score from local SNPs.
Under the null distribution, as proposed by Pasaniuc et al and Gusev et al in the Imp-G





is the LD matrix for the SNPs, as estimated from the reference panel. ￿l and ￿d represent the LD
matrices for local and distal SNPs, respectively. The LD matrix between local and distal SNPs ￿l,d can
be assumed to be zero, though recent studies have showed long-range LD in the human
genome185,186. We allow the user to set cross-chromosomal LD to 0, though by default, we estimate
LD from the reference panel.
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It follows that, under the null hypothesis and given Z̃l = Z̃l,obs,











We can use this null distribution for the one-sided test of H0 : wTd Zd|wTl Zl = Z̃l,obs = 0 against
H1 : wTd Zd|wTl Zl = Z̃l,obs > 0. This test is implemented in MOSTWAS as a follow-up to the
weighted-burden test.
4.1.5 Data acquisition for TCGA-BRCA and iCOGs
We retrieved genotype, RNA expression, miRNA expression, and DNA methylation data for
breast cancer indications in The Cancer Genome Atlas180. Birdseed genotype files of 914 subject
were downloaded from the Genome Data Commons (GDC) legacy (GRCh37/hg19) archive. Genotype
files were merged into a single binary PLINK file format (BED/FAM/BIM) and imputed using the
October 2014 (v.3) release of the 1000 Genomes Project dataset as a reference panel in the standard
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two-stage imputation approach, using SHAPEIT v2.87 for phasing and IMPUTE v2.3.2 for
imputation126–128. We excluded variants (1) with a minor allele frequency of less that 1% based on
genotype dosage, (2) that deviated significantly from Hardy-Weinberg equilibrium (P < 10−8) using
appropriate functions in PLINK v1.90b3187,149, and (3) located on sex chromosomes. Final TCGA
genotype data was coded as dosages, with reference and alternative allele coding as in dbSNP.
TCGA level-3 normalized RNA-seq expression data, miRNA-seq expression data, and DNA
methylation data collected on Illumina Infinium HumanMethylation450 BeadChip were downloaded
from the Broad Institute’s GDAC Firehose (2016/1/28 analysis archive). We intersectted to the subset
of samples assayed for genotype (4,564,962 variants), RNA-seq (15,568 genes), miRNA-seq (1,046
miRNAs), and DNA methylation (485,578 CpG sites), resulting in a total of 563 samples. We only
consider the autosome in our analyses. We adjusted gene and miRNA expression and DNA
methylation by relevant covariates (5 principal components of the genotype matrix, tumor stage at
diagnosis, and age).
For association testing, we downloaded iCOGs GWAS summary statistics for breast
cancer-specific survival for women of European ancestry162. Funding for BCAC and iCOGS came
from: Cancer Research UK [grant numbers C1287/A16563, C1287/A10118, C1287/A10710,
C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565], the
European Union’s Horizon 2020 Research and Innovation Programme (grant numbers 634935 and
633784 for BRIDGES and B-CAST respectively), the European Community’s Seventh Framework
Programme under grant agreement n◦ 223175 [HEALTHF2-2009-223175] (COGS), the National
Institutes of Health [CA128978] and Post-Cancer GWAS initiative [1U19 CA148537, 1U19
CA148065-01 (DRIVE) and 1U19 CA148112 - the GAME-ON initiative], the Department of Defence
[W81XWH-10-1-0341], and the Canadian Institutes of Health Research CIHR) for the CIHR Team in
Familial Risks of Breast Cancer [grant PSR-SIIRI-701]. All studies and funders as listed in Michailidou
et al9,10 and in Guo et al162 are acknowledged for their contributions.
4.1.6 Data acquisition from ROS/MAP, IGAP, and PGC
We retrieved imputed genotype, RNA expression, miRNA expression, and DNA methylation data
from The Religious Orders Study and Memory and Aging Project (ROS/MAP) Study for samples
derived from human pre-frontal cortex188,189. We excluded variants (1) with a minor allele frequency of
less that 1% based on genotype dosage, (2) that deviated significantly from Hardy-Weinberg
equilibrium (P < 10−8) using appropriate functions in PLINK v1.90b3187,149, and (3) located on sex
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chromosomes. Final ROS/MAP genotype data was coded as dosages, with reference and alternative
allele coding as in dbSNP. We intersectted to the subset of samples assayed for genotype (4,141,537
variants), RNA-seq (15,857 genes), miRNA-seq (247 miRNAs), and DNA methylation (391,626 CpG
sites), resulting in a total of 370 samples. We only consider the autosome in our analyses. We
adjusted gene and miRNA expression and DNA methylation by relevant covariates (20 principal
components of the genotype age at death, and sex).
For association testing, we downloaded GWAS summary statistics for risk of late-onset
Alzheimer’s disease from the International Genomics of Alzheimer’s Project (IGAP)2. We also
downloaded GWAS and genome-wide association by proxy (GWAX) summary statistics for risk of
major depressive disorder (MDD) from the Psychiatric Genomics Consortium190 and the UK
Biobank191, respectively.
IGAP is a large two-stage study based on GWAS on individuals of European ancestry. In stage 1,
IGAP used genotyped and imputed data on 7,055,881 single nucleotide polymorphisms (SNPs) to
meta-analyse four previously-published GWAS datasets consisting of 17,008 Alzheimer’s disease
cases and 37,154 controls (The European Alzheimer’s disease Initiative – EADI the Alzheimer
Disease Genetics Consortium – ADGC The Cohorts for Heart and Aging Research in Genomic
Epidemiology consortium – CHARGE The Genetic and Environmental Risk in AD consortium –
GERAD). In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of
8,572 Alzheimer’s disease cases and 11,312 controls. Finally, a meta-analysis was performed
combining results from stages 1 and 2.
4.2 Simulation analysis
We conducted simulations to assess the predictive capability and power to detect gene-trait
associations under various phenotype (h2p), local heritability of expression (h2e,l), distal heritability of
expression (h2e,d), and proportion of causal local (pc,l) and distal (pc,e) SNPs for MeTWAS and DePMA.
We considered two scenarios for each combination of (h2p, h2e,l, h2e,d, pc,l, pc,e): (1) the simulated
distal-eQTL (association between SNP and gene of interest) exists in both the reference and
imputation panel, and (2) the distal-eQTL exists in the reference panel, but the distal SNP does not
affect gene expression in the imputation panel (i.e. h2e,d ≡ 0 in the imputation panel regardless of h2e,d
in the reference panel).
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Using TCGA data in breast cancer, we extracted 2,592 genotypes local to the gene ESR1 on
Chromosome 6 and 1,431 genotypes local to the gene FOXA1. Though the choice of these loci were
arbitrary for simulations, there is evidence that ESR1 and FOXA1 are highly co-expressed in breast
tumors and local-eQTLs of FOXA1 have been shown to be distal-eQTLs of ESR1192. We believe
these loci served as a strong reference for these simulations. We generated (1) a reference panel with
sample size 400 with simulated genotypes, expressions, and one mediators and (2) a GWAS panel of
1,500 samples with simulated genotypes and phenotypes using the following data generating process,
modified from Mancuso et al’s framework55:
• We estimated the linkage disequilibrium LD matrix of the genotypes XG with n samples and p








We computed the Cholesky decomposition of LD for faster sampling. We simulated genotypes
for a 400-sample reference panel Xg,ref and 1,500-sample GWAS panel Xg,GWAS.
• We then simulated effect sizes for pc,l of the 2,592 local genotypes wg,l from a standard Normal




with ϵl ∼ N(0, 1− h2e,l) and wg,l scaled to ensure the given h2e,l.
Similarly, we simulated effect sizes for pc,d of the 1,431 distal genotypes wg,d and generated the
distally heritable intensity of the mediator Mg,d. We constructed the distally heritable expression
Eg,d by scaling Mg,d by β ∼ N(0, 1) and adding random noise that scaled distal heritability to h2e,d.
We lastly formed the total expression Eg = Eg,l + Eg, d.
• Next, we simulated the phenotype in the GWAS panel such that the variance explained in the
phenotype reflects only that due to genetics. We drew a causal effect size from gene expression







Here, we also considered a “null” case as well, where the distal eQTLs were not present in the
GWAS panel (i.e. wg,d = 0 for all distal SNPs). GWAS summary statistics were computed in this
step for downstream weighted burden testing.
• We then fitted predictive models using MeTWAS, DePMA, and local-only models (i.e. FUSION3),
computed the adjusted predictive R2 in the reference panel, and tested the gene-trait association
in the GWAS panel using a weighted burden test.
The association study power was defined as the proportion of gene-trait association tests with
P < 2.5× 10−6, the Bonferroni-corrected significance threshold for testing 20,000 independent genes.
In these simulation studies, we found that MOSTWAS methods performed well in prediction
across different causal proportions and local and distal mRNA expression heritabilities. Furthermore,
across all simulation settings, we observed that MOSTWAS showed greater or equal power to detect
gene-trait associations as local-only models. We saw that, as the proportion of total expression
heritability that is attributed to distal genetic variation, the positive difference in predictive performance
between the best MOSTWAS model and the local-only model increased (Supplemental Figure S28).
Similarly, we found that, under the setting that distal variation contributes to trait heritability, the best
MOSTWAS model has greater power to detect gene-trait associations than the local-only model, with
the advantage in power over local-only models increasing with increased distal expression heritability
(Figure 4.3A). Under the null case that distal variation influences expression in the reference panel but
does not affect the trait in the GWAS panel, we find that local-only and MOSTWAS models perform
similarly. At low causal proportion (pc = 0.01) and low trait heritability (h2p = 0.2), local-only models
have a modest advantage in TWAS power over MOSTWAS models. This difference is mitigated at
larger causal proportions and trait heritabilities (Figure 4.3). Overall, these results demonstrated the
advantages of MOSTWAS methods for modeling the complex genetic architecture of transcriptomes,
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Figure 4.3: Comparison of TWAS power via simulations using MOSTWAS and local-only models. (A)
Proportion of gene-trait associations at P < 2.5 × 10−6 using local-only (red) and the most predictive
MOSTWAS (blue) models across various local and distal expression heritabilities, trait heritability, and
causal proportions. (B) Proportion of significant gene-trait associations across the same simulation
parameters with no distal effect on the trait in the simulated external GWAS panel.
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4.3 Applications of MOSTWAS in real data
4.3.1 Breast cancer expression and survival outcomes
We wished to apply MOSTWAS in the context of breast tumor multi-omics and disease outcomes,
motivated by recent GWAS and TWAS into breast cancer-specific survival161,9,10,162,102. Breast tumor
eQTL studies have also revealed several signficant distal-eQTLs in trait-associated loci, many of
which are in regulatory or epigenetic hotspots102,193, making breast tumors a natural setting for
MOSTWAS application. Using TCGA-BRCA data on germline SNPs, tumor mRNA expression, DNA
methylation, and miRNA expression, we trained MeTWAS, DePMA, and traditional local-only
predictive models for the mRNA expression of all genes with germline heritability h2 > 0 at P < 0.05.
Estimates of heritability for genes were considerably larger when we considered distal variation using
MOSTWAS methods (mean heritabilities in Supplemental Table S3). We also found that MeTWAS
and DePMA perform better in cross-validation R2 in cross-validation, with larger numbers of models at
R2 ≥ 0.01 using MOSTWAS methods than local-only models (Figures 4.3A-C). Mean predictive R2 for
local-only models was 0.011 (25% to 75% inter-quartile interval (0.0,0.013)), for MeTWAS models was
0.028 (0.013, 0.032), and for DePMA models was 0.051 (0.019, 0.068).
In addition to cross-validation, we used 351 paired samples in TCGA-BRCA with genotype and
mRNA expression data that were not used in model training to test the portability of MOSTWAS
models in independent external cohorts. As shown in Figure 4.4A, DePMA models obtain the highest
predictive adjusted R2 in the external cohort (mean 0.016, 25% to 75% inter-quartile interval (0.003,
0.018)), with local-only models (0.013, (0.00,0.013)) outperforming MeTWAS models (0.011, (0.002,
0.012)), considering only genes that attained cross-validation adjusted R2 ≥ 0.01 using a given
method. Overall, among genes with cross-validation adjusted R2 ≥ 0.01, 37 out of 280 genes
achieved external predictive R2 ≥ 0.01 using local-only models, 89 out of 709 using MeTWAS, and
787 out of 1,185 using DePMA (Figure 4.3A-C).
Lastly, we conducted association studies for breast cancer-specific survival using local-only and
the most predictive (in cross-validation) MOSTWAS model trained in TCGA-BRCA and summary-level
GWAS data from iCOGs. Here, we constructed the weighted burden test, as described above and in
Pasaniuc et al and Gusev et al50,3. We prioritized genes with Benjamini-Hochberg adjusted P < 0.05
for permutation testing. Of the 122 genes that had cross-validation R2 ≥ 0.01 in TCGA-BRCA using
both local-only and MOSTWAS models, we found 2 survival associations at Benjamini-Hochberg
FDR-adjusted 0.05 using both local-only and MOSTWAS models, with the strength of association
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marginally larger with the MOSTWAS model in each case (Supplemental Figure S29). QQ-plots for
TWAS Z-statistics and P -values are provided in Supplemental Figure S30A and Supplemental
Figure S31 for both local-only and MOSTWAS models, showing earlier departure for the local-only
models. Overall, using all heritable genes with cross-validation R2 with the best MOSTWAS model in
TCGA-BRCA, we identified 21 survival-associated loci at Benjamini-Hochberg1 FDR adjusted
P < 0.05. Of these 21 loci, 11 persisted when subjected to permutation testing at a significance
threshold of FDR-adjusted P < 0.05 (Figure 4.4C). Our results in TCGA-BRCA showed improved
transcriptomic prediction using MOSTWAS over local-only modeling and the strength of MOSTWAS to
detect gene-trait associations that are influenced by distal variation.
4.3.1.1 Functional hypothesis generation with MOSTWAS
An advantage of MOSTWAS is its ability to aid in functional hypothesis generation for mechanistic
follow-up studies. The added-last test allows users to identify genes where trait association from distal
variation is significant given the strength of the local association. For 8 of the TWAS-associated 11 loci,
at FDR-adjusted P < 0.05 we found significant distal variation added-last associations (see Section
4.1.4), suggesting that distal variation may contribute to the gene-trait association. All 8 of these loci
showed distal association with the gene of interest mediated through a set of four transcription factors
(NAA50, ATP6V1A, ROCK2, USF3), all highly interconnected with the critical MAPK pathway194–199.
These regulatory sites serve as an example of how distal genomic regions can be prioritized for
functional follow-up studies to elucidate the mechanisms underlying the SNP-gene-trait associations.
4.3.2 Brain gene expression and psychiatric disorders
We also applied MOSTWAS to transcriptomic data on samples of prefrontal cortex, a tissue that
has been used previously in studying neuropsychiatric traits and disorders with TWAS200,201. There
has been ample evidence in brain tissue, especially the prefrontal cortex, that non-coding variants (up
to 80%) regulate distal genes, providing a prime example to assess MOSTWAS200,202. Using
ROS/MAP data on germline SNPs, tumor mRNA expression, DNA methylation, and miRNA
expression, we trained MeTWAS, DePMA, and traditional local-only predictive models for the mRNA
expression of all genes with germline heritability h2 > 0 at P < 0.05. Consistent with results in
TCGA-BRCA, estimates of heritability for genes were considerably larger when we considered distal
variation using MOSTWAS methods (Supplemental Table S3). We also find that MeTWAS and
DePMA perform better in cross-validation R2 than local-only models (Figures 4.4D-F). Mean
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predictive R2 for local-only models was 0.029 (25% to 75% inter-quartile interval (0.0,0.015)), for
MeTWAS models was 0.079 (0.019, 0.082), and for DePMA models was 0.045 (0.013, 0.037).
In addition to cross-validation, we used 87 samples in ROS/MAP with genotype and mRNA
expression data that were not used in model training to test the portability of MOSTWAS models in
independent external cohorts. As shown in Figure 4.4A, DePMA models obtain the highest predictive
adjusted R2 in the external cohort (0.042 (25% quantile 0.009, 75% quantile 0.057)), with MeTWAS
models (0.040 (0.010, 0.054)) outperforming local-only models (0.031 (0.007, 0.039)), considering only
genes that attained cross-validation adjusted R2 ≥ 0.01 using a given method. Overall, among genes
with cross-validation adjusted R2 ≥ 0.01, 187 out of 267 genes achieved external predictive R2 ≥ 0.01
using local-only models, 683 out of 911 using MeTWAS, and 2,135 out of 2,934 using DePMA (Figure
4.3D-F).
We next conducted association tests for known Alzheimer’s disease risk loci using local-only and
the best MOSTWAS model (comparing MeTWAS and DePMA cross-validation R2) trained in
ROS/MAP and summary-level GWAS data from IGAP. From literature, we identified 14 known common
and rare loci of late-onset Alzheimer’s disease2,203–205, 11 of which had MOSTWAS models with
cross-validation R2 ≥ 0.01. Five of these 11 loci (APOE, CLU, PLCG2, SORL1, ZCWPW1) showed
significant association at Benjamini-Hochberg FDR-adjusted P ≤ 0.05 (Supplemental Table S4). We
also compared these all 11 associations to those identified by local-only models and by latent Dirichlet
process regression (DPR) as implemented in TIGAR54, with raw P -values of association shown in
Figure 4.5B. MOSTWAS showed stronger associations at 8 of these loci than both local-only and DPR
models. We followed up on the 5 significantly associated loci using the permutation and added-last
tests. The added-last test assesses whether the association from distal loci, given the strength of the
association in the local locus, is significant. Three of these loci (APOE, SORL1, ZCWPW1) persisted
permutation testing at FDR-adjusted P < 0.05 and showed significant associations with distal variants,
given the association with local variants, at FDR-adjusted P < 0.05 (Supplemental Table S4).
We then conducted a transcriptome-wide association study for risk of major depressive disorder
(MDD) using summary statistics from the Psychiatric Genomics Consortium (PGC) genome-wide
meta-analysis that excludes data from the UK Biobank and 23andMe190. QQ-plots for TWAS
Z-statistics and P -values are provided in Supplemental Figure S30B and Supplemental Figure S31.
for both local-only and MOSTWAS models. Overall, using all heritable genes with cross-validation R2
with the best MOSTWAS model in ROS/MAP, we identified 102 MDD risk-associated loci with
FDR-adjusted P < 0.05 that persisted when subjected to permutation testing at an FDR-adjusted









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































● ● ●Both (541) DePMA (2393) MeTWAS (332)
F
ROS/MAP
Figure 4.4: Comparison of predictive adjusted R2 in cross-validation using local-only, MeTWAS, and
DePMA models. If a given gene does not have h2 > 0 with P < 0.05, we set the predictive adjusted
R2 to 0 here for comparison. We compare local-only and MeTWAS in TCGA-BRCA (A) and ROS/MAP
(D), local-only and DePMA in TCGA-BRCA (B) and ROS/MAP (E), and MeTWAS and DePMA in TCGA-
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Figure 4.5: External validation of MOSTWAS and gene-trait associations using MOSTWAS models.
(A) Predictive adjusted R2 in held-out cohorts from TCGA-BRCA and ROS/MAP in local-only, MeTWAS,
and DePMA models that have in-sample significant heritability and cross-validation R2 ≥ 0.01. The
interval shows the 25% and 75% quantiles for external cohort predictive R2. (B) Associations with
12 known Alzheimer’s risk lock, as identified in literature, using MOSTWAS, local-only, and TIGAR
Dirichlet process regression (DPR). (C) TWAS associations for breast cancer-specific survival using
GWAS summary statistics from iCOGs. Loci are colored and labelled if the overall association achieves
FDR-adjusted P < 0.05 and the permutation test also achieves FDR-adjusted P < 0.05. (D) TWAS
associations for major depressive disorder risk using GWAS summary statistics from PGC. Loci are
colored red if the overall association achieves FDR-adjusted P < 0.05 and the permutation test also
achieves FDR-adjusted P < 0.05. We label the 12 loci that were independently validated with UK
Biobank GWAX summary statistics at FDR-adjusted P < 0.05 for both the overall association test and
permutation test.
78
association study by proxy (GWAX) summary statistics from the UK Biobank191 for replication analysis
of loci identified using PGC summary statistics. We found that 7 of these 102 loci (labelled in Figure
4.4D) also show an association in UK Biobank GWAX that is in the same direction as in PGC.
Summary statistics for TWAS associations in PGC and UK Biobank are provided in Supplemental
Table S5. It is important to note the UK Biobank dataset is not a GWAS dataset as it defines a case of
MDD as any subject who has the disorder or a first-degree relative with MDD, leading to lower power
to detect associations in this dataset.
We observed that MOSTWAS models generally had higher predictive R2 that local-only models
both in training and independent cohorts. We also found that MOSTWAS has recapitulated 5 known
Alzheimer’s risk loci that were not detected by local-only modeling (both PrediXcan42 and TIGAR54), 3
of which had significant distal associations using our added-last test. We also illustrated that the
MOSTWAS detected MDD-risk loci that were replicable across independent GWAS and GWAX
cohorts190,191.
4.3.3 Comparison of computational time
To assess the difference in computational burden between local-only, MeTWAS, and DePMA
modelling, we randomly selected a set of 50 genes that are heritable across all three models from
TCGA-BRCA and computed per-gene time for fitting using a 24-core, 3.0 GHz processor. We found
that MeTWAS (mean of 225 seconds per gene) and DePMA (mean 312 seconds per gene) takes
approximately 6-10 times longer to fit than a traditional local-only model (mean 36 seconds)
(Supplemental Figure S27). Model-fitting here includes heritability estimation, estimating the
SNP-expression weights, and cross-validation. We have implemented parallel options within a given
gene and recommend fitting an entire set of genes on an RNA-seq panel via a batch computing
approach206. Using parallel implementation with 5 cores and batch computing, we analyzed 15,568
genes from TCGA-BRCA in approximately 28 hours.
4.4 Discussion
Here, through a variety of simulations and real applications in two settings, we have shown that
multi-omic methods that prioritize distal variation in TWAS gave added predictive performance and
power to detect gene-trait associations, especially when distal variation contributed to trait heritability.
We proposed two methods (MeTWAS and DePMA) for identifying and including distal genetic variants
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in gene expression prediction models. We have provided implementations of these methods in the
MOSTWAS (Multi-omic Strategies for Transcriptome-Wide Association Studies) R package, available
freely on Github. MOSTWAS contains functions to train expression models with both MeTWAS and
DePMA and outputs models with 5-fold cross-validation R2 ≥ 0.01 and significant germline heritability.
The package also contains functions and documentation for simulation analyses55, the weighted
burden and follow-up permutation and distal-SNPs added last tests for TWAS50,3 using GWAS
summary statistics, and file-formatting. We also provide guidelines for parallelization to speed up
computational time.
Not only does MOSTWAS improve transcriptomic imputation both in- and out-of-sample, it also
provides a test for the identification of heritable mediators that may affect the eventual transcription of
the gene of interest. These identified mediators can give some insight into the underlying mechanisms
for SNP-gene-trait associations to improve detection of gene-trait associations and prioritize functional
follow-up studies. Using MOSTWAS and iCOGs summary-level GWAS statistics for breast
cancer-specific survival162, we identified 11 survival-associated loci that are enriched for p53 binding
and oxidoreductase activity pathways207,208. These loci include two genes (MAP3K6 and MAP4K5)
encoding mitogen-activated protein kinases, which are signalling transduction molecules involved in
the progression of aggressive breast cancer hormone subtypes209. TWAS using MOSTWAS models
was able to recapitulate 5 out of 14 known Alzheimer’s disease risk loci in IGAP GWAS summary
statistics statistics2, which were not recoverable with local-only models. We showed the utility of the
distal-SNPs added last test to prioritize significant distal SNP-gene-trait associations from follow-up. In
PGC GWAS summary-level data for major depressive disorder190, we found 102 risk loci, 7 of which
were replicated in independent GWAX summary statistics from the UK Biobank191. Three of these
seven loci (SYT1, CACNA2D3, ADAD2) encode important proteins involved in synaptic transmission
in the brain and RNA editing. Studies have shown that variation at these loci may lead to loss of
function at synapses and RNA editing that lead to psychiatric disorders210–214. All survival- or
risk-associated loci identified by MOSTWAS were not detected using local-only models.
An admitted and considerable limitation of MOSTWAS is the increased computational burden
over local-only modelling, especially in DePMA’s permutation-based mediation analysis for multiple
genome-wide mediators. We believe a Monte-Carlo resampling method will aid in scalability by
making some standard distributional assumptions on the effect sizes of SNPs and mediators in the
DePMA mediation model215. Nevertheless, we believe that MOSTWAS’s gain in predictive
performance and power to detect gene-trait associations may outweigh this computational time.
Another limitation of MOSTWAS is the general lack of rich multi-omic panels, like TCGA-BRCA and
80
ROS/MAP, that provide a large set of mediating biomarkers that may be mechanistically involved in
gene regulation. However, we believe that mRNA expression data could be re-used as mediator data
to identify distal-eQTLs local to genes that code for transcription factors67,68,72, which is an area of
future development in MOSTWAS.
In conclusion, MOSTWAS provides a user-friendly and intuitive tool that extends transcriptomic
imputation and association studies to include distal genetic variants. MOSTWAS enables users to
utilize rich reference multi-omic datasets for enhanced gene mapping to better understand the genetic
etiology of polygenic traits and diseases with more direct insight into functional follow-up studies.
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CHAPTER 5: CELL-TYPE DECONVOLUTION IN TARGETED RNA EXPRESSION
PANELS
In this chapter, we outline a semi-reference-free cell-type deconvolution method using mRNA
expression data from targeted panels. As mentioned in Chapter 1, targeted panels are particularly
attractive for clinical settings and for longitudinal studies that use archival specimens18. However, a
major limiting factor for targeted panels, especially for cell-type deconvolution, is the limited feature
space; reference-free deconvolution methods rely on identifying genes that can indicate different
cell-types, but targeted panels do not afford a large enough feature space to search for these cell-type
specific genes13,15,17,14. We introduce DeCompress, a semi-reference-free method that uses
compressed sensing to expand the targeted expression panel to a larger feature space using a
reference RNA-seq or microarray dataset as a reference. We benchmark DeCompress against
reference-free methods in simulated and published datasets and show that DeCompress generally
estimates cell-type proportions with less error than competing reference-free methods. We then show
some advantages of including these estimated cell-type proportions in clinical and academic settings
(e.g. eQTL mapping, subtyping and outcome prediction) using data from the Carolina Breast Cancer
Study (CBCS)122,24. DeCompress is available as an R software package at
https://github.com/bhattacharya-a-bt/DeCompress.
5.1 Overview of DeCompress
DeCompress takes in two expression matrices from similar bulk tissue as inputs: the target matrix
T, an n× k matrix from a targeted panel of gene expression, and the reference matrix R, an N ×K
matrix from an RNA-seq or microarray panel, such that K > k. For a user-defined c cell-types,
DeCompress outputs Ŝ, a c×K ′ matrix of cell-type specific expression profiles and P̂, a c× n matrix
of cell-type proportions. The method follows three general steps, as detailed in Figure 5.1: (1)
selection of approximate cell-type specific genes, (2) compressed sensing to expand the feature space
of T, and (3) ensemble reference-free deconvolution on expanded expression dataset. DeCompress is
































































Figure 5.1: Schematic for the DeCompress algorithm. DeCompress takes in a reference RNA-seq or
microarray matrix with N samples and K genes, and the target expression with n samples and k < K
genes. The algorithm has three general steps: (1) finding the K ′ < K genes in the reference that
are cell-type specific, (2) training the compressed sensing model that projects the feature space in the
target from k genes to the K ′ cell-type specific genes, and (3) decompressing the target to an expanded
dataset and deconvolving this expanded dataset. DeCompress outputs cell-type proportions and cell-
type specific profiles for the K ′ genes.
5.1.1 Selection of cell-type specific genes
The first step of DeCompress is to find a set of K ′ < K genes that are representative of the
different cell types that comprise the bulk tissue. These K ′ genes, called the cell-type specific (CTS)
genes, can be supplied by the user if prior gene signatures can be applied. If any such gene
signatures are not available, DeCompress borrows methods from two previous reference-free
deconvolution methods to select a parsimonious gene set.
We include methods from Zaitsev et al’s LINear Subspace identification for gene Expression
Deconvolution (LINSEED) method13 that assumes mutual linearity (i.e. y1 = ky2, where y1 and y2 are
the expressions of gene 1 and gene 2, respectively) between cell-type specific genes to generate
gene signatures. Briefly, LINSEED transforms the gene expression space to form a c-vertex simplex,
where each vertex represents a distinct cluster of mutually linear genes corresponding to a cell type.
The algorithm then picks the closest genes to each vertex to represent a cell-type specific gene
signature13. We also include Li and Wu’s feature selection method, TOols for the Analysis of
heterogeneouS Tissues (TOAST)14, which iteratively searches for cell type-specific genes and
performs reference-free estimation at each step. TOAST uses a novel hypothesis testing framework to
conduct cross-cell type differential analysis and identify gene signatures14.
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5.1.2 Compressed sensing framework
After a suitable set of K ′ CTS genes are determined, we take the K ′ corresponding columns of R
to form R′N×K′ and the k genes corresponding to columns in T to form R(k)N×k. Consider the following




We can break down Equation 5.1 into a system of equations. For the ith column of R′, denoted r′i,




We estimate ϕ̂i with the following optimization methods: least angle regression (using R package
lars)216, elastic net with elastic net mixture penalty α ∈ {0, 0.5, 1} (using the R package glmnet)48, and
l1, l2, and total variation l1 (TV-L1) non-linear optimization (using R package R1magic)217–220..
Functions in DeCompress allow the user to select any to all of these optimization methods and picks
the best method through 5-fold cross-validation.
Especially when N is sufficiently large, non-linear optimization is computationally expensive (see
comparison of run times in Supplemental Figure S32). We implement parallelization across columns
of R′ using the future package in R221 and recommend linear optimization methods as they are faster
and give generally similar prediction (Supplemental Figure S33).
5.1.2.1 Optimization methods for compressed sensing





We convert this into a system of equations. For the ith column of R′, denoted r′i, we wish to find a




DeCompress implements several regularized regression or optimization methods to estimate ϕ̂i:
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• Elastic net 48 finds
ϕ̂i = arg min
ϕi
{







We have implemented α ∈ {0, 0.5, 1}, where α = 0 represents ridge regression with no
sparsification of ϕi and α = 1 represents traditional LASSO47. This optimization is carried out in
DeCompress with the glmnet package48.
• Least angle regression (LARS) minimizes the LASSO objective function in Expression 5.5 that
speeds ups stage-wise forward selection. The algorithm starts with all elements of ϕi equal to
zero and finds the predict most correlated with the response. The largest step possible is take in
the direction of these predictor until some other predictor has as much correlation with the
residual. LARS then proceeds in a direction equiangular between these two predictors until a
third variable shares an equal correlation with the residual. The full mathematical justification
and details are provided by Efron et al216.
• l1 non-linear optimization solves the following optimization using the nlm function in R, as
implemented in the R1magic package217:





|R(k)Tϕi − r′i|2 + λ|ϕi|
}
, (5.6)
where T is a K ′ ×K ′ matrix of sparsity bases and λ is a tuned penalty parameter.
• l2 non-linear optimization solves the following optimization using the nlm function in R, as
implemented in the R1magic package217:










where T is a K ′ ×K ′ matrix of sparsity bases and λ is a tuned penalty parameter.
• total-variation l1 non-linear optimization solves the following optimization using the nlm function
in R, as implemented in the R1magic package217:









where T is a K ′ ×K ′ matrix of sparsity bases, λ is a penalty parameter, and TV (·) is the





5.1.3 Ensemble deconvolution on expanded dataset
After the estimated compression matrix Φ̂ is obtained, we then expand the expression matrix from
the targetted panel Tn×k into a larger features space by multiplying T with Φ̂:
T̃n×K′ = Tn×k￿k×K′ .
This expanded expression matrix T̃, called the decompressed expression matrix, is then used for
ensemble deconvolution. DeCompress includes multiple options for deconvolution, summarized in
Supplemental Table S6: (1) reference-free methods, such as deconf12, CellDistinguisher15, TOAST
with non-negative matrix factorization14, Linseed13, and DeconICA17, and (2) reference-based
methods using cell-type specific expression profiles from factorization of R′N×K′ , unmix from the
DESeq2 package16. These methods are summarized in detail in the Supplemental Methods. The
optimal estimated cell-type proportion matrix P̂ and cell-type specific expression profiles matrix Ŝ are
selected from the method that best recreates T̃ (i.e. minimizes ∥T̃− ŜT P̂∥).
5.2 Methods for benchmarking and real data analysis
5.2.1 In-silico GTEx mixing experiments
We downloaded median tissue-specific expression profiles from the Genotype-Tissue Expression
(GTEx) Project222,223 for mammary tissue, lymphocytes, fibroblasts, and adipose tissue. Call these
median expression profiles Eprofile. We randomly generated a matrix of mixing proportions P for n
samples and c ∈ {2, 3, 4} of the tissue types. We then generated mixed expression profiles with the
following model:
Emixed = EprofilePT .
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We then multiplied each element of Emixed with a randomly generated error term drawn from a
Normal distribution with 0 mean and standard deviation of either 4 or 8 (low and high noise). This
simulates natural perturbation to mixed expression profiles. We then randomly generated 25 simulated
pseudo-targeted panels each of K ∈ {200, 500, 800, 1000} genes that have means and variances
above the median mean and variance of all genes in the simulated genes. These simulated datasets
have sample size 200. For benchmarking, in each of these simulated datasets, we selected 100 of the
200 samples as a test set for deconvolution. The other 100 samples are considered only in
DeCompress deconvolution and simulated expression for all genes are kept as the reference. We
added more multiplicative noise to the reference drawn from a Normal distribution with zero mean and
standard deviation of 10 to simulate batch differences between the reference and target.
5.2.2 Benchmarking in published datasets
We downloaded four datasets, summarized in Supplemental Table S7: (1) microarray
expression for mixed rat brain, liver, and lung biospecimens (GEO Accession Number: GSE19830),
commonly used as a benchmarking dataset in deconvolution studies (N = 42)6, (2) RNA-seq
expression (GEO Accession Number: GSE123604) for a mixture of breast cancer cells, fibroblasts,
normal mammary cells, and Burkitt’s lymphoma cells (N = 40)5, (3) microarray expression for laser
capture micro-dissected prostate tumors (N = 30)7, and (4) RNA-seq expression for a mixture of two
lung adenocarcinoma cell lines (N = 40)8. Here, we detail the process of generating pseudo-targeted
panels from these RNA-seq or microarray datasets. Assume the downloaded datasets are coded in
the matrix E with K rows corresponding to genes and n columns corresponding to samples. We take
the K ′ genes such that the means and variances of each of these K ′ genes are in the top 50% of
means and variances of all K genes. This restriction is placed on the K ′ genes so as to not include
lowly expressed genes with no variation across cell-types or other conditions. We then generated 25
pseudo-targeted panels with randomly selected 200, 500, 800, and 100 of the K ′ genes.
For the rat mixture dataset, we used 30 of the 42 samples as a reference microarray matrix (with
multiplicative noise, as in GTEx, to simulate a batch effect) and deconvolved on the remaining 12
samples in the target matrix. In the remaining three datasets, we obtained normalized RNA-seq
reference matrices from The Cancer Genome Atlas180: TCGA-BRCA breast tumor expression for the
breast cancer cell line mixture, TCGA-PRAD prostate tumor expression for the prostate tumor
microarray study, and TCGA-LUAD for the lung adenocarcinoma mixing study.
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5.2.3 Benchmarking in Carolina Breast Cancer Study
We lastly used expression data from the CBCS for validation and analysis122,24.
Paraffin-embedded tumor blocks were requested from participating pathology laboratories for each
samples, reviewed, and assayed for gene expression using the NanoString nCounter system, as
discussed previously24. As described before102,224, the expression data was pre-processed and
normalized using quality control steps from the NanoStringQCPro package, upper quartile
normalization using DESeq299,16, and estimation and removal of unwanted technical variation using
the RUVSeq and limma packages29,130. The resulting normalized dataset comprised of samples from
1,199 patients (628 women of African descent and 571 women of European descent). A study
pathologist analyzed tumor microarrays (TMAs) from 148 of the 1,199 patients to estimate area of
dissections originating from epithelial tumor, intratumoral stroma, immune infiltrate, and adipose
tissue102. These cell-type proportions of the 148 samples were used for benchmarking of
DeCompress against other reference-free methods.
5.3 Results
5.3.1 Benchmarking DeCompress with reference-free deconvolution methods
We benchmarked DeCompress performance across 6 datasets (see Supplemental Table S7 ):
(1) in-silico mixing experiments using tissue-specific expression profiles from the Genotype-Tissue
Expression (GTEx) Project222,223, (2) expression from 4 published datasets with known cell-type
proportions6,5,7,8, and (3) and tumor expression from the Carolina Breast Cancer Study122,24. We
compared the performance of DeCompress against 5 other reference-free deconvolution methods
(Supplemental Table S6): deconf12, Linseed13, and DeconICA17, iterative non-negative matrix
factorization with feature selection using TOAST (TOAST + NMF)14, and CellDistinguisher15.
Estimated cell-type proportions are compared to simulated or reported true cell-type proportions by
calculate the mean square error (MSE) between the two matrices. In total, we observed that
DeCompress best recapitulates cell-type proportions compared to other reference-free deconvolution
methods.
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5.3.1.1 In-silico GTEx mixing
We generated artificial targeted panels by mixing median tissue specific expression profiles from
GTEx in-silico with randomly simulated cell-type proportions for mammary tissue, EBV-transformed
lymphocytes, transformed fibroblasts, and subcutaneous adipose. We added multiplicative noise to
the mixed expression to simulate measurement error and contributions to the bulk expression signal
from other sources at two levels. Figure 5.2A shows the performance of DeCompress compared to
other reference-free methods across 25 simulated targeted panels of increasing sample sizes and
increasing number of genes from GTEx in-silico mixing experiments. In general, we find that
DeCompress gives more accurate estimates of cell-type proportions than the other 5 methods at both
settings for multiplicative noise. As the number of genes in the targeted panel increased, we largely
see the difference in MSE between DeCompress and the other methods increase. Linseed and
DeconICA, methods that search of mutually independent axes of variation that correspond to
cell-types, consistently perform poorly on these simulated datasets. deconf, TOAST + NMF (matrix
factorization-based methods) and CellDistinguisher (topic modeling) perform similarly to one another
and only moderately worse in comparison to DeCompress.
We also investigated how the number of component cell-types affects the performance of all six
reference-free methods. We generated another set of in-silico mixed targeted panels (500 genes)
using 2 (mammary tissue and lymphocytes), 3 (mammary, lymphocytes, fibroblasts), and 4 (mammary,
fibroblasts, lymphocytes, and adipose) and applied all six methods to estimate the cell-type
proportions. Figure 5.2B provides boxplots of the MSE across 25 simulated targeted panels using
DeCompress and the other 5 benchmarked methods. For all 6 methods, the median MSE for these
datasets remained similar as the number of cell-types increased, though the variance in the MSE
decreases considerably. In particular, the performance of DeconICA increases considerably as more
cell-types were used for mixing, as highlighted by their documentation17. Here again, we found that
DeCompress gave the smallest median MSE between the true and estimated cell proportions. In total,
results from these in-silico mixing experiments show both the accuracy and precision of DeCompress
in estimated cell-type proportions.
5.3.1.2 Publicly available datasets
Although in-silico mixing experiments with GTEx data showed strong performance of
DeCompress, we sought to benchmark DeCompress against reference-free methods in previously
published datasets with known cell-type mixture proportions. We downloaded expression data from a
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Figure 5.2: Benchmarking results for in-silico GTEx mixing experiments and real data examples. (A)
Boxplots of mean square error (Y -axis) between true and estimated cell-type proportions in in-silico
GTEx mixing experiments across simulated targeted panels of 200, 500, 800, and 1,000 genes (X-axis),
with 25 simulated datasets per number of genes. GTEx mixing was done at two levels of multiplicative
noise, such that errors were drawn from a Normal distribution with zero mean and standard deviation 8
(left) and 4 (right). Boxplots are colored by the benchmarked method (legend at bottom). (B) Boxplots of
MSE (Y -axis) between true and estimated cell-type proportions over 25 simulated GTEx mixed expres-
sion datasets with 500 genes, multiplicative noise drawn from a Normal distribution with zero mean and
standard deviation 10, and 2 (left), 3 (middle), and 4 (right) different cell-types. Boxplots are collected
by the benchmarked method. (C) Boxplots of mean square error (Y -axis) between true and estimated
cell-type proportions in 25 simulated targeted panels of 200, 500, 800, and 1,000 genes (X-axis), us-
ing four different datasets: breast cancer cell-line mixture (top-left)5, rat brain, lung, and liver cell-line
mixture (top-right)6, prostate tumor samples (bottom-left)7, and lung adenocarcinoma cell-line mixture
(bottom-right)8. Boxplots are colored by the benchmarked method. The red line indicates the median
null MSE when generating cell-type proportions randomly. If a red line is not provided, then the median
null MSE is above the scale provided on the Y -axis.
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breast cancer cell-line mixture (RNA-seq)5, rat brain, lung, and liver cell-line mixture (microarray)6,
prostate tumor with cell-type proportions estimated with laser-capture microdissection (microarray)7,
and lung adenocarcinoma cell-line mixture (RNA-seq)8 and generated pseudo-targeted panels with
200, 500, 800, and 1000 genes. For the rat mixture dataset, we trained the compression sensing
model on a randomly selected training split; for the other three cancer-related datasets, reference
RNA-seq data was downloaded from The Cancer Genome Atlas (TCGA)180. We then performed
reference-free deconvolution in these datasets using DeCompress and the other reference-free
methods.
Overall, DeCompress showed the lowest MSE across all three datasets, in comparison to the
other reference-free methods (Figure 5.2C). The patterns observed in the GTEx results are evident in
these real datasets, as well. As the number of genes in the targeted panel increases, the variance in
the distribution of cell-type proportions decreases. Deconvolution using Linseed gave variable
performance across datasets, with very precise estimates of MSE in the rat microarray and lung
adenocarcinoma datasets while highly variable estimates in the breast cancer and prostate cancer
datasets. We do not present DeconICA in these comparisons due to its large errors across all
datasets (see Supplemental Figure S34 for comparisons to DeconICA). Specific to DeCompress, we
assessed the performance of different deconvolution methods (4 reference-free methods and unmix
from the DESeq2 package16) on the decompressed expression matrix for the breast, prostate, and
lung cancer datasets (Supplemental Figure S35). We found that unmix gives accurate estimates of
cell-type proportions in the breast cancer and prostate tumor datasets, where the component
cell-types are like those in bulk tumors. However, in the case of the lung adenocarcinoma mixing
dataset (mixture of two lung cancer cell lines), unmix performs poorly, perhaps owing to a dissimilarity
to the TCGA-LUAD reference. We lastly investigated the scenario when the reference and target
assays measure different bulk tissue. Using the breast cancer cell-line mixtures pseudo-targets and a
TCGA-LUAD reference, DeCompress estimated cell-type proportions with larger errors, such that the
distribution of MSEs intersect with a null distribution of MSEs from randomly generated cell-type
proportion matrices (Supplemental Figure S36).
Carolina Breast Cancer Study (CBCS) expression We finally benchmarked DeCompress against
the other 5 reference-free deconvolution methods in breast tumor expression data from the Carolina
Breast Cancer Study (CBCS)122,24 on 406 breast cancer-related genes on 1,199 samples. We used
RNA-seq breast tumor expression from TCGA to train the compression matrix for deconvolution in
CBCS using DeCompress; 393 of the 406 genes on the CBCS panel were measured in TCGA-BRCA.
For validation, a study pathologist analyzed 148 tumor microarrays (TMAs) to estimate cell-type
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proportions for epithelial tumor, adipose, stroma, and immune infiltrate, which we treat here as a “gold
standard.”
To determine whether the decompressed expression matrix accurately predicts expression for
samples in the target, we split the 393 genes into 5 groups and trained TCGA-based predictive models
of genes in each group using those in the other four. Overall, in-sample cross-validation prediction
per-sample in TCGA is strong (median adjusted R2 = 0.53), with a drop-off in out-sample performance
in CBCS (median adjusted R2 = 0.38), shown in Figure 5.3A. We also trained models stratified by
estrogen-receptor (ER) status, a major, biologically-relevant classification in breast tumors107,106.
These ER-specific models showed slightly better out-sample performance (median adjusted
R2 = 0.34), though in-sample performance was similar to overall models with the same median R2
(Figure 5.3B). Next, as in the GTEx mixing simulations and the 4 published datasets, DeCompress
recapitulated true cell-type proportions with the minimum error (Figure 5.3B), approximately 33% less
error than TOAST + NMF, the second-most accurate method. To provide some context to the
magnitude of these errors, we randomly generated 10,000 cell-type proportion matrices for 148
samples and 4 cell-types. The mean MSE is provided in Figure 5.3A, showing that 2 of the 5
benchmarked methods (CellDistinguisher and DeconICA) exceeded this randomly generated null MSE
value. We also observed that correlations between true and DeCompress-estimated cell-type
proportions are positive and significantly non-zero for three of four cell-type components (Figure 5.3C).
Unlike those from TOAST + NMF, DeCompress estimates of compartment-specific cell-type
proportions were positively correlated with the truth ( Figure 5.3C and Supplemental Figure S37).
5.3.2 Comparison of computational speed
The computational cost of DeCompress is high, owing primarily to training the compressed
sensing models. Non-linear estimation of the columns of the compression matrix is particularly slow
(Supplemental Figure S38). In practice, we recommend running an elastic net method (LASSO,
elastic net, or ridge regression) which are both faster (Supplemental Figure S32) and give larger
cross-validation R2 (Supplemental Figure S33). The median cross-validation R2 for elastic net and
ridge regression is approximately 16% larger than least angle regression and LASSO, and nearly 25%
larger than the non-linear optimization methods. Using CBCS data with 1,199 samples and 406 genes,
we ran all benchmarked deconvolution methods 25 times and recorded the total runtimes
(Supplemental Figure S38). For DeCompress, we used TCGA-BRCA data with 1,212 samples as the
reference. As shown in Supplemental Figure S38, running DeCompress in serial (approximately 62
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Figure 5.3: Benchmarking results with Carolina Breast Cancer Study expression data. (A) Kernel
density plots of predicted adjusted R2 per-sample in in-sample TCGA prediction (left) through cross-
validation and out-sample prediction in CBCS (right), colored by overall and ER-specific models. (B)
MSE (Y -axis) between true and estimated cell-type proportions in CBCS across all methods (X-axis).
Random indicates the mean MSE over 10,000 randomly generated cell-type proportion matrices. (C)
Spearman correlations (Y -axis) between compartment-wise true and estimated proportions across all
benchmarked methods (X-axis). Correlations marked with a star are significantly different from 0 at
P < 0.05.
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minutes) takes around 40 times longer than the slowest reference-free deconvolution method (TOAST
+ NMF, approximately 1.5 minutes), though DeCompress can comparable in runtime to TOAST + NMF
if run in parallel with enough workers (approximately 2.6 minutes). These computations were
conducted on a high-performance cluster (RedHat Linux operating system) with 25 GB of RAM.
5.3.3 Applications of DeCompress in the Carolina Breast Cancer Study
Given the strong performance of DeCompress in benchmarking experiments, we estimated
cell-type proportions for 1,199 subjects in CBCS with transcriptomic data assayed with NanoString
nCounter. Using TCGA-BRCA expression as a training set, we iteratively searched for cell
type-specific features14 (Step 1 in Figure 5.1) and included canonical cell-type markers for guidance
using a priori knowledge225–227. After expanding the targeted CBCS expression to these genes, we
estimated proportions for 5 compartments. As reference-free methods output proportions for agnostic
compartments, identifying approximate cell-types for compartments is often difficult. Here, we first
outline a framework for assigning modular identifiers for compartments identified by DeCompress,
guided by compartment-specific gene signatures. Then, we present some advantages of using
compartment-specific proportions in downstream analyses of breast cancer outcomes and gene
regulation.
Date of death and cause of death were identified by linkage to the National Death Index. All
diagnosed with breast cancer have been followed for vital status from diagnosis until date of death or
date of last contact. Breast cancer-related deaths were classified as those that listed breast cancer
(International Statistical Classification of Disease codes 174.9 and C-50.9) as the underlying cause of
death on the death certificate. Of the 1,199 samples deconvolved, 1,153 had associated survival data
with 330 total deaths, 201 attributed to breast cancer.
5.3.3.1 Identifying approximate cell-types for compartments
We leveraged compartment-specific gene signatures to annotate each compartment with modular
identifiers. First, we computed Spearman correlations between the compartment-specific gene
expression profiles and median tissue-specific expression profiles from GTEx222,223 and single cell
RNA-seq profiles of MCF7 breast cancer cells228 (Figure 5.4A). Here, we find that Compartment 4
(C4) shows strong positive correlations with fibroblasts, lymphocytes, multiple collagenous organs
(such as blood vessels, skin and the colon229), and MCF7 cells. The C3 gene signature was
significantly correlated with expression profiles of secretory organs (salivary glands, pancreas, liver)
94
and contained a strong marker of HER2-enriched breast cancer (ERBB2)230. In fact, we see
significant Spearman correlations between C3 and C4 proportions and ER and HER2 scores109,
scores that represent over-expression of genes up-regulated in ER-positive and HER2-enriched
breast tumors; namely, the strong positive correlation (ρ = 0.53) between C3 proportion and HER2
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Figure 5.4: Identification of Decompress-estimated compartments. (A) Heatmap of Pearson correla-
tions between compartment-specific gene signatures (X-axis) and GTEx median expression profiles
and MCF7 single-cell profiles (Y -axis). Significant correlations at nominal P < 0.01 are indicated with
an asterisk. (B) Barplot of − log10 FDR-adjusted P -values for top gene ontologies (Y -axis) enriched in
compartment-specific gene signatures. (C) Boxplots of estimated immune (left) and tumor (C3 and C4
compartments, right) proportions (Y -axis) across PAM50 molecular subtypes (X-axis)
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We conducted over-representation analysis (ORA)231 of gene signatures for all five
compartments, revealing cell cylce regulation ontologies for C3 that are consistent with the hypothesis
generated from GTEx profiles at FDR-adjusted P < 0.05 (Figure 5.4B) We conducted gene set
enrichment analysis (GSEA) for the C4 gene signature232, revealing significant enrichments for cell
differentiation and development process ontologies (Supplemental Figure S9). ORA analysis also
assigned immune-related ontologies to the C2 gene signatures at FDR-adjusted P < 0.05 and ERBB
signaling to C4, though these enrichments did not achieve statistical significance. C1 and C5 gene
signatures were not enriched for ontologies that allowed for conclusive cell-type assignment, showing
catabolic, morphogenic and extracellular process ontologies (Figure 5.4B). From these results, we
hypothesized that C3 and C4 resembled epithelial tumor cells, C2 resembled an immune
compartment, and C1 and C5 resembled stromal and mammary tissue.
Distributions of hypothesized immune (C2) and tumor (C3 and C4 proportions) revealed
significant differences across PAM50 molecular subtypes (Figure 5.4C; Kruskal-Wallis test of
differences with P < 2.2× 10−16)109. These trends across subtypes were consistent with a priori
knowledge, as well: Basal and HER2-enriched subtypes, the most aggressive subtypes, had the
largest proportions of the estimated tumor and immune compartments, while Luminal A, Luminal B,
and Normal-like subtypes showed lower proportions233,109,132. Furthermore, we found strong
differences in C4 and total tumor compartment estimates across race (Supplemental Figure S40A)
C3 and C4 also have strong correlations with ER- (estrogen receptor) and HER2-scores,
gene-expression based continuous variables that indicate clinical subtypes based on ESR1 and
ERBB2 gene modules (Supplemental Figure S40B); however, none of the C3, C4, immune, or tumor
compartment estimates showed significant differences across clinical ER stautus determined by
immunohistochemistry (Supplemental Figure S40C).
5.3.4 Incorporating estimated compartment improves outcome prediction
Next, we considered the impact of including the tumor (C3, C4, and combining C3/C4) and
immune (C2) compartments in survival models. We constructed Cox models for breast-cancer specific
mortality154 with the following covariates: race, age, PAM50 molecular subtype, compartment
proportion, and an interaction between subtype and compartment proportion. Supplemental Table S8
shows hazard ratio estimates and 90% FDR-adjusted confidence intervals234 from Cox models with
the C3, C4, tumor, and immune compartments, along with comparisons to a reduced baseline model
that excludes the compartment estimates and interaction terms. General relationships stay similar
96
across the baseline and interaction models (e.g. protective hazard ratios of Luminal A subtypes in
comparison to the reference Basal subtypes). We also estimated, in the C4-compartment interaction
model, that increased C4 proportion was associated with shorter survival (hazard ratio 1.69,
FDR-adjusted P = 0.026). We also compared these compartment-specific interaction models with the
nested baseline model that did not contain the compartment proportions using a partial likelihood ratio
test. We found that only the interaction model with the C4 proportions gave a significantly better model
fit (χ2 = 11.52 on 4 degrees of freedom, P = 0.02). Estimated survival Kaplan-Meier curves stratified
by molecular subtype and median-stratified C3 and C4 proportions showed significant differences
between low and high proportion groups within molecular subtypes (Supplemental Table S8).
Namely, we observed that the C3 high and low proportion groups only split the HER2-enriched
molecular subtype based on survival outcomes, reinforcing the ERBB signaling annotations assigned
to C3 in ORA analysis. However, the HER2-enriched subtype was enriched for C3-high samples (127
out of 147 samples in the C3-high group). We also found that the C4 groups split the Basal and
Luminal B subtype groups, though the Basal subtype was disproportionately enriched for C4-high
subjects (315 out of 339 subjects). In sum, these results illustrate that incorporating
computationally-derived estimates of compartments may aid in outcome prediction.
5.3.4.1 Incorporating compartment proportions into eQTL models detects more
tissue-specific gene regulators
We investigated how incorporating estimated compartment proportions affect cis-eQTL mapping
in breast tumors, a common application of deconvolution methods in assessing sources of variation in
gene regulation85,235. In previous eQTLs studies using CBCS expression, several bulk breast tumor
cis-eGenes were found in healthy mammary, subcutaenous adipose, or lymphocytes from GTEx102.
We included DeCompress proportion estimates for the tumor (C3 and C4 estimates) and immune (C2)
compartments in a race-stratified, genetic ancestry-adjusted cis-eQTL interaction model, as proposed
by Geeleher et al and Westra et al85,84. We found that sets of compartment-specific cis-eGenes
generally had few intersections with bulk cis-eGenes (Figure 5.5A), but we detected more eQTLs in
tumor- and immune-specific compartments (Supplemental Figure S41). At FDR-adjusted P < 0.05,
of 209 immune-specific cis-eGenes identified in women of European ancestry (EA), 7 were also
mapped in the bulk models (with no compartment proportions covariates), and no tumor-specific
cis-eGenes were identified with the bulk models. Similarly, at FDR-adjusted P < 0.05, in women of
African ancestry (AA), 27 of 331 and 9 of 124 cis-eGenes identified with the immune- and
tumor-compartment interaction models were also mapped with the bulk models, respectively.
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Figure 5.5: Compartment-specific cis-eQTL mapping in the Carolina Breast Cancer Study. (A) Venn
diagram of bulk, tumor-, and immune-specific cis-eGenes identified European-ancestry (left) and African-
ancestry samples (right) in CBCS. (B) Enrichment analysis of immune- (red) and tumor-specific (blue)
cis-eGenes in CBCS plotting the −log10 P -value of enrichment (X-axis) and description of gene ontolo-
gies (Y -axis). The size of the point represents the relative enrichment ratio for the given ontology. (C)
Scatterplots of GTEx (X-axis) and CBCS effect size (Y -axis) for significant CBCS cis-eQTLs that were
mapped in GTEx. Each point is colored by the GTEx tissue in which the cis-eQTL has the lowest P -
value. Reference dotted lines for the X- and Y -axes are provided. (D) For risk variants from GWAS for
breast cancer from iCOGs9–11, scatterplot of −log10 P-values of bulk (X-axis) and compartment-specific
cis-eQTLs (Y -axis), colored blue for tumor- and red for immune-specific models. A 45-degree reference
line is provided. In the top right corner, 3 tumor-specific cis-eQTLs are labeled with the eGene CCR3
as they are significant at FDR-adjusted P < 0.05. (E) Tumor-specific eQTL effect sizes and 95% confi-
dence intervals (Y -axis) for rs56387622 on CCR3 expression across various estimates of tumor purity.
The eQTL effect size from the bulk model is given in blue.
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Manhattan plots for cis-eQTLs across the whole genome across bulk, tumor, and immune show the
differences in eQTL architecture in these compartment-specific eQTL mappings in EA and AA
samples (Supplemental Figures S42 and S43, respectively). Furthermore, we generally detected
more cis-eQTLs at FDR-adjusted P < 0.05 with the immune-specific interactions than the bulk and
tumor-specific interactions (EA: 565 bulk cis-eQTLs, 65 tumor cis-eQTLs, 8927 immune cis-eQTLs;
AA: 237 bulk cis-eQTLs, 449 tumor cis-eQTLs, 7676 immune cis-eQTLs; Supplemental Figure S41).
We analyzed the sets of EA and AA tumor- and immune-specific eGenes in CBCS with ORA
analysis for biological processes (Figure 5.5B). We found that, in general, these sets of eGenes were
concordant with the compartment in which they were mapped. All at FDR-adjusted P < 0.05, AA
tumor-specific eGenes showed enrichment for cell cycle and developmental ontologies, while
immune-specific eGenes were enriched for leukocyte activiation and migration and response to drug
pathways. Similarly, EA tumor-specific eGenes showed enrichments for cell death and proliferation
ontologies, and immune-specific eGenes showed cytokine and lymph vessel-associated processes.
These results from cis-eQTL analysis provide an example of the advantage of including
DeCompress-estimated compartment proportions in downstream genomic analyses.
We then cross-referenced bulk and tumor-specific cis-eGenes found in the CBCS EA sample with
cis-eGenes detected in healthy tissues from GTEx: mammary tissue, fibroblasts, lymphocytes, and
adipose, similar to previous pan-cancer germline eQTL analyses102,137. We attributed several of the
bulk cis-eGenes to healthy GTEx tissue (all but 2), but tumor specific cis-eGenes were less enriched in
these healthy tissues (Supplemental Figure S44). We compared the cis-eQTL effect sizes for
significant CBCS cis-eSNPs found in GTEx. As shown in Figure 5.5C, 98 of 220 bulk cis-eQTLs
detected in CBCS that were also found in GTEx were mapped in healthy tissue, with strong positive
correlation between effect sizes (Spearman ρ = 0.93). The remaining 122 eQTLs that could not be
detected in healthy GTEx tissue contained some discordance in the direction of effects, though
correlations between these effect sizes were also strongly positive (ρ = 0.71). In contrast, we were
unable to detect any of the CBCS tumor-specific cis-eQTLs in GTEx healthy tissue, and the correlation
of these effect sizes across CBCS and GTEx was poor (ρ = −0.07).
We next extracted 932 breast cancer risk-associated SNPs in women of European ancestry9–11 at
FDR-adjusted P < 0.05 that were available on the CBCS OncoArray panel124. Figure 5.5D shows the
raw − log10 P -values of the association of these SNPs with their top cis-eGenes in the bulk and tumor-
and immune-specific interaction models. In large part, none of these eQTLs reached FDR-adjusted
P < 0.05, except for 3 cis-eQTLs, with their strengths of association favoring the bulk eQTLs.
However, we detected 3 tumor-specific EA cis-eQTLs in near-perfect linkage disequilibrium of
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r2 > 0.99 (strongest association with rs56387622) with the chemokine receptor CCR3, previously
found to be associated with breast cancer outcomes in luminal-like subtypes236,237. As estimated
tumor purity increases, the cancer risk allele C at rs56387622 has a consistently stronger negative
effect on CCR3 expression (Figure 5.5E).
5.4 Discussion
Here, we presented DeCompress, a semi-reference-free deconvolution method catered towards
targeted expression panels that are commonly used for archived tissue in clinical and academic
settings18,25. Unlike traditional reference-based methods that require cell-type specific expression
profiles, DeCompress requires only a reference RNA-seq or microarray data on similar bulk tissue to
train a compressed sensing model that projects the targeted panel into a larger feature space for
deconvolution. Such reference datasets are much more widely available than cell-type specific
expression on the same targeted panel. We benchmarked DeCompress against reference-free
methods12,13,17,14,15 using in-silico GTEx mixing experiments222,223, 4 published datasets with known
cell-type proportions6,5,7,8, and a large, heterogeneous NanoString nCounter dataset from the
CBCS122,233. In these analyses, we showed that DeCompress recapitulated true cell-type proportions
with the minimum error and the strongest compartment-specific positive correlations, especially when
the reference dataset is properly aligned with the tissue assayed in the target. Lastly, we outlined the
advantages of incorporating these computationally derived estimates in downstream analyses of
survival outcomes and eQTL mapping in breast cancer.
A disadvantage of DeCompress is its computational cost, owing mainly to its lengthy compressing
sensing training step. We recommend running mainly linear optimization methods in this step and
have implemented parallelization options to bring computation time on par with the iterative framework
proposed in TOAST14. However, DeCompress estimates cell-type proportions both accurately and
precisely, compared to other reference-free methods, and provides a strong computational alternative
that is much faster than costly lab-based measurement of composition. Another disadvantage, which
also affects reference-based methods, is the proper selection of a reference dataset. As seen in the
lung adenocarcinoma example, where TCGA-LUAD data was not an accurate reflection of a mixture of
adenocarcinoma cell-lines, DeCompress performance is slightly worse than with datasets with
properly matched references. Yet, DeCompress performance is on par with that of the other
reference-free methods. The compression model may also be sensitive to phenotypic variation in the
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reference, as evidenced by the increase in out-sample prediction R2 in ER-specific models compared
to overall models in CBCS. This specificity may be leveraged to train more accurate models by using
more than one reference dataset to reflect clinical or biological heterogeneity in the targeted panel.
A universal challenge of reference-free deconvolution methods, like DeCompress, is selecting an
appropriate number of compartments. Previous groups have detailed how important a priori
knowledge is for deconvolving well-studied tissues, such as blood and brain238,239. However, diseased
tissues, like bulk cancerous tumors, especially in understudied subtypes or populations, are more
difficult to deconvolve due to the similarity between compartments, many of which are rare, when
comparing across individuals of different subtypes or phenotypes (e.g. activated and inactivated
stroma in breast tumors)106,226,240,108. For this reason, though DeCompress includes several
data-driven approaches in estimating the number of compartments from variation in the gene
expression, we recommend applying prior domain knowledge about the tissue of interest. Another
challenge for all reference-free methods is assigning gene module-based annotations to the
unidentified estimated compartments. Several previous reference-free methods have leveraged in
vitro mixtures of highly distinct cell lines in training and testing previous reference-free deconvolution
methods6,13, namely the rat cell line mixture (GSE19830). Though this dataset is easy to deconvolve
and thus useful in testing methodology, the extreme differences in gene expression between these
three tissue types renders this dataset sub-optimal for methods benchmarking. Furthermore, assigning
estimated compartments to known tissues in this dataset is straightforward and does not capture how
difficult this task in typical deconvolution applications. Instead, our applications in breast cancer
expression with CBCS provided such a difficult statistical challenge. Our outlined approach of first
comparing compartment-specific gene signatures to known tissue profiles from GTEx or single-cell
profiles, then analyzing these signatures with ORA or GSEA, and lastly searching for known biological
trends provides a structured framework for addressing the compartment identification problem.
Our downstream eQTL analysis in CBCS breast tumor expression also provided some insight into
gene regulation, similar to recent work into deconvolving immune subpopulation eQTL signals from
bulk blood eQTLs235. In breast cancer, Geeleher et al previously showed that a similarly implemented
interaction eQTL model gave better mapping of compartment-specific eQTLs84,85. Our results are
consistent with this finding, especially since tumor- and immune-specific eGenes were enriched for
commonly associated ontologies. However, unlike Geeleher et al, we generally detected a larger
number of immune- and tumor-specific eQTLs and eGenes than in the bulk, unadjusted models. We
believe that this larger number of compartment-specific eGenes may be due to the specificity of the
genes assayed by the CBCS nCounter panel. As the panel included 406 genes, all previously
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implicated in breast cancer pathogenesis, proliferation, or response102,233,241, the interaction model will
detect for SNPs that have large effects on cell-type specific genes. The interaction term is interpreted
as the difference in eQTL effect sizes between a samples of 0% and 100% of the given compartment;
accordingly, for genes implicated in specific breast cancer pathways, we expect to see large
differences in cell-type specific eQTL effects242–244. Though this interaction model is straight-forward
in its interpretation for the tumor compartment (i.e. a sample of 100% tumor cells versus 100%
tumor-associated normal cells), this interpretation may be tenuous for less well-defined compartments,
like an immune compartment that includes several different immune cells. In addition, we did not
consider trans-acting eQTLs that are often attributed to cell-type heterogeneity, though we believe that
methods employing mediation or cross-condition analysis can be integrated with compartment
estimates to map cell-type specific trans-eQTLs relevant in breast cancer245,72,67.
Relevant to risk and proliferation of breast cancer, we detected a locus of cis-eSNPs associated
with expression of CCR3 (C-C chemokine receptor type 3) that were GWAS-identified risk SNPs9–11
but were not significantly associated with CCR3 expression using the bulk models and were not
detected in GTEx. If one or more causal SNPs in this genomic region affects CCR3 expression only in
cancer cells and the effect on CCR3 expression is the main mechanism by which the locus
predisposes individuals to breast cancer, we can hypothesize that an earlier perturbation in the
development of cancer (e.g. transcription factor or microRNA activation) may cause this SNP’s
tumorigenic effect. Given this perturbation in precancerous mammary cells, individuals with the risk
allele would convey the tumorigenic effects of decreased CCR3 expression. It has been previously
shown that increased peritumoral CCR3 expression is associated with improved survival times in
luminal-like breast cancers236,237. The CCR3 receptor has been shown to be the primary binding site
of CCL11 (eotaxin-1), an eosinophil-selective chemoattractant cytokine246,247, and accordingly CCR3
antagonism prohibited chemotaxis of basophils and eosinophils, a phenomenon observed in breast
cancer activation and proliferation248,249. Without DeCompress and the incorporation of compartment
estimated in the eQTL model, this association between eSNP and CCR3 expression would not have
been detected250.
DeCompress, our semi-reference-free deconvolution method, provides a powerful method to
estimate cell-type specific proportions for targeted expression panels that have a limited number of
genes that only requires RNA-seq or microarray expression from a similar bulk tissue. Our method’s
estimates recapitulate known compartments with less error than reference-free methods, and provides
compartments that are biologically relevant, even in complex tissues like bulk breast tumors. We
provided examples of using these estimated compartment proportions in downstream studies of
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outcomes and eQTL analysis. Given the wide applications of reference-free deconvolution, the
popularity of targeted panels in both academic and clinical settings, and increasing need for analyzing
heterogeneous tissues, we anticipate creative implementations of DeCompress to provide further
insight into expression variation in complex diseases.
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CHAPTER 6: CONCLUSION
Here, we proposed several approaches for the analysis of biological data with various sources of
variation. In Chapter 2, we propose a framework for the normalization of NanoString nCounter RNA
expression data, especially in long-term longitudinal, multi-phase or multi-site cohorts. We compare
our iterative framework with the commercially available nSolver software, showing that the nSolver
software insufficiently removes technical variation, leading to potentially inflated biological associations
due to confounding. In Chapter 3, we conduct a transcriptome-wide association study for breast
cancer-specific survival that leverages race-specific, ancestry-adjusted breast tumor eQTLs. We show
that the cis-germline genetically regulated expression of many important breast cancer-related genes
are different across both race and clinical or molecular subtype. We then identify two novel genetic
regions that are associated for breast cancer mortality. This work informs future research into
disentangling genetic ancestry differences from subtype heterogeneity in breast cancer.
In Chapter 4, we propose an extension to transcriptomic prediction and association studies by
considering distal germline varation. We prioritize distal eQTLs in prediction leading to gains in both
expression predictive accuracy and power to detect gene-trait associations. We showed the
advantage of this TWAS extension in identifying relevant pathways in both breast cancer proliferation
and neuropsychiatric disorder. Our novel extension to test distal associations above and beyond the
local genetic-trait association aids in generating hypotheses for potential gene regulatory mechanisms.
Future work here is necessary to improve computational efficiency, but this approach is encouraging in
tissues or diseases that are governed by complex networks of gene regulation. Lastly, in Chapter 5,
we outline a semi-reference-free cell-type deconvolution method for targeted mRNA expression
panels. We show the utility of this method over reference-free methods in a variety of settings and use
deconvolved expression to better explain survival outcomes and compartment-specific eQTLs in bulk
breast cancer tissue. This method can be integrated with other computational approaches to adjust
complex genomic analyses for cell-type heterogeneity.
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APPENDIX: SUPPLEMENTAL FIGURES AND TABLES
Figure S1: Comparison of per-sample expression with and without background threshold. (A) Scatter
plot of per-sample median and per-sample variance of CBCS expression across raw expression (left),
nSolver-normalized data with background correction (middle), and without background correction (right),
with samples colored by study phase. (B) Relative log-expression (RLE) plots of raw expression (top),
nSolver-normalized expression with background correction (middle), and nSolver-normalized expres-
sion without background correction (bottom) for 90 randomly selected CBCS breast cancer samples,
ordered from left to right by increasing per-sample median in the raw expression. The dotted line gives
a reference for a deviation of 0.
105
Software Implementation Method Memory Used(CBCS Used) Notes













RUV-III has been created by the same





Normalized data is recommended to be
used only for downstream differential






20.93 GB High computational cost,even in fast mode
Table S1: Summary of normalization software compared in benchmarking. We provide the implemen-
tation of the software, a brief summary of the methods used by the software, total memory used on a
submitted job on a high performance cluster with 25 GB allocated RAM, and any miscellaneous notes
about the methods (i.e. alternative implementations and disadvantages of each method). The memory
used is calculated from a submitted job that processed the CBCS expression data (417 genes, 1264
samples).
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Figure S2: Comparison of quality control flags and sample quality in CBCS. Boxplot of percent of
zero-counts in endogenous genes (Y-axis) over varying numbers of zero-counts in the 11 housekeeping
genes (X-axis), colored by various QC flags.
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Figure S3: Comparison of sample quality with sample age in CBCS. Boxplots of percent of zero-counts
per sample by CBCS study phase with percent of zero-counts of 406 endogenous genes (A) and percent
of zero-counts of 11 housekeeping genes (B).
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Figure S4: Comparison of normalization methods on reflecting technical and biological variables. Scat-
ter plots of first two principal components of raw, nSolver-, RUVSeq-, NanoStringDiff-, and RCRnorm-
normalized CBCS expression data colored by study phase (A) and PAM50 subtype call (B). PC1 (X-axis)
captures the maximum variation in expression (approximately 9-12% across all datasets), and PC2 (Y -
axis) captures the second most (approximately 3-4%).
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Figure S5: Silhouette analysis of normalized data acros study phase and ER stuatus Boxplots of silhou-
ette widths of raw, nSolver-, RUVSeq-, NanoStringDiff-, and RCRnorm-normalized CBCS expression
data colored by ER status (A) and study phase (B).
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Figure S6: Confusion matrix of PAM50 calls using nSolver-normalized and RUVSeq-normalized ex-
pression
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Figure S7: Gene expression patterns across normalization methods in CBCS. Histograms of raw P -
values of eQTL associations using nSolver-normalized (red) and RUVSeq-normalized (blue) data across
overall (top), cis-eQTLs only (middle), and trans-eQTLs only (bottom) for eQTL associations with FDR-
adjusted P < 0.05.
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Figure S8: Comparison of minor allele frequencies of trans-eSNPs in nSolver- and RUVSeq-normalized
CBCS data. Violin plots of absolute differences in minor allele frequencies of trans-eSNPs specific
to nSolver-normalized data (A) and RUVSeq-normalized data (B) between groups of African ancestry
women (AA) and European ancestry women (EA) and between the three study phases.
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Figure S9: Proposed causal relationships leading to perceived bias in detected trans-eQTLs. Violin
plots of absolute differences in minor allele frequencies of trans-eSNPs specific to nSolver-normalized
data (A) and RUVSeq-normalized data (B) between groups of African ancestry women (AA) and Euro-
pean ancestry women (EA) and between the three study phases.
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Figure S10: Expression patterns in nSolver- and RUVSeq-normalized CBCS data. Heatmap of
nSolver-normalized (left) and RUVSeq-normalized (right) expression of 417 breast cancer-related genes
with hierarchical clustering of samples (horizontal) and genes (vertical). Samples are classified as
Basal-like (red), HER2-enriched (pink), luminal A (dark blue), luminal B (light blue), and normal-like
(green). The left heatmap uses nSolver-normalized normalized data without quality control based on
post-normalization visual inspection. The blue arrow indicates 14 samples without any pre- or post-
normalization quality control flags, but show deviations from expression patterns.
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Figure S11: Technical variation across study groups in Sabry et al data. Relative log-expression (RLE)
plots of raw expression (A), nSolver-normalized expression (B), and RUVSeq-normalized expression (C)
for Sabry et al’s natural killer Nanostring expression profile. Boxplots are colored by various treatment
groups.
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Figure S12: Cis-trans plot of race-stratified eQTL analyses AA eQTLs are shown on the left and WW
on the right. Each point represents an eQTL with BBFDR < 0.125 with the location of the 5’ end of
the corresponding eGenes on the Y-axis and the genomic location of the corresponding eSNP on the
X-axis. A 45-degree line is provided as a reference for cis-eQTLs.
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Figure S13: Minor allele frequency differences of eSNPs across race. Scatter plot of minor allele
frequencies (MAF) of all significant eSNPs (BBFDR < 0.05) in either the AA or WW sample, with the
MAF in the AA sample on the X-axis and in the WW sample on the Y-axis. Points are colored by the
sample in which the eSNP was detected. The 45-degree line is provided for reference.
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Figure S14: Impact of tumor purity adjustment on eQTLs. Example Manhattan plots for eQTL analysis
in bulk tumor LAG-3 expression (A) and tumor purity-adjusted LAG-3 expression (B) in WW women.
Red line represents a genome-wide significance threshold of P = 1 × 10−8 and the dotted black line
corresponds to BBFDR < 0.05.
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Figure S15: Impact of tumor purity adjustment on eQTLs across race. Cis-trans plots, as in Supple-
mentary Figure S12, across self-identified race (top to bottom) and across adjustment for tumor purity
(eQTLs in bulk tumor expression on left and eQTLs in tumor purity-adjusted expression on left)
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Figure S16: Impact of local ancestry adjustment on cis-eQTLs. (A) Kernel density plot of difference
in − log10 P -values for lead cis-eQTLs identified with local ancestry adjustments and genome-wide an-
cestry adjustments. (B) Kernel density plot of difference in − log10 P -values of association of eQTLs
between AA and WW women with genome-wide ancestry adjustment (red) and local ancestry adjusted
(blue) for lead eQTLs identified for AA-specific cis-eGenes. (C) Kernel density plot of difference in
− log10 P -values of association of eQTLs between WW and AA women with genome-wide ancestry ad-
justment (red) and local ancestry adjusted (blue) for lead eQTLs identified for WW-specific cis-eGenes.
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Figure S17: Comparison of eQTL effect sizes across CBCS and GTEx. Each point represents a signif-
icant eQTL for PSPHL (A) and GSTT2 (B) found in both GTEx and the CBCS WW sample, colored by
the strength of linkage disequilibrium to the top eSNP in CBCS. Absolute effect size of significant eQTLs
in WW CBCS is plotted on the X-axis and absolute effect size of significant eQTLs in GTEx multiplied
by the sign of the effect size in CBCS is plotted on the Y-axis.
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Figure S18: Overlap of WW CBCS cis-eQTLs in GTEx and TCGA-BRCA. Each point represents a
given cis-eSNP-eGene pair (cis-eQTL), with the − log10 P -value of the association in CBCS on the X-
axis and the − log10 P -value of the association in the external dataset on the Y-axis. Each cis-eQTL that
is colored orange and labelled is the lead cis-eSNP in CBCS (i.e. the lowest P-value for that eGene in
CBCS).
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Figure S19: Comparison of use of LD-pruning on model performance. For genes with cis-h2 with
P < 0.10, cross-validation R2 with (X-axis) and without (Y-axis) LD-pruning of genotype design matrix.
Points are colored orange if there is increased CV R2 with LD-pruning. The blue line gives the 45-degree
line and the dotted black lines show thresholds for R2 = 0.01, for reference.
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Figure S20: Comparison of heritability and cross-validation predictive performance. Comparison of cis-
h2 estimates (X-axis) and cross-validation R2 (Y-axis) for each gene with likelihood ratio test P < 0.10
for cis-h2 = 0 across AA and WW women in CBCS training set. The 45-degree line (i.e. Y = X) is











































































































































































































































































































































































































































































































































Figure S21: Performance of CBCS expression models in independent external cohorts. Comparison of
EVR2 across race, stratified by PAM50 molecular subtype and estrogen receptor status in TCGA (A) and
CBCS (B). Squared Spearman correlation in WW (X-axis) and AA (Y-axis) for each of the available genes
are plotted. Note that both scales are logarithmic. Dotted lines represent R2 = 0.01. Colors represent
the model with which a given gene can be predicted at cross-validation R2 > 0.01. A representative
gene with variable R2 across subtypes is labelled.
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Figure S22: Assessment of sampling variability on external predictive R2. Storey’s − log10 q-values
from P -values of permutation tests over 10,000 permutations to assess significance of external vali-
dation R2 in TCGA (A) and held-out CBCS (B). Dotted lines represent q = 0.10. Sample sizes are
provided in the form (AA/WW). A representative gene with variable permutation q-value across subtype
is labelled.
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Figure S23: Power analysis of TWAS for survival in CBCS. Comparison of power of TWAS in CBCS
sample of N = 3, 828 and 348 breast cancer-specific deaths. Power (Y-axis) to detect a given hazard
ratio (X-axis) is plotted. Curves correspond to genes of varying cis-h2: DDIT4 (green) has high h2
across AA and WW, AURKA (orange) has average h2 across AA and WW, and KIFC1 (purple) has the
lowest h2 across AA and WW. Power calculations are derived from 1,000 re-samplings of the empirical
distribution function of the GReX of a given gene. Dotted line represents 80% power.
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Figure S24: Directed acyclic graph showing potential backdoor confounding in a case-only study. Mod-
ified from Paternoster et al. Directed acyclic graph that shows how collider bias is introduced (grey path)
in case-only studies. Here, in this case-only study, we condition on breast cancer incidence, which may
open up a potential collider bias with unmeasured confounders in the measure of association between
the GReX of a gene and breast cancer survival.
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Figure S25: Subtype-specific follow-up on TWAS associations. Caterpillar plots for hazard ratio of
breast cancer-specific survival in AA women for an increase of one standard deviation of GReX across
models unadjusted for estrogen receptor subtype and stratifying for estrogen receptor subtype.
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Figure S26: Associations of gene expression and GReX for four TWAS-detected loci in CBCS. Hazard
ratios and 95% confidence intervals, adjusted for false discovery via Benjamini-Hochberg, as estimated
from breast cancer-specific Cox models in AA women. Association with total expression (purple) and
GReX (orange) of 4 TWAS-detected genes are compared.
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TCGA-BRCA ROS/MAP
Local-only 0.037 (0.053) 0.079 (0.119)
MeTWAS 0.040 (0.066) 0.135 (0.099)
DePMA 0.383 (0.194) 0.405 (0.118)
Table S3: Comparison of h2 across local-only, MeTWAS, and DePMA predictive models. The mean and
standard deviation of h2 across all genes that are significantly heritable with the genetic loci considered























Figure S27: Comparison of computation times between local-only and MOSTWAS modelling. Mean
and standard deviation of per-gene computation time across 50 randomly selected genes in TCGA-














Causal proportion = 0.01 Causal proportion = 0.2











Local  h2 ● 0.1 0.25 Method ● ●Local−only MOSTWAS
Predictive  R2
Figure S28: Comparison of predictive R2 in simulations. Mean adjusted R2 across various local and
distal expression heritabilities, trait heritabilities, and causal proportions using local-only (red) and the
best MOSTWAS (blue) models. The error bars reflect a width of 1 standard deviation of the 1,000























































































































































































































































































































































































































































Figure S29: Gene-trait associations in iCOGs and PGC using local-only and MOSTWAS models.
− log10 P -values of weighted burden gene-trait associations using iCOGs survival GWAS in European-
ancestry women (left) and PGC MDD risk GWAS in predominantly European-ancestry patients (right)
among genes that were predicted at cross-validation R2 ≥ 0.01 using both local-only and MOSTWAS
models. The X- and Y -axes display the − log10 P -values for local-only and the best MOSTWAS model,
respectively. Note that the scales of both axes are on a doubly logarithmic scale. Points are colored red
if P -value of association is less than or equal using the MOSTWAS model. The horizontal and vertical









































































































































































































Figure S30: Comparison of QQ-plots from TWAS associations. QQ-plots from TWAS for breast cancer-
specific survival in iCOGs (A) and MDD in PGC (B) with local-only models (left) and MOSTWAS (right)
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Figure S31: Comparison of P -value QQ-plots from TWAS associations. QQ-plots of − log10 P -values
from TWAS for breast cancer-specific survival in iCOGs (A) and MDD in PGC (B) with local-only models
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Figure S32: Comparison of run-times for various methods implemented for compressed sensing in
DeCompress. Over sample sizes of N = 40, N = 200, and N = 1000 and feature sizes of 200, 500,
800, and 100, we plot the mean time of estimation compression model over the 7 methods implemented
in DeCompress: least angle regression (LAR), LASSO, elastic net with α = 0.5, ridge regression, non-
linear optimization with l1 norm, non-linear optimization with total variation-adjusted l1 norm, and non-































Figure S33: Comparison of predictive performance of optimization methods used in DeCompress’s
compressing sensing step. Violin plots for distributions of cross-validation R2 (Y -axis) of the various
optimization methods (X-axis) employed by DeCompress for compression sensing for 100 randomly
selected genes from CBCS. From left to right, least angle regression, LASSO, elastic with alpha = 0.5,
ridge regression, and non-linear optimization with l1 norm. Non-linear optimization with either the total




Non-negative least squares on normalized expression
matrix in log2-space, seeded by initial non-negative
matrix factorization.
R package CellMix 251
TOAST 14
Feature selection used in combination with iterative
reference-free deconvolution. Feature selection is done
using a method for cross-cell type differential analysis
for data from a mixed sample 252.
R package TOAST 14
CellDistinguisher 15
Topic modeling based on a set of input cell-type
distinguishing genes. CellDistinguisher includes
a method to infer distinguishing genes using the
gene-gene conditional expression vectors in a space
where the number of vectors and number of dimensions
are both equal to the number of genes. This step relies
on a large input number of genes to properly function.
R package CellDistinguisher 15
Linseed 13
Solving a convex hull problem by projecting the gene
expression data and find corners using an assumption
that cell-type specific genes are mutually linear. The
cell-type specific expression genes are then inputted
into the Digital Sorting Algorithm, a gene-signature
based deconvolution method 87.
R package linseed
DeconICA 17
Deconvolution using Independent Component Analysis
(ICA), a matrix factorization method for dimension
reduction by projecting the expression into a space
such that distributions of the data point projections
on the new axes are as mutually independent as possible.
R package DeconICA 17
unmix 16,117
Non-negative least squares on the non-log2 scale
with loss calculated in a variance stabilized space.
This is a reference-based method, and is seeded in
DeCompress using the estimated cell-type specific
expression profiles estimated from the reference.
R package DESeq2 16
Table S6: Summary of deconvolution methods benchmarked against or employed in DeCompress.
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Dataset Accession Number Description
In-silico GTEx mixing 222,223 dbGAP: phs000424.v7.p2
Median tissue-specific expression profiles
were mixed at randomly generated mixing
proportions to simulate targeted panels.
Rat tissue cell-line mixture 6 GEO: GSE19830
Rat brain, liver, and lung biospecimens from
one animal were mixed at the cRNA
homogenate level in different proportions.
Expression was measured using microarray.
Human breast cancer
cell-line mixture 5 GEO: GSE123604
Total mRNA was prepared from Namalwa
(Burkitt’s lymphoma), Hs343T (fibroblasts
from mammary gland adenocarcinoma),
hTERT-HME1 (normal mammary
epithelial cells), and MCF7 (estrogen
receptor positive breast cancer cells).
Cell lines were mixed in different






Gene expression profiling of laser capture
microdissected epithelial and stromal
specimens from prostate tumors using
microarray.
Human lung cancer
cell-line mixture 8 GEO: GSE64098
Two lung adenocarcinoma cell lines
(NCI-H1975 and HCC827) were mixed at
different proportions and
expression was measure using RNA-Seq.
Bulk breast tumors from




Expression from bulk breast tumors were
measured using NanoString nCounter. A
pathologist estimated cell-type proportions
for 148 samples from tumor microarrays.
Table S7: Summary of datasets used in benchmarking
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PRAD tumor (c = 2) LUAD mixture (c = 2)
BRCA mixture (c = 4) Rat mixture (c = 3)
K=200 K=500 K=800 K=1000 K=200 K=500 K=800 K=1000




























Figure S34: Benchmarking of deconvolution performance using DeCompress and 5 other reference-
free deconvolution in published data examples. Boxplots of MSE (Y -axis) over 25 pseudo-targeted
panels using four published datasets over 200, 500, 800, and 1000 genes (X-axis). This plot shows the
same results as Figure 5.2C with the addition of DeconICA.
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BRCA mixture (c = 4) PRAD tumor (c = 2) LUAD mixture (c = 2)





















Figure S35: Comparison of deconvolution performance using decompressed matrix in DeCompress
across various methods. Boxplots of MSE (Y -axis) between true and estimated cell-type proportions
across pseudo-targeted panels of differing numbers of genes. We compare four reference-free methods
(deconf12, Linseed13, iterative non-negative matrix factorization with feature selection using TOAST14,
CellDistinguisher15) and a reference-based method (unmix16) that uses cell-type specific expressions
estimated from the reference. Here, we present results from the breast cancer cell line mixtures5,
prostate tumor7, and lung adenocarcinoma cell line mixtures8. We do not include DeconICA17 in this
benchmarking due to large errors across all three datasets.
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Figure S36: Deconvolution of breast cancer cell mixture using TCGA-LUAD reference. MSE (Y -axis)
across 25 psuedo-targeted panels with different numbers of genes (X-axis) of using various reference-
free deconvolution methods on decompresed breast cancer cell line data using TCGA-LUAD reference
data. The yellow box-plot gives a distribution of the MSE for 1,000 randomly generated cell-type pro-
portions
147
Figure S37: Scatter-plot of known and estimated cell-type proportions in CBCS using DeCompress
and TOAST + NMF. Plots of true (X-axis) and estimated (Y -axis) cell-type proportions in CBCS using
DeCompress and TOAST + NMF (most accurate benchmarked reference-free method). True cell-type
proportions are taken as measurement by a study pathologist for 148 samples. A reference smoothed




















































Figure S38: Comparison of run-times for DeCompress and benchmarked reference-free deconvolution
methods. Mean runtimes in seconds (X-axis on logarithmic scale) for methods benchmarked (Y -axis):
CellDistinguisher, DeCompress (in serial), DeCompress (in parallel with 20 cores), deconf, DeconICA,
Linseed, iterative non-negative matrix factorization with feature selection using TOAST. These runtimes
were generated by running all methods on CBCS data (1,199 samples with 407 genes). DeCompress
was run using TCGA-BRCA (1,212 samples) as a reference. The error bar gives an interval of one
standard deviation around the mean runtime. The blue, black, and red dotted lines provide references
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Figure S39: Gene set enrichment plot for combined C3 and C4 gene signature. The green, blue, and
red lines in the top panel of the plot represents the running enrichment score (ES) for the corresponding
gene ontology as the analysis goes down the ranked list. The peak gives the final ES. The green, blue,
and red lines in the middle of the plot shows where the members of ontological groups in the dataset
first appear in the ranked list. The bottom panel shows the value of the ranking metric as it moves down
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Figure S40: Comparison of compartment proportion estimates with race and different clinical subtype
metrics. (A) Boxplot of C3, C4, and C3 + C4 proportions across race with P -value of Wilcoxon rank-sum
test provided. (B) Scatterplot of compartment proportions (X-axis) and ER or HER2 score from PAM50
classification algorithm. A regression line is provided with a Spearman correlation ρ for reference. (C)
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Figure S41: QQ-plots for bulk, tumor-, and immune-specific eQTL models. QQ-plots from cis-eQTL
analysis with expected − log10 P -values (X-axis) and observed − log10 P -values (Y -axis) colored by




Covariate Hazard Ratio (90% adjusted CI) FDR-adjusted P
PAM50: HER2 1.37 (0.97,1.95) 0.310
PAM50: LumA 0.55 (0.39, 0.79) 0.041
PAM50: LumB 1.22 (0.86, 1.72) 0.220
Race: White 0.76 (0.59, 1.00) 0.110






PAM50: HER2 1.65 (0.87, 3.11) 0.260
PAM50: LumA 0.52 (0.30, 0.89) 0.064
PAM50: LumB 1.15 (0.64, 2.05) 0.782
Race: White 0.76 (0.57, 1.03) 0.214
Age (in 10 yrs) 0.84 ( 0.74, 0.96) 0.064
Compartment (in 10%) 1.07 (0.68, 1.68) 0.782
HER2/Compartment 0.86 (0.50, 2.41) 0.782
LumA/Compartment 1.12 (0.59, 2.11) 0.782
LumB/Compartment 1.11 (0.51, 2.41) 0.782
C4
PAM50: HER2 2.57 (1.42, 4.67) 0.026
PAM50: LumA 0.90 (0.51, 1.60) 0.761
PAM50: LumB 2.30 (1.34, 3.94) 0.026
Race: White 0.76 (0.59, 0.98) 0.125
Age (in 10 yrs) 0.86 (0.77, 0.96) 0.045
Compartment (in 10%) 1.69 (1.21, 2.37) 0.026
HER2/Compartment 0.47 (0.19, 1.16) 0.200
LumA/Compartment 0.66 (0.27, 1.59) 0.475
LumB/Compartment 0.40 (0.15, 1.02) 0.146
Tumor
PAM50: HER2 2.51 (1.17, 5.41) 0.070
PAM50: LumA 0.75 (0.37, 1.50) 0.450
PAM50: LumB 1.88 (0.90, 3.92) 0.124
Race: White 0.77 (0.57, 1.04) 0.124
Age (in 10 yrs) 0.84 (0.74, 0.96) 0.070
Compartment (in 10%) 1.32 (1.01, 1.74) 0.101
HER2/Compartment 0.69 (0.48, 1.00) 0.101
LumA/Compartment 0.87 (0.55, 1.39) 0.562
LumB/Compartment 0.75 (0.41, 1.38) 0.446
Immune
PAM50: HER2 1.64 (1.08, 2.50) 0.096
PAM50: LumA 0.51 (0.33, 0.79) 0.042
PAM50: LumB 1.30 (0.86, 1.98) 0.369
Race: White 0.77 (0.59, 1.01) 0.183
Age (in 10 yrs) 0.84 (0.75, 0.95) 0.042
Compartment (in 10%) 1.03 (0.70, 1.53) 0.878
HER2/Compartment 0.48 (0.19, 1.19) 0.250
LumA/Compartment 1.47 (0.65, 3.33) 0.494
LumB/Compartment 0.74 (0.29, 1.84) 0.606
Table S8: Results from bulk and compartment-specific survival models with PAM50 molecular subtype.
Hazard ratio estimates, 90% FDR-adjusted confidence intervals, and FDR-adjusted P-values for base-
line and compartment-specific interaction Cox models for breast cancer-specific survival.
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Figure S42: Manhattan plot of cis-eQTLs across the genome in EA CBCS samples. − log10 P -values
of eQTL association (Y -axis) across chromosomal position of cis-eQTLs across bulk (top), immune
(middle), and tumor (bottom) models. Top cis-eGenes are labelled.
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Figure S43: Manhattan plot of cis-eQTLs across the genome in AA CBCS samples. − log10 P -values
of eQTL association (Y -axis) across chromosomal position of cis-eQTLs across bulk (top), immune



































































GTEx Tissue ● ● ● ● ●Adipose Breast Fibroblast Immune Insignificant
Figure S44: Cross-referencing of bulk and tumor-specific CBCS EA cis-eGenes with GTEx. Com-
parison of absolute effect sizes of eGenes with significant cis-eQTLs in EA CBCS (Y -axis) and GTEx
(X-axis) over tissue type, stratified by bulk and tumor-specific eQTLs. eGenes are colored by the GTEx
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Figure S45: Associations of CCR3 expression across clinical variables, subtypes, and mortality. Violin
plots of CCR3 expression across breast tumor stage (A), estrogen status (B), and PAM50 molecular
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